CN116036278A - 用于治疗具有非典型braf突变的癌症的组合物和方法 - Google Patents
用于治疗具有非典型braf突变的癌症的组合物和方法 Download PDFInfo
- Publication number
- CN116036278A CN116036278A CN202210881186.0A CN202210881186A CN116036278A CN 116036278 A CN116036278 A CN 116036278A CN 202210881186 A CN202210881186 A CN 202210881186A CN 116036278 A CN116036278 A CN 116036278A
- Authority
- CN
- China
- Prior art keywords
- combinations
- inhibitors
- cancer
- cas
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 160
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 121
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 title claims abstract description 108
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title abstract description 79
- 239000000203 mixture Substances 0.000 title description 31
- 201000011510 cancer Diseases 0.000 claims abstract description 68
- 102200055464 rs113488022 Human genes 0.000 claims abstract description 52
- 239000012824 ERK inhibitor Substances 0.000 claims abstract description 40
- 239000003112 inhibitor Substances 0.000 claims description 187
- 239000003814 drug Substances 0.000 claims description 184
- 230000037361 pathway Effects 0.000 claims description 99
- 150000003839 salts Chemical class 0.000 claims description 76
- -1 2- (2 '-amino-3' -methoxyphenyl) -oxynaphthalen-4-one Chemical compound 0.000 claims description 66
- KSERXGMCDHOLSS-LJQANCHMSA-N n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical group C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 claims description 45
- 229940126656 GS-4224 Drugs 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- 229940124597 therapeutic agent Drugs 0.000 claims description 41
- 108091000080 Phosphotransferase Proteins 0.000 claims description 35
- 102000020233 phosphotransferase Human genes 0.000 claims description 35
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 32
- 239000003053 toxin Substances 0.000 claims description 27
- 231100000765 toxin Toxicity 0.000 claims description 27
- 108700012359 toxins Proteins 0.000 claims description 27
- 108091007960 PI3Ks Proteins 0.000 claims description 25
- 102000038030 PI3Ks Human genes 0.000 claims description 25
- 229940088597 hormone Drugs 0.000 claims description 25
- 239000005556 hormone Substances 0.000 claims description 25
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 23
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 23
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 21
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 20
- 229960003787 sorafenib Drugs 0.000 claims description 20
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 20
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 19
- 229960003862 vemurafenib Drugs 0.000 claims description 19
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 18
- 229960003301 nivolumab Drugs 0.000 claims description 18
- 229940002612 prodrug Drugs 0.000 claims description 18
- 239000000651 prodrug Substances 0.000 claims description 18
- 229960004641 rituximab Drugs 0.000 claims description 18
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims description 17
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 17
- RZIDZIGAXXNODG-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CCC1(N)CC1=CC=C(Cl)C=C1 RZIDZIGAXXNODG-UHFFFAOYSA-N 0.000 claims description 16
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 16
- KPQQGHGDBBJGFA-QNGWXLTQSA-N MK-8353 Chemical compound C([C@@](C1)(SC)C(=O)NC=2C=C3C(C=4C=NC(OC(C)C)=CC=4)=NNC3=CC=2)CN1CC(=O)N(CC=1)CCC=1C(C=C1)=CC=C1C=1N=CN(C)N=1 KPQQGHGDBBJGFA-QNGWXLTQSA-N 0.000 claims description 16
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 16
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 16
- 206010009944 Colon cancer Diseases 0.000 claims description 15
- 229940127089 cytotoxic agent Drugs 0.000 claims description 15
- 239000002254 cytotoxic agent Substances 0.000 claims description 15
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 15
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 15
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 14
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 14
- 108091008611 Protein Kinase B Proteins 0.000 claims description 14
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 14
- 229950005837 entinostat Drugs 0.000 claims description 14
- 239000002955 immunomodulating agent Substances 0.000 claims description 14
- 229940121354 immunomodulator Drugs 0.000 claims description 14
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 14
- 229960004961 mechlorethamine Drugs 0.000 claims description 14
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 229960002621 pembrolizumab Drugs 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- ZKZXNDJNWUTGDK-NSCUHMNNSA-N (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide Chemical compound C1=CC(Br)=CC=C1\C=C\CNCCNS(=O)(=O)C1=CC=CC2=CN=CC=C12 ZKZXNDJNWUTGDK-NSCUHMNNSA-N 0.000 claims description 12
- ZNRYCIVTNLZOGI-UHFFFAOYSA-N 1-(5-chloronaphthalen-1-yl)sulfonyl-1,4-diazepane;hydron;chloride Chemical compound Cl.C1=CC=C2C(Cl)=CC=CC2=C1S(=O)(=O)N1CCCNCC1 ZNRYCIVTNLZOGI-UHFFFAOYSA-N 0.000 claims description 12
- LFWGZXMTCUOPFI-UHFFFAOYSA-N 2,3-diphenyl-6-quinoxalinecarboxylic acid Chemical compound C=1C=CC=CC=1C1=NC2=CC(C(=O)O)=CC=C2N=C1C1=CC=CC=C1 LFWGZXMTCUOPFI-UHFFFAOYSA-N 0.000 claims description 12
- BYWWNRBKPCPJMG-UHFFFAOYSA-N 4-dodecyl-n-(1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound C1=CC(CCCCCCCCCCCC)=CC=C1S(=O)(=O)NC1=NN=CS1 BYWWNRBKPCPJMG-UHFFFAOYSA-N 0.000 claims description 12
- JEGHXKRHKHPBJD-UHFFFAOYSA-N 5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine Chemical compound CS(=O)(=O)N1CCC2=C1N=C(N1CCOCC1)N=C2C1=CN=C(N)N=C1 JEGHXKRHKHPBJD-UHFFFAOYSA-N 0.000 claims description 12
- HWUHTJIKQZZBRA-UHFFFAOYSA-N 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2h-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochloride Chemical compound Cl.Cl.C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 HWUHTJIKQZZBRA-UHFFFAOYSA-N 0.000 claims description 12
- 241000193738 Bacillus anthracis Species 0.000 claims description 12
- 102000055006 Calcitonin Human genes 0.000 claims description 12
- 108060001064 Calcitonin Proteins 0.000 claims description 12
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 claims description 12
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 12
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 12
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 12
- 108010065805 Interleukin-12 Proteins 0.000 claims description 12
- ZHEHVZXPFVXKEY-RUAOOFDTSA-N KT 5720 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@@H]1C[C@](C(=O)OCCCCCC)(O)[C@@]4(C)O1 ZHEHVZXPFVXKEY-RUAOOFDTSA-N 0.000 claims description 12
- 229940124647 MEK inhibitor Drugs 0.000 claims description 12
- FCKJZIRDZMVDEM-UHFFFAOYSA-N N-(7,8-dimethoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene)pyridine-3-carboxamide Chemical compound COC1=C(C2=NC(=NC(=O)C3=CN=CC=C3)N4CCNC4=C2C=C1)OC FCKJZIRDZMVDEM-UHFFFAOYSA-N 0.000 claims description 12
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 12
- 102000005157 Somatostatin Human genes 0.000 claims description 12
- 108010056088 Somatostatin Proteins 0.000 claims description 12
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 12
- 229960000397 bevacizumab Drugs 0.000 claims description 12
- 229960004015 calcitonin Drugs 0.000 claims description 12
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 12
- 201000010175 gallbladder cancer Diseases 0.000 claims description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 12
- 229960003445 idelalisib Drugs 0.000 claims description 12
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims description 12
- 201000002314 small intestine cancer Diseases 0.000 claims description 12
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 12
- 229960000553 somatostatin Drugs 0.000 claims description 12
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 claims description 12
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims description 11
- NGFFVZQXSRKHBM-FKBYEOEOSA-N 5-[[(1r,1as,6br)-1-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound N1C(=O)CCC2=C1N=CC=C2OC(C=C1[C@@H]23)=CC=C1O[C@@H]3[C@H]2C1=NC2=CC=C(C(F)(F)F)C=C2N1 NGFFVZQXSRKHBM-FKBYEOEOSA-N 0.000 claims description 11
- 102200055529 rs121913351 Human genes 0.000 claims description 11
- MWUFVYLAWAXDHQ-HMNLTAHHSA-N (2e,5s,6s,8z,10r,11s)-17-(ethylamino)-5,6,15-trihydroxy-10,11-dimethyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,8,14,16-pentaene-7,13-dione Chemical compound O([C@@H](C)[C@H](C)\C=C/C(=O)[C@@H](O)[C@@H](O)C/C=C/1)C(=O)C=2C\1=CC(NCC)=CC=2O MWUFVYLAWAXDHQ-HMNLTAHHSA-N 0.000 claims description 10
- 102400000739 Corticotropin Human genes 0.000 claims description 10
- 101800000414 Corticotropin Proteins 0.000 claims description 10
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 claims description 10
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 claims description 10
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 10
- 229960000258 corticotropin Drugs 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 229960005184 panobinostat Drugs 0.000 claims description 10
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims description 10
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 10
- 229960003452 romidepsin Drugs 0.000 claims description 10
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 10
- 108010091666 romidepsin Proteins 0.000 claims description 10
- 229960000548 alemtuzumab Drugs 0.000 claims description 9
- 229960003094 belinostat Drugs 0.000 claims description 9
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 9
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 9
- 229960005386 ipilimumab Drugs 0.000 claims description 9
- 229960001612 trastuzumab emtansine Drugs 0.000 claims description 9
- 108010076365 Adiponectin Proteins 0.000 claims description 8
- 102000011690 Adiponectin Human genes 0.000 claims description 8
- 229950009791 durvalumab Drugs 0.000 claims description 8
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 229960003347 obinutuzumab Drugs 0.000 claims description 8
- 229960001972 panitumumab Drugs 0.000 claims description 8
- 102220025535 rs121913366 Human genes 0.000 claims description 8
- 229940055760 yervoy Drugs 0.000 claims description 8
- YYACLQUDUDXAPA-MRXNPFEDSA-N (3r)-n-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide Chemical compound C1[C@H](F)CCN1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=NC(=NC=2)C2CC2)=C1F YYACLQUDUDXAPA-MRXNPFEDSA-N 0.000 claims description 7
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 7
- XCPPIJCBCWUBNT-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-2-[2-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]pyrimidin-4-yl]acetonitrile Chemical compound N=1C2=CC=CC=C2SC=1C(C#N)C(N=1)=CC=NC=1OCC(C=C1)=CC=C1CN1CCOCC1 XCPPIJCBCWUBNT-UHFFFAOYSA-N 0.000 claims description 7
- YQAXFVHNHSPUPO-RNJOBUHISA-N 2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1N(C(=O)CN)CCC1 YQAXFVHNHSPUPO-RNJOBUHISA-N 0.000 claims description 7
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims description 7
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 7
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 claims description 7
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims description 7
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 7
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 7
- 108010006654 Bleomycin Proteins 0.000 claims description 7
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 7
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 7
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 7
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 7
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 7
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 7
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 7
- 101150015280 Cel gene Proteins 0.000 claims description 7
- 101800001982 Cholecystokinin Proteins 0.000 claims description 7
- 102100025841 Cholecystokinin Human genes 0.000 claims description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 7
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 7
- 108010092160 Dactinomycin Proteins 0.000 claims description 7
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 7
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 7
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 7
- 229930192392 Mitomycin Natural products 0.000 claims description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 7
- VNBRGSXVFBYQNN-UHFFFAOYSA-N N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-3-pyridinecarboxamide Chemical compound O=C1C(C(=O)NC=2C=C(F)C(OC=3C(=C(N)N=CC=3)Cl)=CC=2)=C(OCC)C=CN1C1=CC=C(F)C=C1 VNBRGSXVFBYQNN-UHFFFAOYSA-N 0.000 claims description 7
- 241000288906 Primates Species 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 7
- VWMJHAFYPMOMGF-ZCFIWIBFSA-N TAK-580 Chemical compound N([C@H](C)C=1SC(=CN=1)C(=O)NC=1N=CC(Cl)=C(C=1)C(F)(F)F)C(=O)C1=NC=NC(N)=C1Cl VWMJHAFYPMOMGF-ZCFIWIBFSA-N 0.000 claims description 7
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 7
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 7
- 229950008805 abexinostat Drugs 0.000 claims description 7
- 229930183665 actinomycin Natural products 0.000 claims description 7
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 7
- 108010082685 antiarrhythmic peptide Proteins 0.000 claims description 7
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims description 7
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 7
- 229950006785 bentamapimod Drugs 0.000 claims description 7
- 229960001561 bleomycin Drugs 0.000 claims description 7
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 7
- 229960002092 busulfan Drugs 0.000 claims description 7
- 229960004117 capecitabine Drugs 0.000 claims description 7
- 229960004562 carboplatin Drugs 0.000 claims description 7
- 229960005243 carmustine Drugs 0.000 claims description 7
- 229940107137 cholecystokinin Drugs 0.000 claims description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 7
- 229960004316 cisplatin Drugs 0.000 claims description 7
- 229960004397 cyclophosphamide Drugs 0.000 claims description 7
- 229960003901 dacarbazine Drugs 0.000 claims description 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 7
- 229960000975 daunorubicin Drugs 0.000 claims description 7
- 229960003603 decitabine Drugs 0.000 claims description 7
- 229960004679 doxorubicin Drugs 0.000 claims description 7
- 229960001904 epirubicin Drugs 0.000 claims description 7
- 229960000390 fludarabine Drugs 0.000 claims description 7
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 7
- 229960002949 fluorouracil Drugs 0.000 claims description 7
- 230000004927 fusion Effects 0.000 claims description 7
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 7
- 229960005277 gemcitabine Drugs 0.000 claims description 7
- 229960000908 idarubicin Drugs 0.000 claims description 7
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 7
- 229960001101 ifosfamide Drugs 0.000 claims description 7
- 229960002247 lomustine Drugs 0.000 claims description 7
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 7
- 229960001924 melphalan Drugs 0.000 claims description 7
- 229960001428 mercaptopurine Drugs 0.000 claims description 7
- 229960000485 methotrexate Drugs 0.000 claims description 7
- 229960003775 miltefosine Drugs 0.000 claims description 7
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims description 7
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 7
- 229960004857 mitomycin Drugs 0.000 claims description 7
- 229960001156 mitoxantrone Drugs 0.000 claims description 7
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 7
- 229950007221 nedaplatin Drugs 0.000 claims description 7
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims description 7
- 229960001756 oxaliplatin Drugs 0.000 claims description 7
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 7
- 229960005079 pemetrexed Drugs 0.000 claims description 7
- 229960003171 plicamycin Drugs 0.000 claims description 7
- 102200055466 rs121913364 Human genes 0.000 claims description 7
- 102220014066 rs397516896 Human genes 0.000 claims description 7
- 229960005399 satraplatin Drugs 0.000 claims description 7
- 190014017285 satraplatin Chemical compound 0.000 claims description 7
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 7
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 7
- 229960001052 streptozocin Drugs 0.000 claims description 7
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- 229960004964 temozolomide Drugs 0.000 claims description 7
- 229960001055 uracil mustard Drugs 0.000 claims description 7
- 229960004914 vedolizumab Drugs 0.000 claims description 7
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 6
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 6
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 claims description 6
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 claims description 6
- ONKCBKDTKZIWHZ-MRWFHJSOSA-N (4r)-4-[[(2r)-6-amino-2-[[(2r)-2-[[4-(aminocarbamothioylamino)benzoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-[[(2r)-1-amino-6-[bis[2-[[4-[2-(1h-imidazol-5-yl)ethylamino]-4-oxobutanoyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-5-oxope Chemical compound C([C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN(C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(N)=O)NC(=O)C=1C=CC(NC(=S)NN)=CC=1)C1=CC=C(O)C=C1 ONKCBKDTKZIWHZ-MRWFHJSOSA-N 0.000 claims description 6
- SQWZFLMPDUSYGV-POHAHGRESA-N (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=N2)C2=C1 SQWZFLMPDUSYGV-POHAHGRESA-N 0.000 claims description 6
- SRLVNYDXMUGOFI-YWEYNIOJSA-N (5e)-5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2OC(F)(F)OC2=CC=C1\C=C1/SC(=O)NC1=O SRLVNYDXMUGOFI-YWEYNIOJSA-N 0.000 claims description 6
- QXPNJMHRUZCEAP-UXBSLASESA-N (5s,6s,8z,11s)-5,6,15-trihydroxy-17-methoxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(18),8,14,16-tetraene-7,13-dione Chemical compound O([C@@H](C)C\C=C/C(=O)[C@@H](O)[C@@H](O)CCC1)C(=O)C=2C1=CC(OC)=CC=2O QXPNJMHRUZCEAP-UXBSLASESA-N 0.000 claims description 6
- IUGRBTCJEYEDIY-VZUCSPMQSA-N (e)-2-(3,4-dihydroxybenzoyl)-3-(2-oxo-3h-1,3-benzoxazol-5-yl)prop-2-enenitrile Chemical compound C1=C(O)C(O)=CC=C1C(=O)C(\C#N)=C\C1=CC=C(OC(=O)N2)C2=C1 IUGRBTCJEYEDIY-VZUCSPMQSA-N 0.000 claims description 6
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims description 6
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 6
- DVEXZJFMOKTQEZ-UHFFFAOYSA-N 2,3-bis[amino-[(2-aminophenyl)thio]methylidene]butanedinitrile Chemical compound C=1C=CC=C(N)C=1SC(N)=C(C#N)C(C#N)=C(N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-UHFFFAOYSA-N 0.000 claims description 6
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 6
- PUYVJBBSBPUKBT-AWEZNQCLSA-N 2-[(1s)-1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3NC=NC=3N=C(N)N=2)C)=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1C PUYVJBBSBPUKBT-AWEZNQCLSA-N 0.000 claims description 6
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 6
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 6
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims description 6
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 claims description 6
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 claims description 6
- DOCINCLJNAXZQF-LBPRGKRZSA-N 6-fluoro-3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=C(F)C=C2C(=O)N1C1=CC=CC=C1 DOCINCLJNAXZQF-LBPRGKRZSA-N 0.000 claims description 6
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 claims description 6
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 6
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 claims description 6
- 229960005531 AMG 319 Drugs 0.000 claims description 6
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 6
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 6
- 201000003076 Angiosarcoma Diseases 0.000 claims description 6
- 102400000068 Angiostatin Human genes 0.000 claims description 6
- 108010079709 Angiostatins Proteins 0.000 claims description 6
- 108090001067 Angiotensinogen Proteins 0.000 claims description 6
- 102000004881 Angiotensinogen Human genes 0.000 claims description 6
- 102000015427 Angiotensins Human genes 0.000 claims description 6
- 108010064733 Angiotensins Proteins 0.000 claims description 6
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims description 6
- RFLHBLWLFUFFDZ-UHFFFAOYSA-N BML-210 Chemical compound NC1=CC=CC=C1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 RFLHBLWLFUFFDZ-UHFFFAOYSA-N 0.000 claims description 6
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims description 6
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 6
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 6
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 6
- 102400001047 Endostatin Human genes 0.000 claims description 6
- 108010079505 Endostatins Proteins 0.000 claims description 6
- 108050009340 Endothelin Proteins 0.000 claims description 6
- 102000002045 Endothelin Human genes 0.000 claims description 6
- 108010092674 Enkephalins Proteins 0.000 claims description 6
- 102000003951 Erythropoietin Human genes 0.000 claims description 6
- 108090000394 Erythropoietin Proteins 0.000 claims description 6
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 6
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 6
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims description 6
- 102400001370 Galanin Human genes 0.000 claims description 6
- 101800002068 Galanin Proteins 0.000 claims description 6
- 102400000921 Gastrin Human genes 0.000 claims description 6
- 108010052343 Gastrins Proteins 0.000 claims description 6
- 108060003199 Glucagon Proteins 0.000 claims description 6
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 6
- 108010051696 Growth Hormone Proteins 0.000 claims description 6
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 6
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 6
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 claims description 6
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 108010004250 Inhibins Proteins 0.000 claims description 6
- 102000002746 Inhibins Human genes 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 101150093335 KIN1 gene Proteins 0.000 claims description 6
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 6
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 6
- 102000017578 LAG3 Human genes 0.000 claims description 6
- 101150030213 Lag3 gene Proteins 0.000 claims description 6
- 108010092277 Leptin Proteins 0.000 claims description 6
- 102000016267 Leptin Human genes 0.000 claims description 6
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 6
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 6
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims description 6
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims description 6
- 102000002419 Motilin Human genes 0.000 claims description 6
- 101800002372 Motilin Proteins 0.000 claims description 6
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 6
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 claims description 6
- 244000061176 Nicotiana tabacum Species 0.000 claims description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 6
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 claims description 6
- 102000002512 Orexin Human genes 0.000 claims description 6
- 102400000050 Oxytocin Human genes 0.000 claims description 6
- 101800000989 Oxytocin Proteins 0.000 claims description 6
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 6
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 6
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 6
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 6
- 102100036154 Platelet basic protein Human genes 0.000 claims description 6
- 108090000778 Platelet factor 4 Proteins 0.000 claims description 6
- 102000003946 Prolactin Human genes 0.000 claims description 6
- 108010057464 Prolactin Proteins 0.000 claims description 6
- 108010087786 Prolactin-Releasing Hormone Proteins 0.000 claims description 6
- 108090000103 Relaxin Proteins 0.000 claims description 6
- 102000003743 Relaxin Human genes 0.000 claims description 6
- 108090000783 Renin Proteins 0.000 claims description 6
- 102100028255 Renin Human genes 0.000 claims description 6
- 108010040181 SF 1126 Proteins 0.000 claims description 6
- 108010086019 Secretin Proteins 0.000 claims description 6
- 102100037505 Secretin Human genes 0.000 claims description 6
- 101710142969 Somatoliberin Proteins 0.000 claims description 6
- 102100022831 Somatoliberin Human genes 0.000 claims description 6
- 102100038803 Somatotropin Human genes 0.000 claims description 6
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 6
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 6
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 claims description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 6
- 102000036693 Thrombopoietin Human genes 0.000 claims description 6
- 108010041111 Thrombopoietin Proteins 0.000 claims description 6
- 102000002938 Thrombospondin Human genes 0.000 claims description 6
- 108060008245 Thrombospondin Proteins 0.000 claims description 6
- 102000011923 Thyrotropin Human genes 0.000 claims description 6
- 108010061174 Thyrotropin Proteins 0.000 claims description 6
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 6
- 108010004977 Vasopressins Proteins 0.000 claims description 6
- 102000002852 Vasopressins Human genes 0.000 claims description 6
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 6
- 229960002833 aflibercept Drugs 0.000 claims description 6
- 229960002478 aldosterone Drugs 0.000 claims description 6
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 claims description 6
- 229960003473 androstanolone Drugs 0.000 claims description 6
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 6
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 6
- 150000004056 anthraquinones Chemical class 0.000 claims description 6
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 6
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 6
- 229940120638 avastin Drugs 0.000 claims description 6
- 210000003050 axon Anatomy 0.000 claims description 6
- 239000002774 b raf kinase inhibitor Substances 0.000 claims description 6
- 150000001556 benzimidazoles Chemical class 0.000 claims description 6
- 229960005084 calcitriol Drugs 0.000 claims description 6
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 6
- 235000020964 calcitriol Nutrition 0.000 claims description 6
- 239000011612 calcitriol Substances 0.000 claims description 6
- 210000000845 cartilage Anatomy 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 6
- 229960005395 cetuximab Drugs 0.000 claims description 6
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 229960002271 cobimetinib Drugs 0.000 claims description 6
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims description 6
- 229940104302 cytosine Drugs 0.000 claims description 6
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 6
- HXINDCTZKGGRDE-JPKZNVRTSA-L disodium;[3-[5-[2-[[(3r)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate Chemical compound [Na+].[Na+].CN1C=CC(S(=O)(=O)N2C[C@@H](CCC2)NC=2N=C(C=CN=2)C=2N3C=COC3=NC=2C=2C=C(OCOP([O-])([O-])=O)C=CC=2)=N1 HXINDCTZKGGRDE-JPKZNVRTSA-L 0.000 claims description 6
- 229940056913 eftilagimod alfa Drugs 0.000 claims description 6
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 6
- 229940082789 erbitux Drugs 0.000 claims description 6
- 229940105423 erythropoietin Drugs 0.000 claims description 6
- 229960005309 estradiol Drugs 0.000 claims description 6
- 229930182833 estradiol Natural products 0.000 claims description 6
- 229960001348 estriol Drugs 0.000 claims description 6
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 6
- 229960003399 estrone Drugs 0.000 claims description 6
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 6
- 201000000223 gallbladder squamous cell carcinoma Diseases 0.000 claims description 6
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims description 6
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 6
- 229960004666 glucagon Drugs 0.000 claims description 6
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 6
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 6
- 239000000122 growth hormone Substances 0.000 claims description 6
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 6
- 229960000890 hydrocortisone Drugs 0.000 claims description 6
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 6
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 6
- 229960002751 imiquimod Drugs 0.000 claims description 6
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 230000002584 immunomodulator Effects 0.000 claims description 6
- 239000000893 inhibin Substances 0.000 claims description 6
- 229940125396 insulin Drugs 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 229960004130 itraconazole Drugs 0.000 claims description 6
- 229960004891 lapatinib Drugs 0.000 claims description 6
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 6
- 229940039781 leptin Drugs 0.000 claims description 6
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 6
- 231100000518 lethal Toxicity 0.000 claims description 6
- 230000001665 lethal effect Effects 0.000 claims description 6
- 150000002617 leukotrienes Chemical class 0.000 claims description 6
- 229940040129 luteinizing hormone Drugs 0.000 claims description 6
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 6
- 229960000282 metronidazole Drugs 0.000 claims description 6
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical group COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 claims description 6
- 229950010514 misonidazole Drugs 0.000 claims description 6
- 229950007812 mocetinostat Drugs 0.000 claims description 6
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims description 6
- KWRYMZHCQIOOEB-LBPRGKRZSA-N n-[(1s)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=C(F)C=C2N=C1C1=CC=CC=N1 KWRYMZHCQIOOEB-LBPRGKRZSA-N 0.000 claims description 6
- 229960000858 naltrexone hydrochloride Drugs 0.000 claims description 6
- 108060005714 orexin Proteins 0.000 claims description 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 6
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 6
- 229960001723 oxytocin Drugs 0.000 claims description 6
- 239000000199 parathyroid hormone Substances 0.000 claims description 6
- 229960001319 parathyroid hormone Drugs 0.000 claims description 6
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 claims description 6
- 229950010632 perifosine Drugs 0.000 claims description 6
- 229950002592 pimasertib Drugs 0.000 claims description 6
- 230000003169 placental effect Effects 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 6
- JHDKZFFAIZKUCU-ZRDIBKRKSA-N pracinostat Chemical compound ONC(=O)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-ZRDIBKRKSA-N 0.000 claims description 6
- 229960002847 prasterone Drugs 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 229960003387 progesterone Drugs 0.000 claims description 6
- 239000000186 progesterone Substances 0.000 claims description 6
- 229940097325 prolactin Drugs 0.000 claims description 6
- 239000002877 prolactin releasing hormone Substances 0.000 claims description 6
- 150000003815 prostacyclins Chemical class 0.000 claims description 6
- 150000003180 prostaglandins Chemical class 0.000 claims description 6
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 6
- 229960004836 regorafenib Drugs 0.000 claims description 6
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 6
- 238000011160 research Methods 0.000 claims description 6
- FECGNJPYVFEKOD-VMPITWQZSA-N resminostat Chemical compound C1=CC(CN(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C(=O)NO)C=C1 FECGNJPYVFEKOD-VMPITWQZSA-N 0.000 claims description 6
- 229950002821 resminostat Drugs 0.000 claims description 6
- 102220197825 rs1057519719 Human genes 0.000 claims description 6
- 102220197823 rs121913338 Human genes 0.000 claims description 6
- 102220197909 rs121913338 Human genes 0.000 claims description 6
- 102200055453 rs121913340 Human genes 0.000 claims description 6
- 102200055449 rs121913341 Human genes 0.000 claims description 6
- 102200055517 rs121913348 Human genes 0.000 claims description 6
- 102200055523 rs121913348 Human genes 0.000 claims description 6
- 102220014058 rs121913353 Human genes 0.000 claims description 6
- 102200055451 rs121913361 Human genes 0.000 claims description 6
- 102200055461 rs121913366 Human genes 0.000 claims description 6
- 102200055434 rs121913370 Human genes 0.000 claims description 6
- 102200043531 rs140806722 Human genes 0.000 claims description 6
- 102200055501 rs180177032 Human genes 0.000 claims description 6
- 102200055521 rs180177033 Human genes 0.000 claims description 6
- 102200001486 rs397514547 Human genes 0.000 claims description 6
- 102200103547 rs398123064 Human genes 0.000 claims description 6
- 102200031604 rs750730042 Human genes 0.000 claims description 6
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 6
- 230000000580 secretagogue effect Effects 0.000 claims description 6
- 229960002101 secretin Drugs 0.000 claims description 6
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 6
- 229950003647 semaxanib Drugs 0.000 claims description 6
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 6
- PZMRMUOIKLGCDL-UHFFFAOYSA-M sodium syringate Chemical compound [Na+].COC1=CC(C([O-])=O)=CC(OC)=C1O PZMRMUOIKLGCDL-UHFFFAOYSA-M 0.000 claims description 6
- 229960005314 suramin Drugs 0.000 claims description 6
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 6
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims description 6
- 229960001967 tacrolimus Drugs 0.000 claims description 6
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 6
- 229960003604 testosterone Drugs 0.000 claims description 6
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 claims description 6
- 229960003433 thalidomide Drugs 0.000 claims description 6
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 6
- 229960003726 vasopressin Drugs 0.000 claims description 6
- 101150061136 yopJ gene Proteins 0.000 claims description 6
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 5
- QSENMPAGYMUVDE-UHFFFAOYSA-N 4-[3-chloro-4-(1-methylimidazol-2-yl)sulfanylanilino]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1NC(C=C1Cl)=CC=C1SC1=NC=CN1C QSENMPAGYMUVDE-UHFFFAOYSA-N 0.000 claims description 5
- 241001415342 Ardea Species 0.000 claims description 5
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 5
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 5
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims description 5
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 claims description 5
- 229960002450 ofatumumab Drugs 0.000 claims description 5
- 229960000639 pazopanib Drugs 0.000 claims description 5
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 5
- 229950004423 plozalizumab Drugs 0.000 claims description 5
- 102220197819 rs121913227 Human genes 0.000 claims description 5
- 102220197822 rs121913337 Human genes 0.000 claims description 5
- 102200055463 rs121913369 Human genes 0.000 claims description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 229940127121 immunoconjugate Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000008707 rearrangement Effects 0.000 claims description 4
- 102220021470 rs397509343 Human genes 0.000 claims description 4
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 3
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 229940041967 corticotropin-releasing hormone Drugs 0.000 claims description 3
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 claims description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical group C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940080856 gleevec Drugs 0.000 claims description 3
- 229960003685 imatinib mesylate Drugs 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims description 3
- UEPXBTCUIIGYCY-UHFFFAOYSA-N n-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide Chemical group C1=C(C=2C=C(N=C(OCCO)C=2)N2CCOCC2)C(C)=CC=C1NC(=O)C1=CC=NC(C(F)(F)F)=C1 UEPXBTCUIIGYCY-UHFFFAOYSA-N 0.000 claims description 3
- 102200055455 rs121913338 Human genes 0.000 claims description 3
- 102200055421 rs121913355 Human genes 0.000 claims description 3
- 229960004066 trametinib Drugs 0.000 claims description 3
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 102220117598 rs121913349 Human genes 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- WWWTWPXKLJTKPM-UHFFFAOYSA-N 2-aminooxyethanol Chemical compound NOCCO WWWTWPXKLJTKPM-UHFFFAOYSA-N 0.000 claims 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 claims 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 claims 1
- 102400000321 Glucagon Human genes 0.000 claims 1
- 102100030304 Platelet factor 4 Human genes 0.000 claims 1
- 102000009087 Prolactin-Releasing Hormone Human genes 0.000 claims 1
- 102220530866 Serine/threonine-protein kinase NLK_L357S_mutation Human genes 0.000 claims 1
- 206010054184 Small intestine carcinoma Diseases 0.000 claims 1
- 201000003761 Vaginal carcinoma Diseases 0.000 claims 1
- 229940061641 androsterone Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 claims 1
- 229940111707 ixempra Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 102200014493 rs121909124 Human genes 0.000 claims 1
- 208000020989 salivary duct carcinoma Diseases 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 26
- 230000008901 benefit Effects 0.000 abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 description 27
- 230000004044 response Effects 0.000 description 22
- 102000043136 MAP kinase family Human genes 0.000 description 19
- 108091054455 MAP kinase family Proteins 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 16
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 13
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 13
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 13
- 239000003085 diluting agent Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 239000012472 biological sample Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 125000003275 alpha amino acid group Chemical class 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 208000037821 progressive disease Diseases 0.000 description 8
- 102200055537 rs121913355 Human genes 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 7
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 229940050390 benzoate Drugs 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000002489 hematologic effect Effects 0.000 description 6
- 102000016914 ras Proteins Human genes 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 206010046885 vaginal cancer Diseases 0.000 description 6
- 208000013139 vaginal neoplasm Diseases 0.000 description 6
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 5
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 5
- 102000051325 Glucagon Human genes 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 5
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 5
- 102000004211 Platelet factor 4 Human genes 0.000 description 5
- 102100028850 Prolactin-releasing peptide Human genes 0.000 description 5
- 241000219492 Quercus Species 0.000 description 5
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 5
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 5
- 229960005471 androstenedione Drugs 0.000 description 5
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 5
- 208000021780 appendiceal neoplasm Diseases 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 229940126401 izorlisib Drugs 0.000 description 5
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 210000001581 salivary duct Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- 102000014777 Adipokines Human genes 0.000 description 4
- 108010078606 Adipokines Proteins 0.000 description 4
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 4
- 102000003964 Histone deacetylase Human genes 0.000 description 4
- 108090000353 Histone deacetylase Proteins 0.000 description 4
- 102220534326 Kynurenine formamidase_S602A_mutation Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 229940078123 Ras inhibitor Drugs 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000000478 adipokine Substances 0.000 description 4
- 229960002932 anastrozole Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 229940087861 faslodex Drugs 0.000 description 4
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- OMEUGRCNAZNQLN-UHFFFAOYSA-N isis 5132 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(S)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(O)C1 OMEUGRCNAZNQLN-UHFFFAOYSA-N 0.000 description 4
- 229960003881 letrozole Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000003488 releasing hormone Substances 0.000 description 4
- 102200115534 rs55638457 Human genes 0.000 description 4
- 102220076709 rs746079131 Human genes 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101710165567 Extracellular signal-regulated kinase 1 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 3
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 3
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 101150048834 braF gene Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229960002465 dabrafenib Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940087476 femara Drugs 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical class O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 2
- 239000005660 Abamectin Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000012623 DNA damaging agent Substances 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 101150105088 Dele1 gene Proteins 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 2
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 2
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229940126560 MAPK inhibitor Drugs 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940044684 anti-microtubule agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012350 deep sequencing Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 235000020232 peanut Nutrition 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 102000009929 raf Kinases Human genes 0.000 description 2
- 108010077182 raf Kinases Proteins 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- KSJVAYBCXSURMQ-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-[2,6-dinitro-4-(trifluoromethyl)anilino]thiourea Chemical compound C1=C(Cl)C(C)=CC=C1NC(=S)NNC1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O KSJVAYBCXSURMQ-UHFFFAOYSA-N 0.000 description 1
- NNPBSITXCGPXJC-UHFFFAOYSA-N 1-[2,6-dinitro-4-(trifluoromethyl)anilino]-3-(4-fluorophenyl)thiourea Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC([N+]([O-])=O)=C1NNC(=S)NC1=CC=C(F)C=C1 NNPBSITXCGPXJC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JCTJISIFGZHOFY-UHFFFAOYSA-N 2-(4,6-dichloro-2-methyl-1h-indol-3-yl)ethanamine Chemical compound ClC1=CC(Cl)=C2C(CCN)=C(C)NC2=C1 JCTJISIFGZHOFY-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 101150019464 ARAF gene Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 1
- 101100513486 Caenorhabditis elegans mkk-4 gene Proteins 0.000 description 1
- 101100237797 Caenorhabditis elegans mlk-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102100032606 Heat shock factor protein 1 Human genes 0.000 description 1
- 101710190344 Heat shock factor protein 1 Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 1
- 101001115390 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 5 Proteins 0.000 description 1
- 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 description 1
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 108010068305 MAP Kinase Kinase 5 Proteins 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 108010075656 MAP Kinase Kinase Kinase 2 Proteins 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 102100033058 Mitogen-activated protein kinase kinase kinase 2 Human genes 0.000 description 1
- 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 description 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 229950008486 carperitide Drugs 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000002687 childhood acute myeloid leukemia Diseases 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
- SALVHVNECODMJP-GNUCVDFRSA-N diazepinomicin Chemical compound O=C1N(C/C=C(C)/CC/C=C(C)/CCC=C(C)C)C2=CC(O)=CC(O)=C2NC2=C(O)C=CC=C21 SALVHVNECODMJP-GNUCVDFRSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940104788 entyvio Drugs 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 210000002603 extrahepatic bile duct Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229950010415 givinostat Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 1
- 102000050152 human BRAF Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000002664 langerhans' cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- 229950001750 lonafarnib Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000016035 malignant germ cell tumor of ovary Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000008042 ovarian germ cell cancer Diseases 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 208000010639 renal pelvis urothelial carcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 102220197820 rs121913227 Human genes 0.000 description 1
- 102200055469 rs121913377 Human genes 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- WUILNKCFCLNXOK-CFBAGHHKSA-N salirasib Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O WUILNKCFCLNXOK-CFBAGHHKSA-N 0.000 description 1
- 229950008669 salirasib Drugs 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 101150101156 slc51a gene Proteins 0.000 description 1
- 208000014680 small intestine neoplasm Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000000334 ureter transitional cell carcinoma Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Optics & Photonics (AREA)
- Plant Pathology (AREA)
Abstract
本发明尤其提供了用于在携带非典型BRAF突变(即非V600E/K BRAF突变)的受试者中治疗或缓解癌症的影响的方法、药物组合物和试剂盒,所述方法、药物组合物和试剂盒包含ERK抑制剂。还提供了用于鉴定将从包含ERK抑制剂的疗法中受益的患有非典型BRAF突变癌症的受试者的方法。
Description
本申请是申请号为201880040655.8的中国专利申请的分案申请。
相关申请的交叉引用
本申请要求2017年5月16日提交的美国临时专利申请号62/506,995的权益,其全部内容通过引用并入本文。
公开领域
本公开涉及使用一种或多种抗癌剂治疗或缓解具有非典型基因突变的癌症的影响的方法、试剂盒和药物组合物。
通过参考并入序列表
本申请包含对氨基酸和/或核酸序列的参考,所述氨基酸和/或核酸序列已经同时提交为序列表文本文件“2391211.txt”,文件大小为246KB,于2018年5月15日创建。根据37C.F.R.§1.52(e)(5),上述序列表通过引用全文并入本文。
发明背景
丝裂原活化蛋白激酶(MAPK)或RAS/RAF/MEK/ERK信号传导负责涉及控制增殖、分化和细胞凋亡的几种细胞信号传导途径。发现MAPK细胞信号传导途径在人类癌症中被破坏,通常是由于KRAS、NRAS或BRAF基因的活化突变。已经开发出选择性BRAF抑制剂,例如维罗非尼(vemurafenib)和达拉非尼(dabrafenib),以靶向BRAF突变肿瘤。例如,维罗非尼被批准用于具有BRAF V600E突变的不可切除或转移性黑色素瘤,并且对BRAF V600E突变的检测已成为预测对维罗非尼、达拉非尼和曲美替尼(trametinib)治疗有应答的护理标准。
尽管V600E突变是在许多肿瘤类型中观察到的最常见的BRAF突变,但是Catologof Somatic Mutations in Cancer(COSMIC)数据库已经报道了BRAF基因的外显子11和15内的100多个其他突变。在V600密码子以外的BRAF突变的临床重要性在很大程度上尚不清楚。
鉴于上述情况,需要新颖的治疗剂,该治疗剂将靶向携带除V600E以外的BRAF突变的细胞类型中的MAPK途径。本申请旨在满足这些和其他需求。
发明内容
根据一个方面,本公开提供了用于在具有非V600E/K BRAF突变的受试者中治疗或缓解癌症的影响的方法,该方法包括向受试者施用有效量的ERK抑制剂或其药学上可接受的盐。
根据一些实施方案,ERK抑制剂选自BVD-523、SCH-722984(Merck&Co.)、SCH-772984(Merck&Co.)、SCH-900353(MK-8353)(Merck&Co.)、LY3214996(Lilly)、AEZS-140(Aeterna Zentaris)、AEZS-131(Aeterna Zentaris)、AEZS-136(Aeterna Zentaris)、LTT-462(Novartis)、RG-7842(Genentech)、CC-90003(Celgene)、KIN-4050(Kinentia)及其组合。
根据一些实施方案,ERK抑制剂是BVD-523。
根据一些实施方案,非V600E/K BRAF突变是激酶活化的突变、激酶受损的突变或激酶未知的突变及其组合。
根据一些实施方案,激酶活化的突变选自R462I、I463S、G464E、G464R、G464V、G466A、G469A、N581S、E586K、F595L、L597Q、L597R、L597S、L597V、A598V、T599E、V600R、K601E、S602D、A728V及其组合。
根据一些实施方案,激酶受损的突变选自G466E、G466R、G466V、Y472C、K483M、D594A、D594E、D594G、D594H、D594N、D594V、G596R、T599A、S602A及其组合。
根据一些实施方案,激酶未知的突变选自T440I、S467L、G469E、G469R、G469S、G469V、L584F、L588F、V600_K601delinsE、S605I、Q609L、E611Q及其组合。
根据一些实施方案,非V600E/K BRAF突变选自D594、G469、K601E、L597、T599重复、L485W、F247L、G466V、BRAF融合、BRAF-AGAP3重排、BRAF外显子15剪接变体及其组合。
根据一些实施方案,受试者是哺乳动物。
根据一些实施方案,哺乳动物选自人、灵长类动物、农场动物和家养动物。
根据一些实施方案,哺乳动物是人。
根据一些实施方案,癌症是实体瘤癌症或血液癌症。
根据一些实施方案,癌症选自胶质母细胞瘤、黑素瘤、胆管癌、小细胞肺癌、结肠直肠癌、前列腺癌、阴道癌、血管肉瘤、非小细胞肺癌、阑尾癌、鳞状细胞癌、唾液管癌、腺样囊性癌、小肠癌和胆囊癌。
根据一些实施方案,癌症选自小肠癌、非小细胞肺癌、胆囊癌和鳞状细胞癌。
根据一些实施方案,该方法进一步包括向受试者施用选自MEK抑制剂、RAF抑制剂、HDAC抑制剂及其组合的至少一种另外的治疗剂。
根据一些实施方案,MEK抑制剂选自炭疽毒素、蒽醌(Golden Biotechnology)、ARRY-142886(6-(4-溴-2-氯-苯基氨基)-7-氟-3-甲基-3H-苯并咪唑-5-羧酸(2-羟基-乙氧基)-酰胺)(Array BioPharma)、ARRY-438162(Array BioPharma)贝美替尼(binimetinib)(MEK162,ARRY-1662)、AS-1940477(Astellas)、AS-703988(Merck KGaA)、bentamapimod(Merck KGaA)、BI-847325(Boehringer Ingelheim)、E-6201(Eisai)、GDC-0623(Hoffmann-La Roche)、GDC-0973(考比替尼(cobimetinib))(Hoffmann-La Roche)、L783277(Merck)、炭疽毒素的致死因子部分、MEK162(Array BioPharma)、PD 098059(2-(2'-氨基-3'-甲氧苯基)-氧萘-4-酮)(Pfizer)、PD 184352(CI-1040)(Pfizer)、PD-0325901(Pfizer)、PD318088(Pfizer)、PD334581(Pfizer)、6-甲氧基-7-(3-吗啉-4-基-丙氧基)-4-(4-苯氧基-苯基氨基)-喹啉-3-甲腈、4-[3-氯-4-(1-甲基-1H-咪唑-2-基硫烷基)-苯基氨基]-6-甲氧基-7-(3-吗啉-4-基-丙氧基)-喹啉-3-甲腈、pimasertib(pimasertib)(SantheraPharmaceuticals)、RDEA119(Ardea Biosciences/Bayer)、瑞美替尼(refametinib)(AstraZeneca)、RG422(Chugai Pharmaceutical Co.)、R0092210(Roche)、R04987655(Hoffmann-La Roche)、R05126766(Hoffmann-La Roche)、司美替尼(selumetinib)(AZD6244)(AstraZeneca)、SL327(Sigma)、TAK-733(Takeda)、曲美替尼(trametinib)(Japan Tobacco)、U0126(1,4-二氨基-2,3-二氰基-1,4-双(2-氨基苯硫基)丁二烯)(Sigma)、WX-554(Wilex)、YopJ多肽(Mittal等人,2010)、其药学上可接受的盐及其组合。
根据一些实施方案,RAF抑制剂选自AAL881(Novartis)、AB-024(AmbitBiosciences)、ARQ-736(ArQule)、ARQ-761(ArQule)、AZ628(Axon Medchem BV)、BAY 43-9006索拉非尼、BeiGene-283(BeiGene)、BUB-024(MLN 2480)(Sunesis&Takeda)、b-raf抑制剂(Sareum)、BRAF激酶抑制剂(Selexagen Therapeutics)、BRAF siRNA 313(tacaccagcaagctagatgca)和523(cctatcgttagagtcttcctg)(Liu等人,2007)、CHIR-265(Novartis)、CTT239065(Institute of Cancer Research)、达拉非尼(GSK2118436)、DP-4978(Deciphera Pharmaceuticals)、HM-95573(Hanmi)、GDC-0879(Genentech)、GW-5074(Sigma Aldrich)、ISIS 5132(Novartis)、L779450(Merck)、LBT613(Novartis)、LXH254(Novartis)、LErafAON(NeoPharm,Inc.)、LGX-818(Novartis)、帕唑帕尼(pazopanib)(GlaxoSmithKline)、PLX3202(Plexxikon)、PLX4720(Plexxikon)、PLX5568(Plexxikon)、PLX3603(Daiichi Sankyo)、PLX8394(Daiichi Sankyo)、RAF-265(Novartis)、RAF-365(Novartis)、REDX0535(RedX Pharma Plc)、瑞戈非尼(regorafenib)(Bayer HealthcarePharmaceuticals,Inc.)、RO 5126766(Hoffmann-La Roche)、SB-590885(GlaxoSmithKline)、SB699393(GlaxoSmithKline)、索拉非尼(sorafenib)(OnyxPharmaceuticals)、TAK 632(Takeda)、TL-241(Teligene)、维拉非尼(vemurafenib)(RG7204或PLX4032)(Daiichi Sankyo)、XL-281(Exelixis)、ZM-336372(AstraZeneca)、其药学上可接受的盐及其组合。
根据一些实施方案,HDAC抑制剂选自艾贝司他(Abexinostat)(PCI-24781)、吉诺司他(Givinostat)、恩替司他(Entinostat)、扶林司他(Vorinostat)、CI-994、CUDC-101、恩替司他(Entinostat)、BML-210、M344、NVP-LAQ824、帕比司他(Panobinostat)、Pracinosat(SB939)、Mocetinostat、Resminostat、罗米地辛(Romidepsin)、贝利诺司他(Belinostat)、其药学上可接受的盐及其组合。
根据一些实施方案,该方法进一步包括向受试者施用选自抗体、抗体片段、抗体缀合物、细胞毒性剂、毒素、放射性核素、免疫调控剂、光活化治疗剂、放射增敏剂、激素、抗血管生成剂及其组合的至少一种另外的治疗剂。
根据一些实施方案,抗体、其片段或其缀合物选自利妥昔单抗(Rituxan)、布伦妥昔单抗维多汀(Brentuximab Vedotin)(Adcetriz)、阿多曲妥珠单抗艾坦肽(Ado-trastuzumab emtansine)(Kadcyla)西妥昔单抗(Erbitux)、贝伐单抗(bevacizumab)(Avastin)、替伊莫单抗(Ibritumomab)(Zevalin)、维多珠单抗(vedolizumab)(Entyvio)、伊匹单抗(Ipilimumab)(Yervoy)、纳武单抗(Nivolumab)(Opdivo)、派姆单抗(pembrolizumab)(Keytruda)、阿伦单抗(Alemtuzamab)阿特朱单抗(atezolizumab)(Tecentriq)、阿维鲁单抗(avelumab)(Bavencio)、德鲁瓦单抗(durvalumab)(Imfinzi)、B-701、奥法木单抗(Ofatumumab)、阿托珠单抗(Obinutuzumab)(Gazyva)帕尼单抗(Panitumumab)、plozalizumab、BI-754091、OREG-103、COM-701、BI-754111及其组合。
根据一些实施方案,细胞毒性剂选自环磷酰胺、甲氯乙胺、尿嘧啶氮芥、美法仑、苯丁酸甲氯乙胺、异环磷酰胺、卡莫司汀、洛莫司汀、链脲霉素、白消安、替莫唑胺、顺铂、卡铂、奥沙利铂、奈达铂、沙铂、三硝酸四铂、阿霉素、柔红霉素、伊达比星、米托蒽醌、甲氨蝶呤、培美曲塞、6-巯基嘌呤、达卡巴嗪、氟达拉滨、5-氟尿嘧啶、阿拉伯糖胞嘧啶、卡培他滨、吉西他滨、地西他滨、长春花生物碱、紫杉醇(Taxol)、多西他赛(Taxotere)、依沙贝比隆(Ixempra)、放线菌素、蒽环类、缬沙星、表柔比星、博来霉素、普卡霉素、丝裂霉素、其药学上可接受的盐、前药及其组合。
根据一些实施方案,毒素是白喉毒素或其部分。
根据一些实施方案,放射性核素选自I-125、At-211、Lu-177、Cu-67、I-131、Sm-153、Re-186、P-32、Re-188、In-114m、Y-90及其组合。
根据一些实施方案,免疫调控剂选自粒细胞集落刺激因子(G-CSF)、LAG-3、IMP-321、JCAR-014、ASLAN-002(BMS-777607)、干扰素、咪喹莫特和来自细菌的细胞膜组分、IL-2、IL-7、IL-12、CCL3、CCL26、CXCL7、合成的胞嘧啶磷酸鸟苷(CpG)、免疫检查点抑制剂及其组合。
根据一些实施方案,放射增敏剂选自米索硝唑、甲硝唑、替拉帕明、反式丁香酸钠及其组合。
根据一些实施方案,激素选自前列腺素、白三烯、前列环素、血栓烷、淀粉纤维素、抗苗勒管激素、脂联素、促肾上腺皮质激素、血管紧张素原、血管紧张素、血管加压素、心房肽(atriopeptin)、脑钠尿肽、降血钙素、胆囊收缩素、促肾上腺皮质激素释放激素、脑啡肽、内皮素、促红细胞生成素、促卵泡激素、甘丙肽、胃泌素、生长激素释放肽、胰高血糖素、促性腺激素释放激素、生长激素释放激素、人绒毛膜促性腺激素、人胎盘促泌素、生长激素、抑制素、胰岛素、生长调节素(somatomedin)、瘦素、促脂素、促黄体生成素、黑素细胞刺激激素、胃动素、食欲素、催产素、胰多肽、甲状旁腺激素、催乳素、催乳素释放激素、松弛素、肾素、分泌素、生长抑素(somatostain)、血小板生成素、促甲状腺激素、睾丸酮、脱氢表雄酮、雄烯二酮、二氢睾丸酮、醛固酮、雌二醇、雌酮、雌三醇、皮质醇、孕酮、骨化三醇、骨化二醇、他莫昔芬(Nolvadex)、阿那曲唑(Arimidex)、来曲唑(Femara)、氟司韦特(Faslodex)及其组合。
根据一些实施方案,抗血管生成剂选自2-甲氧基雌二醇、血管抑制素、贝伐单抗、软骨衍生的血管生成抑制因子、内皮抑素、IFN-α、IL-12、伊曲康唑、利诺米特、血小板因子4、催乳素、SU5416、苏拉明、他克莫尼、替加仑、四硫代钼酸盐、沙利度胺、血小板反应蛋白、血小板反应蛋白、TNP-470、齐夫-阿柏西普、其药学上可接受的盐、前药及其组合。
根据一些实施方案,另外的治疗剂是PI3K/Akt途径的抑制剂。
根据一些实施方案,PI3K/Akt途径的抑制剂选自A-674563(CAS#552325-73-2)、AGL 2263、AMG-319(Amgen,Thousand Oaks,CA)、AS-041164(5-苯并[1,3]二恶唑-5-基亚甲基-噻唑烷-2,4-二酮)、AS-604850(5-(2,2-二氟-苯并[1,3]二恶唑-5-基亚甲基)-噻唑烷-2,4-二酮)、AS-605240(5-喹喔啉-6-亚甲基-1,3-噻唑烷-2,4-二酮)、AT7867(CAS#857531-00-1)、苯并咪唑系列,Genentech(Roche Holdings Inc.,South San Francisco,CA)、BML-257(CAS#32387-96-5)、BVD-723、CAL-120(Gilead Sciences,Foster City,CA)、CAL-129(Gilead Sciences)、CAL-130(Gilead Sciences)、CAL-253(Gilead Sciences)、CAL-263(Gilead Sciences)、CAS#612847-09-3、CAS#681281-88-9、CAS#75747-14-7、CAS#925681-41-0、CAS#98510-80-6、CCT128930(CAS#885499-61-6)、CH5132799(CAS#1007207-67-1)、CHR-4432(Chroma Therapeutics,Ltd.,Abingdon,UK)、FPA 124(CAS#902779-59-3)、GS-1101(CAL-101)(Gilead Sciences)、GSK 690693(CAS#937174-76-0)、H-89(CAS#127243-85-0)、Honokiol、IC87114(Gilead Science)、IPI-145(Intellikine Inc.)、KAR-4139(Karus Therapeutics,Chilworth,UK)、KAR-4141(Karus Therapeutics)、KIN-1(KarusTherapeutics)、KT 5720(CAS#108068-98-0)、米替福新(Miltefosine)、MK-2206二盐酸化物(CAS#1032350-13-2)、ML-9(CAS#105637-50-1)、盐酸纳曲通、OXY-111A(NormOxys Inc.,Brighton,MA)、perifosine、PHT-427(CAS#1191951-57-1)、PI3激酶δ抑制剂,Merck KGaA(Merck&Co.,Whitehouse Station,NJ)、PI3激酶δ抑制剂,Genentech(Roche HoldingsInc.)、PI3激酶δ抑制剂,Incozen(Incozen Therapeutics,Pvt.Ltd.,Hydrabad,India)、PI3激酶δ抑制剂2,Incozen(Incozen Therapeutics)、PI3激酶抑制剂,Roche-4(RocheHoldings Inc.)、PI3激酶抑制剂,Roche(Roche Holdings Inc.)、PI3激酶抑制剂,Roche-5(Roche Holdings Inc.)、PI3-α/δ抑制剂,Pathway Therapeutics(Pathway TherapeuticsLtd.,South San Francisco,CA)、PI3-δ抑制剂,Cellzome(Cellzome AG,Heidelberg,Germany)、PI3-δ抑制剂,Intellikine(Intellikine Inc.,La Jolla,CA)、PI3-δ抑制剂,Pathway Therapeutics-1(Pathway Therapeutics Ltd.)、PI3-δ抑制剂,PathwayTherapeutics-2(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,Cellzome(CellzomeAG)、PI3-δ/γ抑制剂,Cellzome(Cellzome AG)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Pathway Therapeutics(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,PathwayTherapeutics(Pathway Therapeutics Ltd.)、PI3-γ抑制剂,Evotec(Evotec)、PI3-γ抑制剂,Cellzome(Cellzome AG)、PI3-γ抑制剂,Pathway Therapeutics(PathwayTherapeutics Ltd.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、pictilisib(Roche Holdings Inc.)、PIK-90(CAS#677338-12-4)、SC-103980(Pfizer,New York,NY)、SF-1126(SemaforePharmaceuticals,Indianapolis,IN)、SH-5、SH-6、四氢姜黄素、TG100-115(TargegenInc.,San Diego,CA)、曲西瑞宾(Triciribine)、X-339(Xcovery,West Palm Beach,FL)、XL-499(Evotech,Hamburg,Germany)、其药学上可接受的盐及其组合。
根据一个方面,本公开内容提供了用于在受试者中治疗或缓解癌症的影响的方法,包括:(a)鉴定携带非V600E/K BRAF突变的患有癌症的受试者;和(b)对受试者施用有效量的ERK抑制剂或其药学上可接受的盐。
根据一些实施方案,ERK抑制剂选自BVD-523、SCH-722984(Merck&Co.)、SCH-772984(Merck&Co.)、SCH-900353(MK-8353)(Merck&Co.)、LY3214996(Lilly)、AEZS-140(Aeterna Zentaris)、AEZS-131(Aeterna Zentaris)、AEZS-136(Aeterna Zentaris)、LTT-462(Novartis)、RG-7842(Genentech)、CC-90003(Celgene)、KIN-4050(Kinentia)及其组合。
根据一些实施方案,ERK抑制剂是BVD-523。
根据一些实施方案,非V600E/K BRAF突变是激酶活化的突变、激酶受损的突变或激酶未知的突变及其组合。
根据一些实施方案,激酶活化的突变选自R462I、I463S、G464E、G464R、G464V、G466A、G469A、N581S、E586K、F595L、L597Q、L597R、L597S、L597V、A598V、T599E、V600R、K601E、S602D、A728V及其组合。
根据一些实施方案,激酶受损的突变选自G466E、G466R、G466V、Y472C、K483M、D594A、D594E、D594G、D594H、D594N、D594V、G596R、T599A、S602A及其组合。
根据一些实施方案,激酶未知的突变选自T440I、S467L、G469E、G469R、G469S、G469V、L584F、L588F、V600_K601delinsE、S605I、Q609L、E611Q及其组合。
根据一些实施方案,受试者是哺乳动物。
根据一些实施方案,哺乳动物选自人、灵长类动物、农场动物和家养动物。
根据一些实施方案,哺乳动物是人。
根据一些实施方案,癌症是实体瘤癌症或血液癌症。
根据一些实施方案,癌症选自胶质母细胞瘤、黑素瘤、胆管癌、小细胞肺癌、结肠直肠癌、前列腺癌、阴道癌、血管肉瘤、非小细胞肺癌、阑尾癌、鳞状细胞癌、唾液管癌、腺样囊性癌、小肠癌和胆囊癌。
根据一些实施方案,癌症选自小肠癌、非小细胞肺癌、胆囊癌和鳞状细胞癌。
根据一些实施方案,该方法进一步包括:(i)从受试者获得生物样品;和(ii)筛选样品以确定受试者是否具有非V600E/K BRAF突变。
根据一些实施方案,该方法进一步包括向受试者施用选自MEK抑制剂、RAF抑制剂、HDAC抑制剂及其组合的至少一种另外的治疗剂。
根据一些实施方案,MEK抑制剂选自炭疽毒素、蒽醌(Golden Biotechnology)、ARRY-142886(6-(4-溴-2-氯-苯基氨基)-7-氟-3-甲基-3H-苯并咪唑-5-羧酸(2-羟基-乙氧基)-酰胺)(Array BioPharma)、ARRY-438162(Array BioPharma)贝美替尼(MEK162,ARRY-1662)、AS-1940477(Astellas)、AS-703988(Merck KGaA)、bentamapimod(Merck KGaA)、BI-847325(Boehringer Ingelheim)、E-6201(Eisai)、GDC-0623(Hoffmann-La Roche)、GDC-0973(考比替尼)(Hoffmann-La Roche)、L783277(Merck)、炭疽毒素的致死因子部分、MEK162(Array BioPharma)、PD 098059(2-(2'-氨基-3'-甲氧苯基)-氧萘-4-酮)(Pfizer)、PD 184352(CI-1040)(Pfizer)、PD-0325901(Pfizer)、PD318088(Pfizer)、PD334581(Pfizer)、6-甲氧基-7-(3-吗啉-4-基-丙氧基)-4-(4-苯氧基-苯基氨基)-喹啉-3-甲腈、4-[3-氯-4-(1-甲基-1H-咪唑-2-基硫烷基)-苯基氨基]-6-甲氧基-7-(3-吗啉-4-基-丙氧基)-喹啉-3-甲腈、pimasertib(Santhera Pharmaceuticals)、RDEA119(ArdeaBiosciences/Bayer)、瑞美替尼(refametinib)(AstraZeneca)、RG422(ChugaiPharmaceutical Co.)、R0092210(Roche)、R04987655(Hoffmann-La Roche)、R05126766(Hoffmann-La Roche)、司美替尼(selumetinib)(AZD6244)(AstraZeneca)、SL327(Sigma)、TAK-733(Takeda)、曲美替尼(trametinib)(Japan Tobacco)、U0126(1,4-二氨基-2,3-二氰基-1,4-双(2-氨基苯硫基)丁二烯)(Sigma)、WX-554(Wilex)、YopJ多肽(Mittal等人,2010)、其药学上可接受的盐及其组合。
根据一些实施方案,RAF抑制剂选自AAL881(Novartis)、AB-024(AmbitBiosciences)、ARQ-736(ArQule)、ARQ-761(ArQule)、AZ628(Axon Medchem BV)、BAY 43-9006索拉非尼、BeiGene-283(BeiGene)、BUB-024(MLN 2480)(Sunesis&Takeda)、b-raf抑制剂(Sareum)、BRAF激酶抑制剂(Selexagen Therapeutics)、BRAF siRNA 313(tacaccagcaagctagatgca)和523(cctatcgttagagtcttcctg)(Liu等人,2007)、CHIR-265(Novartis)、CTT239065(Institute of Cancer Research)、达拉非尼(GSK2118436)、DP-4978(Deciphera Pharmaceuticals)、HM-95573(Hanmi)、GDC-0879(Genentech)、GW-5074(Sigma Aldrich)、ISIS 5132(Novartis)、L779450(Merck)、LBT613(Novartis)、LXH254(Novartis)、LErafAON(NeoPharm,Inc.)、LGX-818(Novartis)、帕唑帕尼(GlaxoSmithKline)、PLX3202(Plexxikon)、PLX4720(Plexxikon)、PLX5568(Plexxikon)、PLX3603(Daiichi Sankyo)、PLX8394(Daiichi Sankyo)、RAF-265(Novartis)、RAF-365(Novartis)、REDX0535(RedX Pharma Plc)、瑞戈非尼(Bayer HealthcarePharmaceuticals,Inc.)、RO 5126766(Hoffmann-La Roche)、SB-590885(GlaxoSmithKline)、SB699393(GlaxoSmithKline)、索拉非尼(Onyx Pharmaceuticals)、TAK 632(Takeda)、TL-241(Teligene)、维拉非尼(RG7204或PLX4032)(Daiichi Sankyo)、XL-281(Exelixis)、ZM-336372(AstraZeneca)、其药学上可接受的盐及其组合。
根据一些实施方案,HDAC抑制剂选自艾贝司他(PCI-24781)、吉诺司他、恩替司他、扶林司他、CI-994、CUDC-101、恩替司他、BML-210、M344、NVP-LAQ824、帕比司他、Pracinosat(SB939)、Mocetinostat、Resminostat、罗米地辛、贝利诺司他、其药学上可接受的盐及其组合。
根据一些实施方案,该方法进一步包括向受试者施用选自抗体或其片段、细胞毒性剂、毒素、放射性核素、免疫调控剂、光活化治疗剂、放射增敏剂、激素、抗血管生成剂及其组合的至少一种另外的治疗剂。
根据一些实施方案,抗体、其片段或其缀合物选自利妥昔单抗(Rituxan)、布伦妥昔单抗维多汀(Adcetriz)、阿多曲妥珠单抗艾坦肽(Kadcyla)西妥昔单抗(Erbitux)、贝伐单抗(Avastin)、替伊莫单抗(Zevalin)、维多珠单抗(Entyvio)、伊匹单抗(Yervoy)、纳武单抗(Opdivo)、派姆单抗(Keytruda)、阿伦单抗阿特朱单抗(Tecentriq)、阿维鲁单抗(Bavencio)、德鲁瓦单抗(Imfinzi)、B-701、奥法木单抗、阿托珠单抗(Gazyva)帕尼单抗、plozalizumab、BI-754091、OREG-103、COM-701、BI-754111及其组合。
根据一些实施方案,细胞毒性剂选自环磷酰胺、甲氯乙胺、尿嘧啶氮芥、美法仑、苯丁酸甲氯乙胺、异环磷酰胺、卡莫司汀、洛莫司汀、链脲霉素、白消安、替莫唑胺、顺铂、卡铂、奥沙利铂、奈达铂、沙铂、三硝酸四铂、阿霉素、柔红霉素、伊达比星、米托蒽醌、甲氨蝶呤、培美曲塞、6-巯基嘌呤、达卡巴嗪、氟达拉滨、5-氟尿嘧啶、阿拉伯糖胞嘧啶、卡培他滨、吉西他滨、地西他滨、长春花生物碱、紫杉醇(Taxol)、多西他赛(Taxotere)、依沙贝比隆(Ixempra)、放线菌素、蒽环类、缬沙星、表柔比星、博来霉素、普卡霉素、丝裂霉素、其药学上可接受的盐、前药及其组合。
根据一些实施方案,毒素是白喉毒素或其部分。
根据一些实施方案,放射性核素选自I-125、At-211、Lu-177、Cu-67、I-131、Sm-153、Re-186、P-32、Re-188、In-114m、Y-90及其组合。
根据一些实施方案,免疫调控剂选自粒细胞集落刺激因子(G-CSF)、LAG-3、IMP-321、JCAR-014、ASLAN-002(BMS-777607)、干扰素、咪喹莫特和来自细菌的细胞膜组分、IL-2、IL-7、IL-12、CCL3、CCL26、CXCL7、合成的胞嘧啶磷酸鸟苷(CpG)、免疫检查点抑制剂及其组合。
根据一些实施方案,放射增敏剂选自米索硝唑、甲硝唑、替拉帕明、反式丁香酸钠及其组合。
根据一些实施方案,激素选自前列腺素、白三烯、前列环素、血栓烷、淀粉纤维素、抗苗勒管激素、脂联素、促肾上腺皮质激素、血管紧张素原、血管紧张素、血管加压素、心房肽、脑钠尿肽、降血钙素、胆囊收缩素、促肾上腺皮质激素释放激素、脑啡肽、内皮素、促红细胞生成素、促卵泡激素、甘丙肽、胃泌素、生长激素释放肽、胰高血糖素、促性腺激素释放激素、生长激素释放激素、人绒毛膜促性腺激素、人胎盘促泌素、生长激素、抑制素、胰岛素、生长调节素、瘦素、促脂素、促黄体生成素、黑素细胞刺激激素、胃动素、食欲素、催产素、胰多肽、甲状旁腺激素、催乳素、催乳素释放激素、松弛素、肾素、分泌素、生长抑素、血小板生成素、促甲状腺激素、睾丸酮、脱氢表雄酮、雄烯二酮、二氢睾丸酮、醛固酮、雌二醇、雌酮、雌三醇、皮质醇、孕酮、骨化三醇、骨化二醇、他莫昔芬(Nolvadex)、阿那曲唑(Arimidex)、来曲唑(Femara)、氟司韦特(Faslodex)及其组合。
根据一些实施方案,抗血管生成剂选自2-甲氧基雌二醇、血管抑制素、贝伐单抗、软骨衍生的血管生成抑制因子、内皮抑素、IFN-α、IL-12、伊曲康唑、利诺米特、血小板因子4、催乳素、SU5416、苏拉明、他克莫尼、替加仑、四硫代钼酸盐、沙利度胺、血小板反应蛋白、血小板反应蛋白、TNP-470、齐夫-阿柏西普、其药学上可接受的盐、前药及其组合。
根据一些实施方案,另外的治疗剂是PI3K/Akt途径的抑制剂。
根据一些实施方案,PI3K/Akt途径的抑制剂选自A-674563(CAS#552325-73-2)、AGL 2263、AMG-319(Amgen,Thousand Oaks,CA)、AS-041164(5-苯并[1,3]二恶唑-5-基亚甲基-噻唑烷-2,4-二酮)、AS-604850(5-(2,2-二氟-苯并[1,3]二恶唑-5-基亚甲基)-噻唑烷-2,4-二酮)、AS-605240(5-喹喔啉-6-亚甲基-1,3-噻唑烷-2,4-二酮)、AT7867(CAS#857531-00-1)、苯并咪唑系列,Genentech(Roche Holdings Inc.,South San Francisco,CA)、BML-257(CAS#32387-96-5)、BVD-723、CAL-120(Gilead Sciences,Foster City,CA)、CAL-129(Gilead Sciences)、CAL-130(Gilead Sciences)、CAL-253(Gilead Sciences)、CAL-263(Gilead Sciences)、CAS#612847-09-3、CAS#681281-88-9、CAS#75747-14-7、CAS#925681-41-0、CAS#98510-80-6、CCT128930(CAS#885499-61-6)、CH5132799(CAS#1007207-67-1)、CHR-4432(Chroma Therapeutics,Ltd.,Abingdon,UK)、FPA 124(CAS#902779-59-3)、GS-1101(CAL-101)(Gilead Sciences)、GSK 690693(CAS#937174-76-0)、H-89(CAS#127243-85-0)、Honokiol、IC87114(Gilead Science)、IPI-145(Intellikine Inc.)、KAR-4139(Karus Therapeutics,Chilworth,UK)、KAR-4141(Karus Therapeutics)、KIN-1(KarusTherapeutics)、KT 5720(CAS#108068-98-0)、米替福新、MK-2206二盐酸化物(CAS#1032350-13-2)、ML-9(CAS#105637-50-1)、盐酸纳曲通、OXY-111A(NormOxys Inc.,Brighton,MA)、perifosine、PHT-427(CAS#1191951-57-1)、PI3激酶δ抑制剂,Merck KGaA(Merck&Co.,Whitehouse Station,NJ)、PI3激酶δ抑制剂,Genentech(Roche HoldingsInc.)、PI3激酶δ抑制剂,Incozen(Incozen Therapeutics,Pvt.Ltd.,Hydrabad,India)、PI3激酶δ抑制剂2,Incozen(Incozen Therapeutics)、PI3激酶抑制剂,Roche-4(RocheHoldings Inc.)、PI3激酶抑制剂,Roche(Roche Holdings Inc.)、PI3激酶抑制剂,Roche-5(Roche Holdings Inc.)、PI3-α/δ抑制剂,Pathway Therapeutics(Pathway TherapeuticsLtd.,South San Francisco,CA)、PI3-δ抑制剂,Cellzome(Cellzome AG,Heidelberg,Germany)、PI3-δ抑制剂,Intellikine(Intellikine Inc.,La Jolla,CA)、PI3-δ抑制剂,Pathway Therapeutics-1(Pathway Therapeutics Ltd.)、PI3-δ抑制剂,PathwayTherapeutics-2(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,Cellzome(CellzomeAG)、PI3-δ/γ抑制剂,Cellzome(Cellzome AG)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Pathway Therapeutics(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,PathwayTherapeutics(Pathway Therapeutics Ltd.)、PI3-γ抑制剂,Evotec(Evotec)、PI3-γ抑制剂,Cellzome(Cellzome AG)、PI3-γ抑制剂,Pathway Therapeutics(PathwayTherapeutics Ltd.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、pictilisib(Roche Holdings Inc.)、PIK-90(CAS#677338-12-4)、SC-103980(Pfizer,New York,NY)、SF-1126(SemaforePharmaceuticals,Indianapolis,IN)、SH-5、SH-6、四氢姜黄素、TG100-115(TargegenInc.,San Diego,CA)、曲西瑞宾、X-339(Xcovery,West Palm Beach,FL)、XL-499(Evotech,Hamburg,Germany)、其药学上可接受的盐及其组合。
根据一个方面,本公开内容提供了鉴定将从ERK抑制剂或其药学上可接受的盐的疗法中受益的患有癌症的受试者的方法,该方法包括:(a)从受试者获得生物样品;和(b)筛选样品以确定受试者是否具有非V600E/K BRAF突变,
其中非V600E/K BRAF突变的存在证实受试者将从ERK抑制剂或其药学上可接受的盐的疗法中受益。
根据一些实施方案,ERK抑制剂选自BVD-523、SCH-722984(Merck&Co.)、SCH-772984(Merck&Co.)、SCH-900353(MK-8353)(Merck&Co.)、LY3214996(Lilly)、AEZS-140(Aeterna Zentaris)、AEZS-131(Aeterna Zentaris)、AEZS-136(Aeterna Zentaris)、LTT-462(Novartis)、RG-7842(Genentech)、CC-90003(Celgene)、KIN-4050(Kinentia)及其组合。
根据一些实施方案,ERK抑制剂是BVD-523。
根据一些实施方案,非V600E/K BRAF突变是激酶活化的突变、激酶受损的突变或激酶未知的突变及其组合。
根据一些实施方案,激酶活化的突变选自R462I、I463S、G464E、G464R、G464V、G466A、G469A、N581S、E586K、F595L、L597Q、L597R、L597S、L597V、A598V、T599E、V600R、K601E、S602D、A728V及其组合。
根据一些实施方案,激酶受损的突变选自G466E、G466R、G466V、Y472C、K483M、D594A、D594E、D594G、D594H、D594N、D594V、G596R、T599A、S602A及其组合。
根据一些实施方案,激酶未知的突变选自T440I、S467L、G469E、G469R、G469S、G469V、L584F、L588F、V600_K601delinsE、S605I、Q609L、E611Q及其组合。
根据一些实施方案,受试者是哺乳动物。
根据一些实施方案,哺乳动物选自人、灵长类动物、农场动物和家养动物。
根据一些实施方案,哺乳动物是人。
根据一些实施方案,癌症是实体瘤癌症或血液癌症。
根据一些实施方案,癌症选自胶质母细胞瘤、黑素瘤、胆管癌、小细胞肺癌、结肠直肠癌、前列腺癌、阴道癌、血管肉瘤、非小细胞肺癌、阑尾癌、鳞状细胞癌、唾液管癌、腺样囊性癌、小肠癌和胆囊癌。
根据一些实施方案,癌症选自小肠癌、非小细胞肺癌、胆囊癌和鳞状细胞癌。
根据一些实施方案,该方法进一步包括将ERK抑制剂或其药学上可接受的盐施用给具有非V600E/K BRAF突变的受试者。
根据一些实施方案,该方法进一步包括向受试者施用选自MEK抑制剂、RAF抑制剂、HDAC抑制剂及其组合的至少一种另外的治疗剂。
根据一些实施方案,MEK抑制剂选自炭疽毒素、蒽醌(Golden Biotechnology)、ARRY-142886(6-(4-溴-2-氯-苯基氨基)-7-氟-3-甲基-3H-苯并咪唑-5-羧酸(2-羟基-乙氧基)-酰胺)(Array BioPharma)、ARRY-438162(Array BioPharma)贝美替尼(MEK162,ARRY-1662)、AS-1940477(Astellas)、AS-703988(Merck KGaA)、bentamapimod(Merck KGaA)、BI-847325(Boehringer Ingelheim)、E-6201(Eisai)、GDC-0623(Hoffmann-La Roche)、GDC-0973(考比替尼)(Hoffmann-La Roche)、L783277(Merck)、炭疽毒素的致死因子部分、MEK162(Array BioPharma)、PD 098059(2-(2'-氨基-3'-甲氧苯基)-氧萘-4-酮)(Pfizer)、PD 184352(CI-1040)(Pfizer)、PD-0325901(Pfizer)、PD318088(Pfizer)、PD334581(Pfizer)、6-甲氧基-7-(3-吗啉-4-基-丙氧基)-4-(4-苯氧基-苯基氨基)-喹啉-3-甲腈、4-[3-氯-4-(1-甲基-1H-咪唑-2-基硫烷基)-苯基氨基]-6-甲氧基-7-(3-吗啉-4-基-丙氧基)-喹啉-3-甲腈、pimasertib(Santhera Pharmaceuticals)、RDEA119(ArdeaBiosciences/Bayer)、瑞美替尼(AstraZeneca)、RG422(Chugai Pharmaceutical Co.)、R0092210(Roche)、R04987655(Hoffmann-La Roche)、R05126766(Hoffmann-La Roche)、司美替尼(AZD6244)(AstraZeneca)、SL327(Sigma)、TAK-733(Takeda)、曲美替尼(JapanTobacco)、U0126(1,4-二氨基-2,3-二氰基-1,4-双(2-氨基苯硫基)丁二烯)(Sigma)、WX-554(Wilex)、YopJ多肽(Mittal等人,2010)、其药学上可接受的盐及其组合。
根据一些实施方案,RAF抑制剂选自AAL881(Novartis)、AB-024(AmbitBiosciences)、ARQ-736(ArQule)、ARQ-761(ArQule)、AZ628(Axon Medchem BV)、BAY 43-9006索拉非尼、BeiGene-283(BeiGene)、BUB-024(MLN 2480)(Sunesis&Takeda)、b-raf抑制剂(Sareum)、BRAF激酶抑制剂(Selexagen Therapeutics)、BRAF siRNA 313(tacaccagcaagctagatgca)和523(cctatcgttagagtcttcctg)(Liu等人,2007)、CHIR-265(Novartis)、CTT239065(Institute of Cancer Research)、达拉非尼(GSK2118436)、DP-4978(Deciphera Pharmaceuticals)、HM-95573(Hanmi)、GDC-0879(Genentech)、GW-5074(Sigma Aldrich)、ISIS 5132(Novartis)、L779450(Merck)、LBT613(Novartis)、LXH254(Novartis)、LErafAON(NeoPharm,Inc.)、LGX-818(Novartis)、帕唑帕尼(GlaxoSmithKline)、PLX3202(Plexxikon)、PLX4720(Plexxikon)、PLX5568(Plexxikon)、PLX3603(Daiichi Sankyo)、PLX8394(Daiichi Sankyo)、RAF-265(Novartis)、RAF-365(Novartis)、REDX0535(RedX Pharma Plc)、瑞戈非尼(Bayer HealthcarePharmaceuticals,Inc.)、RO 5126766(Hoffmann-La Roche)、SB-590885(GlaxoSmithKline)、SB699393(GlaxoSmithKline)、索拉非尼(Onyx Pharmaceuticals)、TAK 632(Takeda)、TL-241(Teligene)、维拉非尼(RG7204或PLX4032)(Daiichi Sankyo)、XL-281(Exelixis)、ZM-336372(AstraZeneca)、其药学上可接受的盐及其组合。
根据一些实施方案,HDAC抑制剂选自艾贝司他(PCI-24781)、吉诺司他、恩替司他、扶林司他、CI-994、CUDC-101、恩替司他、BML-210、M344、NVP-LAQ824、帕比司他、Pracinosat(SB939)、Mocetinostat、Resminostat、罗米地辛、贝利诺司他、其药学上可接受的盐及其组合。
根据一些实施方案,该方法进一步包括向具有非V600E/K BRAF突变的受试者施用选自抗体、抗体片段、抗体缀合物、细胞毒性剂、毒素、放射性核素、免疫调控剂、光活化治疗剂、放射增敏剂、激素、抗血管生成剂及其组合的至少一种另外的治疗剂。
根据一些实施方案,抗体或其片段选自利妥昔单抗(Rituxan)、布伦妥昔单抗维多汀(Adcetriz)、阿多曲妥珠单抗艾坦肽(Kadcyla)西妥昔单抗(Erbitux)、贝伐单抗(Avastin)、替伊莫单抗(Zevalin)、维多珠单抗(Entyvio)、伊匹单抗(Yervoy)、纳武单抗(Opdivo)、派姆单抗(Keytruda)、阿伦单抗阿特朱单抗(Tecentriq)、阿维鲁单抗(Bavencio)、德鲁瓦单抗(Imfinzi)、B-701、奥法木单抗、阿托珠单抗(Obinutuzumab)(Gazyva)帕尼单抗、plozalizumab、BI-754091、OREG-103、COM-701、BI-754111及其组合。
根据一些实施方案,细胞毒性剂选自环磷酰胺、甲氯乙胺、尿嘧啶氮芥、美法仑、苯丁酸甲氯乙胺、异环磷酰胺、卡莫司汀、洛莫司汀、链脲霉素、白消安、替莫唑胺、顺铂、卡铂、奥沙利铂、奈达铂、沙铂、三硝酸四铂、阿霉素、柔红霉素、伊达比星、米托蒽醌、甲氨蝶呤、培美曲塞、6-巯基嘌呤、达卡巴嗪、氟达拉滨、5-氟尿嘧啶、阿拉伯糖胞嘧啶、卡培他滨、吉西他滨、地西他滨、长春花生物碱、紫杉醇(Taxol)、多西他赛(Taxotere)、依沙贝比隆(Ixempra)、放线菌素、蒽环类、缬沙星、表柔比星、博来霉素、普卡霉素、丝裂霉素、其药学上可接受的盐、前药及其组合。
根据一些实施方案,毒素是白喉毒素或其部分。
根据一些实施方案,放射性核素选自I-125、At-211、Lu-177、Cu-67、I-131、Sm-153、Re-186、P-32、Re-188、In-114m、Y-90及其组合。
根据一些实施方案,免疫调控剂选自粒细胞集落刺激因子(G-CSF)、LAG-3、IMP-321、JCAR-014、ASLAN-002(BMS-777607)、干扰素、咪喹莫特和来自细菌的细胞膜组分、IL-2、IL-7、IL-12、CCL3、CCL26、CXCL7、合成的胞嘧啶磷酸鸟苷(CpG)、免疫检查点抑制剂及其组合。
根据一些实施方案,放射增敏剂选自米索硝唑、甲硝唑、替拉帕明、反式丁香酸钠及其组合。
根据一些实施方案,激素选自前列腺素、白三烯、前列环素、血栓烷、淀粉纤维素、抗苗勒管激素、脂联素、促肾上腺皮质激素、血管紧张素原、血管紧张素、血管加压素、心房肽、脑钠尿肽、降血钙素、胆囊收缩素、促肾上腺皮质激素释放激素、脑啡肽、内皮素、促红细胞生成素、促卵泡激素、甘丙肽、胃泌素、生长激素释放肽、胰高血糖素、促性腺激素释放激素、生长激素释放激素、人绒毛膜促性腺激素、人胎盘促泌素、生长激素、抑制素、胰岛素、生长调节素、瘦素、促脂素、促黄体生成素、黑素细胞刺激激素、胃动素、食欲素、催产素、胰多肽、甲状旁腺激素、催乳素、催乳素释放激素、松弛素、肾素、分泌素、生长抑素、血小板生成素、促甲状腺激素、睾丸酮、脱氢表雄酮、雄烯二酮、二氢睾丸酮、醛固酮、雌二醇、雌酮、雌三醇、皮质醇、孕酮、骨化三醇、骨化二醇、他莫昔芬(Nolvadex)、阿那曲唑(Arimidex)、来曲唑(Femara)、氟司韦特(Faslodex)及其组合。
根据一些实施方案,抗血管生成剂选自2-甲氧基雌二醇、血管抑制素、贝伐单抗、软骨衍生的血管生成抑制因子、内皮抑素、IFN-α、IL-12、伊曲康唑、利诺米特、血小板因子4、催乳素、SU5416、苏拉明、他克莫尼、替加仑、四硫代钼酸盐、沙利度胺、血小板反应蛋白、血小板反应蛋白、TNP-470、齐夫-阿柏西普、其药学上可接受的盐、前药及其组合。
根据一些实施方案,另外的治疗剂是PI3K/Akt途径的抑制剂。
根据一些实施方案,PI3K/Akt途径的抑制剂选自A-674563(CAS#552325-73-2)、AGL 2263、AMG-319(Amgen,Thousand Oaks,CA)、AS-041164(5-苯并[1,3]二恶唑-5-基亚甲基-噻唑烷-2,4-二酮)、AS-604850(5-(2,2-二氟-苯并[1,3]二恶唑-5-基亚甲基)-噻唑烷-2,4-二酮)、AS-605240(5-喹喔啉-6-亚甲基-1,3-噻唑烷-2,4-二酮)、AT7867(CAS#857531-00-1)、苯并咪唑系列,Genentech(Roche Holdings Inc.,South San Francisco,CA)、BML-257(CAS#32387-96-5)、BVD-723、CAL-120(Gilead Sciences,Foster City,CA)、CAL-129(Gilead Sciences)、CAL-130(Gilead Sciences)、CAL-253(Gilead Sciences)、CAL-263(Gilead Sciences)、CAS#612847-09-3、CAS#681281-88-9、CAS#75747-14-7、CAS#925681-41-0、CAS#98510-80-6、CCT128930(CAS#885499-61-6)、CH5132799(CAS#1007207-67-1)、CHR-4432(Chroma Therapeutics,Ltd.,Abingdon,UK)、FPA 124(CAS#902779-59-3)、GS-1101(CAL-101)(Gilead Sciences)、GSK 690693(CAS#937174-76-0)、H-89(CAS#127243-85-0)、Honokiol、IC87114(Gilead Science)、IPI-145(Intellikine Inc.)、KAR-4139(Karus Therapeutics,Chilworth,UK)、KAR-4141(Karus Therapeutics)、KIN-1(KarusTherapeutics)、KT 5720(CAS#108068-98-0)、米替福新、MK-2206二盐酸化物(CAS#1032350-13-2)、ML-9(CAS#105637-50-1)、盐酸纳曲通、OXY-111A(NormOxys Inc.,Brighton,MA)、perifosine、PHT-427(CAS#1191951-57-1)、PI3激酶δ抑制剂,Merck KGaA(Merck&Co.,Whitehouse Station,NJ)、PI3激酶δ抑制剂,Genentech(Roche HoldingsInc.)、PI3激酶δ抑制剂,Incozen(Incozen Therapeutics,Pvt.Ltd.,Hydrabad,India)、PI3激酶δ抑制剂2,Incozen(Incozen Therapeutics)、PI3激酶抑制剂,Roche-4(RocheHoldings Inc.)、PI3激酶抑制剂,Roche(Roche Holdings Inc.)、PI3激酶抑制剂,Roche-5(Roche Holdings Inc.)、PI3-α/δ抑制剂,Pathway Therapeutics(Pathway TherapeuticsLtd.,South San Francisco,CA)、PI3-δ抑制剂,Cellzome(Cellzome AG,Heidelberg,Germany)、PI3-δ抑制剂,Intellikine(Intellikine Inc.,La Jolla,CA)、PI3-δ抑制剂,Pathway Therapeutics-1(Pathway Therapeutics Ltd.)、PI3-δ抑制剂,PathwayTherapeutics-2(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,Cellzome(CellzomeAG)、PI3-δ/γ抑制剂,Cellzome(Cellzome AG)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Pathway Therapeutics(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,PathwayTherapeutics(Pathway Therapeutics Ltd.)、PI3-γ抑制剂,Evotec(Evotec)、PI3-γ抑制剂,Cellzome(Cellzome AG)、PI3-γ抑制剂,Pathway Therapeutics(PathwayTherapeutics Ltd.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、pictilisib(Roche Holdings Inc.)、PIK-90(CAS#677338-12-4)、SC-103980(Pfizer,New York,NY)、SF-1126(SemaforePharmaceuticals,Indianapolis,IN)、SH-5、SH-6、四氢姜黄素、TG100-115(TargegenInc.,San Diego,CA)、曲西瑞宾、X-339(Xcovery,West Palm Beach,FL)、XL-499(Evotech,Hamburg,Germany)、其药学上可接受的盐及其组合。
根据一方面,本公开内容提供了用于在携带非V600E/K BRAF突变的受试者中治疗或缓解癌症的影响的药物组合物,该组合物包含药学上可接受的载体或稀释剂和有效量的ERK抑制剂或其药学上可接受的盐。
根据一些实施方案,ERK抑制剂选自BVD-523、SCH-722984(Merck&Co.)、SCH-772984(Merck&Co.)、SCH-900353(MK-8353)(Merck&Co.)、LY3214996(Lilly)、LY3214996(Lilly)、AEZS-140(Aeterna Zentaris)、AEZS-131(Aeterna Zentaris)、AEZS-136(Aeterna Zentaris)、LTT-462(Novartis)、RG-7842(Genentech)、CC-90003(Celgene)、KIN-4050(Kinentia)及其组合。
根据一些实施方案,ERK抑制剂是BVD-523。
根据一些实施方案,非V600E/K BRAF突变是激酶活化的突变、激酶受损的突变或激酶未知的突变及其组合。
根据一些实施方案,激酶活化的突变选自R462I、I463S、G464E、G464R、G464V、G466A、G469A、N581S、E586K、F595L、L597Q、L597R、L597S、L597V、A598V、T599E、V600R、K601E、S602D、A728V及其组合。
根据一些实施方案,激酶受损的突变选自G466E、G466R、G466V、Y472C、K483M、D594A、D594E、D594G、D594H、D594N、D594V、G596R、T599A、S602A及其组合。
根据一些实施方案,激酶未知的突变选自T440I、S467L、G469E、G469R、G469S、G469V、L584F、L588F、V600_K601delinsE、S605I、Q609L、E611Q及其组合。
根据一些实施方案,受试者是哺乳动物。
根据一些实施方案,哺乳动物选自人、灵长类动物、农场动物和家养动物。
根据一些实施方案,哺乳动物是人。
根据一些实施方案,癌症是实体瘤癌症或血液癌症。
根据一些实施方案,癌症选自胶质母细胞瘤、黑素瘤、胆管癌、小细胞肺癌、结肠直肠癌、前列腺癌、阴道癌、血管肉瘤、非小细胞肺癌、阑尾癌、鳞状细胞癌、唾液管癌、腺样囊性癌、小肠癌和胆囊癌。
根据一些实施方案,癌症选自小肠癌、非小细胞肺癌、胆囊癌和鳞状细胞癌。
根据一些实施方案,组合物口服或通过注射施用给受试者。
根据一些实施方案,组合物以片剂施用给受试者。
根据一些实施方案,药物组合选自MEK抑制剂、RAF抑制剂、HDAC抑制剂及其组合的至少一种另外的治疗剂。
根据一些实施方案,MEK抑制剂选自炭疽毒素、蒽醌(Golden Biotechnology)、ARRY-142886(6-(4-溴-2-氯-苯基氨基)-7-氟-3-甲基-3H-苯并咪唑-5-羧酸(2-羟基-乙氧基)-酰胺)(Array BioPharma)、ARRY-438162(Array BioPharma)贝美替尼(MEK162,ARRY-1662)、AS-1940477(Astellas)、AS-703988(Merck KGaA)、bentamapimod(Merck KGaA)、BI-847325(Boehringer Ingelheim)、E-6201(Eisai)、GDC-0623(Hoffmann-La Roche)、GDC-0973(考比替尼)(Hoffmann-La Roche)、L783277(Merck)、炭疽毒素的致死因子部分、MEK162(Array BioPharma)、PD 098059(2-(2'-氨基-3'-甲氧苯基)-氧萘-4-酮)(Pfizer)、PD 184352(CI-1040)(Pfizer)、PD-0325901(Pfizer)、PD318088(Pfizer)、PD334581(Pfizer)、6-甲氧基-7-(3-吗啉-4-基-丙氧基)-4-(4-苯氧基-苯基氨基)-喹啉-3-甲腈、4-[3-氯-4-(1-甲基-1H-咪唑-2-基硫烷基)-苯基氨基]-6-甲氧基-7-(3-吗啉-4-基-丙氧基)-喹啉-3-甲腈、pimasertib(Santhera Pharmaceuticals)、RDEA119(ArdeaBiosciences/Bayer)、瑞美替尼(AstraZeneca)、RG422(Chugai Pharmaceutical Co.)、R0092210(Roche)、R04987655(Hoffmann-La Roche)、R05126766(Hoffmann-La Roche)、司美替尼(AZD6244)(AstraZeneca)、SL327(Sigma)、TAK-733(Takeda)、曲美替尼(JapanTobacco)、U0126(1,4-二氨基-2,3-二氰基-1,4-双(2-氨基苯硫基)丁二烯)(Sigma)、WX-554(Wilex)、YopJ多肽(Mittal等人,2010)、其药学上可接受的盐及其组合。
根据一些实施方案,RAF抑制剂选自AAL881(Novartis)、AB-024(AmbitBiosciences)、ARQ-736(ArQule)、ARQ-761(ArQule)、AZ628(Axon Medchem BV)、BAY 43-9006索拉非尼、BeiGene-283(BeiGene)、BUB-024(MLN 2480)(Sunesis&Takeda)、b-raf抑制剂(Sareum)、BRAF激酶抑制剂(Selexagen Therapeutics)、BRAF siRNA313(tacaccagcaagctagatgca)和523(cctatcgttagagtcttcctg)(Liu等人,2007)、CHIR-265(Novartis)、CTT239065(Institute of Cancer Research)、达拉非尼(GSK2118436)、DP-4978(Deciphera Pharmaceuticals)、HM-95573(Hanmi)、GDC-0879(Genentech)、GW-5074(Sigma Aldrich)、ISIS 5132(Novartis)、L779450(Merck)、LBT613(Novartis)、LXH254(Novartis)、LErafAON(NeoPharm,Inc.)、LGX-818(Novartis)、帕唑帕尼(GlaxoSmithKline)、PLX3202(Plexxikon)、PLX4720(Plexxikon)、PLX5568(Plexxikon)、PLX3603(Daiichi Sankyo)、PLX8394(Daiichi Sankyo)、RAF-265(Novartis)、RAF-365(Novartis)、REDX0535(RedX Pharma Plc)、瑞戈非尼(Bayer HealthcarePharmaceuticals,Inc.)、RO 5126766(Hoffmann-La Roche)、SB-590885(GlaxoSmithKline)、SB699393(GlaxoSmithKline)、索拉非尼(Onyx Pharmaceuticals)、TAK 632(Takeda)、TL-241(Teligene)、维拉非尼(RG7204或PLX4032)(Daiichi Sankyo)、XL-281(Exelixis)、ZM-336372(AstraZeneca)、其药学上可接受的盐及其组合。
根据一些实施方案,HDAC抑制剂选自艾贝司他(PCI-24781)、吉诺司他、恩替司他、扶林司他、CI-994、CUDC-101、恩替司他、BML-210、M344、NVP-LAQ824、帕比司他、Pracinosat(SB939)、Mocetinostat、Resminostat、罗米地辛、贝利诺司他、其药学上可接受的盐及其组合。
根据一些实施方案,药物组合物进一步包含选自抗体或其片段、细胞毒性剂、毒素、放射性核素、免疫调控剂、光活化治疗剂、放射增敏剂、激素、抗血管生成剂及其组合的至少一种另外的治疗剂。
根据一些实施方案,抗体、其片段或其缀合物选自利妥昔单抗(Rituxan)、布伦妥昔单抗维多汀(Adcetriz)、阿多曲妥珠单抗艾坦肽(Kadcyla)西妥昔单抗(Erbitux)、贝伐单抗(Avastin)、替伊莫单抗(Zevalin)、维多珠单抗(Entyvio)、伊匹单抗(Yervoy)、纳武单抗(Opdivo)、派姆单抗(Keytruda)、阿伦单抗阿特朱单抗(Tecentriq)、阿维鲁单抗(Bavencio)、德鲁瓦单抗(Imfinzi)、B-701、奥法木单抗、阿托珠单抗(Gazyva)帕尼单抗、plozalizumab、BI-754091、OREG-103、COM-701、BI-754111及其组合。
根据一些实施方案,细胞毒性剂选自环磷酰胺、甲氯乙胺、尿嘧啶氮芥、美法仑、苯丁酸甲氯乙胺、异环磷酰胺、卡莫司汀、洛莫司汀、链脲霉素、白消安、替莫唑胺、顺铂、卡铂、奥沙利铂、奈达铂、沙铂、三硝酸四铂、阿霉素、柔红霉素、伊达比星、米托蒽醌、甲氨蝶呤、培美曲塞、6-巯基嘌呤、达卡巴嗪、氟达拉滨、5-氟尿嘧啶、阿拉伯糖胞嘧啶、卡培他滨、吉西他滨、地西他滨、长春花生物碱、紫杉醇(Taxol)、多西他赛(Taxotere)、依沙贝比隆(Ixempra)、放线菌素、蒽环类、缬沙星、表柔比星、博来霉素、普卡霉素、丝裂霉素、其药学上可接受的盐、前药及其组合。
根据一些实施方案,毒素是白喉毒素或其部分。
根据一些实施方案,放射性核素选自I-125、At-211、Lu-177、Cu-67、I-131、Sm-153、Re-186、P-32、Re-188、In-114m、Y-90及其组合。
根据一些实施方案,免疫调控剂选自粒细胞集落刺激因子(G-CSF)、LAG-3、IMP-321、JCAR-014、ASLAN-002(BMS-777607)、干扰素、咪喹莫特和来自细菌的细胞膜组分、IL-2、IL-7、IL-12、CCL3、CCL26、CXCL7、合成的胞嘧啶磷酸鸟苷(CpG)、免疫检查点抑制剂及其组合。
根据一些实施方案,放射增敏剂选自米索硝唑、甲硝唑、替拉帕明、反式丁香酸钠及其组合。
根据一些实施方案,激素选自前列腺素、白三烯、前列环素、血栓烷、淀粉纤维素、抗苗勒管激素、脂联素、促肾上腺皮质激素、血管紧张素原、血管紧张素、血管加压素、心房肽、脑钠尿肽、降血钙素、胆囊收缩素、促肾上腺皮质激素释放激素、脑啡肽、内皮素、促红细胞生成素、促卵泡激素、甘丙肽、胃泌素、生长激素释放肽、胰高血糖素、促性腺激素释放激素、生长激素释放激素、人绒毛膜促性腺激素、人胎盘促泌素、生长激素、抑制素、胰岛素、生长调节素、瘦素、促脂素、促黄体生成素、黑素细胞刺激激素、胃动素、食欲素、催产素、胰多肽、甲状旁腺激素、催乳素、催乳素释放激素、松弛素、肾素、分泌素、生长抑素、血小板生成素、促甲状腺激素、睾丸酮、脱氢表雄酮、雄烯二酮、二氢睾丸酮、醛固酮、雌二醇、雌酮、雌三醇、皮质醇、孕酮、骨化三醇、骨化二醇、他莫昔芬(Nolvadex)、阿那曲唑(Arimidex)、来曲唑(Femara)、氟司韦特(Faslodex)及其组合。
根据一些实施方案,抗血管生成剂选自2-甲氧基雌二醇、血管抑制素、贝伐单抗、软骨衍生的血管生成抑制因子、内皮抑素、IFN-α、IL-12、伊曲康唑、利诺米特、血小板因子4、催乳素、SU5416、苏拉明、他克莫尼、替加仑、四硫代钼酸盐、沙利度胺、血小板反应蛋白、血小板反应蛋白、TNP-470、齐夫-阿柏西普、其药学上可接受的盐、前药及其组合。
根据一些实施方案,另外的治疗剂是PI3K/Akt途径的抑制剂。
根据一些实施方案,PI3K/Akt途径的抑制剂选自A-674563(CAS#552325-73-2)、AGL 2263、AMG-319(Amgen,Thousand Oaks,CA)、AS-041164(5-苯并[1,3]二恶唑-5-基亚甲基-噻唑烷-2,4-二酮)、AS-604850(5-(2,2-二氟-苯并[1,3]二恶唑-5-基亚甲基)-噻唑烷-2,4-二酮)、AS-605240(5-喹喔啉-6-亚甲基-1,3-噻唑烷-2,4-二酮)、AT7867(CAS#857531-00-1)、苯并咪唑系列,Genentech(Roche Holdings Inc.,South San Francisco,CA)、BML-257(CAS#32387-96-5)、BVD-723、CAL-120(Gilead Sciences,Foster City,CA)、CAL-129(Gilead Sciences)、CAL-130(Gilead Sciences)、CAL-253(Gilead Sciences)、CAL-263(Gilead Sciences)、CAS#612847-09-3、CAS#681281-88-9、CAS#75747-14-7、CAS#925681-41-0、CAS#98510-80-6、CCT128930(CAS#885499-61-6)、CH5132799(CAS#1007207-67-1)、CHR-4432(Chroma Therapeutics,Ltd.,Abingdon,UK)、FPA124(CAS#902779-59-3)、GS-1101(CAL-101)(Gilead Sciences)、GSK 690693(CAS#937174-76-0)、H-89(CAS#127243-85-0)、Honokiol、IC87114(Gilead Science)、IPI-145(Intellikine Inc.)、KAR-4139(Karus Therapeutics,Chilworth,UK)、KAR-4141(Karus Therapeutics)、KIN-1(KarusTherapeutics)、KT 5720(CAS#108068-98-0)、米替福新、MK-2206二盐酸化物(CAS#1032350-13-2)、ML-9(CAS#105637-50-1)、盐酸纳曲通、OXY-111A(NormOxys Inc.,Brighton,MA)、perifosine、PHT-427(CAS#1191951-57-1)、PI3激酶δ抑制剂,Merck KGaA(Merck&Co.,Whitehouse Station,NJ)、PI3激酶δ抑制剂,Genentech(Roche HoldingsInc.)、PI3激酶δ抑制剂,Incozen(Incozen Therapeutics,Pvt.Ltd.,Hydrabad,India)、PI3激酶δ抑制剂2,Incozen(Incozen Therapeutics)、PI3激酶抑制剂,Roche-4(RocheHoldings Inc.)、PI3激酶抑制剂,Roche(Roche Holdings Inc.)、PI3激酶抑制剂,Roche-5(Roche Holdings Inc.)、PI3-α/δ抑制剂,Pathway Therapeutics(Pathway TherapeuticsLtd.,South San Francisco,CA)、PI3-δ抑制剂,Cellzome(Cellzome AG,Heidelberg,Germany)、PI3-δ抑制剂,Intellikine(Intellikine Inc.,La Jolla,CA)、PI3-δ抑制剂,Pathway Therapeutics-1(Pathway Therapeutics Ltd.)、PI3-δ抑制剂,PathwayTherapeutics-2(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,Cellzome(CellzomeAG)、PI3-δ/γ抑制剂,Cellzome(Cellzome AG)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Pathway Therapeutics(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,PathwayTherapeutics(Pathway Therapeutics Ltd.)、PI3-γ抑制剂,Evotec(Evotec)、PI3-γ抑制剂,Cellzome(Cellzome AG)、PI3-γ抑制剂,Pathway Therapeutics(PathwayTherapeutics Ltd.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、pictilisib(Roche Holdings Inc.)、PIK-90(CAS#677338-12-4)、SC-103980(Pfizer,New York,NY)、SF-1126(SemaforePharmaceuticals,Indianapolis,IN)、SH-5、SH-6、四氢姜黄素、TG100-115(TargegenInc.,San Diego,CA)、曲西瑞宾、X-339(Xcovery,West Palm Beach,FL)、XL-499(Evotech,Hamburg,Germany)、其药学上可接受的盐及其组合。
根据一些实施方案,药物组合物是包含ERK抑制剂和另外的治疗剂的单位剂型。
根据一些实施方案,药物组合物ERK抑制剂为第一单位剂型和另外的治疗剂为与第一单位剂型分开的第二单位剂型。
根据一些实施方案,将ERK抑制剂和另外的治疗剂共同施用给受试者。
根据一些实施方案,将ERK抑制剂和另外的治疗剂逐次地施用给受试者。
根据一些实施方案,ERK抑制剂在另外的治疗剂的施用之前或之后施用给受试者。
根据一方面,本公开内容提供了用于在携带非V600E/K BRAF突变的受试者中治疗或缓解癌症的影响的方法,该方法包括向受试者施用有效量的BVD-523或其药学上可接受的盐。
根据一方面,本公开内容提供了用于在受试者中治疗或改善癌症的影响的方法,包括:(a)鉴定携带非V600E/K BRAF突变的患有癌症的受试者;和(b)向受试者施用有效量的BVD-523或其药学上可接受的盐。
根据一方面,本公开内容提供了用于鉴定将从BVD-523或其药学上可接受的盐的疗法中受益的患有癌症的受试者的方法,该方法包括:(a)从受试者获得生物样品;和(b)筛选样品以确定受试者是否具有非V600E/K BRAF突变,其中非V600E/K BRAF突变的存在证实受试者将从BVD-523或其药学上可接受的盐疗法中受益。
根据一方面,本公开内容提供了用于在携带非V600E/K BRAF突变的受试者中治疗或缓解癌症的影响的药物组合物,该组合物包含药学上可接受的载体或稀释剂和有效量的BVD-523或其药学上可接受的盐。
根据一方面,本公开内容提供了用于在携带非V600E/K BRAF突变的受试者中治疗或缓解癌症的影响的试剂盒,该试剂盒包括根据权利要求88、103和107中任一项的药物组合物及包装在一起的其使用说明书。
根据一些实施方案,RAF抑制剂选自厄洛替尼(Tarceva)、吉非替尼(Iressa)、甲磺酸伊马替尼(Gleevec)、拉帕替尼(Tyverb)、苹果酸舒尼替尼(Sutent)、其药学上可接受的盐及其组合。
根据一些实施方案,RAF抑制剂选自LXH254(Novartis)、PLX3603(DaiichiSankyo)、PLX8394(Daiichi Sankyo)、REDX0535(RedX Pharma Plc)、其药学上可接受的盐及其组合。
根据一些实施方案,HDAC抑制剂选自扶林司他、帕诺比司他、罗米地辛、贝利司他、其药学上可接受的盐及其组合。
根据一些实施方案,抗体、其片段或其缀合物选自利妥昔单抗(Rituxan)、布伦妥昔单抗维多汀(Adcetriz)、阿多曲妥珠单抗艾坦肽(Kadcyla)、伊匹单抗(Yervoy)、纳武单抗(Opdivo)、派姆单抗(Keytruda)、阿伦单抗阿特朱单抗(Tecentriq)、德鲁瓦单抗(Imfinzi)、奥法木单抗、阿托珠单抗(Gazyva)、帕尼单抗及其组合。
根据一些实施方案,PI3K/Akt途径的抑制剂是BVD-723。
附图的简要说明
图1显示了丝裂原活化蛋白激酶(MAPK)途径的示意图。
图2显示了用BVD-523治疗的患者的应答。包括通过RECIST v1.1测量的所有患病患者,他们接受了一剂或更多的研究治疗以及一次以上的治疗中肿瘤评估。应答被测量为每个靶病变最长直径的总和相对于基线的变化。实线指示根据RECIST v1.1对于部分应答的阈值。缩写:GBM,胶质母细胞瘤;NSCLC,非小细胞肺癌;CRC,结肠直肠癌。指示了与每个患者的癌症相关的非典型BRAF突变。
图3显示了按组分类的游泳者图(Swimmer’s plot)中的治疗持续时间。第一组的成员是在除结肠直肠癌(CRC)和非小细胞肺癌(NSCLC)以外的任何肿瘤类型中具有任何BRAF突变,并且先前未接受过MAPK途径抑制剂的治疗的任何患者。第2组的成员是在CRC中具有任何BRAF突变,先前未接受MAPK途径抑制剂的治疗的患者。第3组的成员是患有具有BRAF V600E/K突变的肿瘤,该肿瘤对MAPK抑制剂治疗无效的患者。第6组的成员是具有在NSCLC中存在的任何BRAF突变的患者。如图3所示,包括所有28名患者通过横线表示,每个受试者一个横线。从组的顶部(最长治疗持续时间)到底部(最短治疗持续时间)说明了每个组中每个受试者的治疗持续时间。水平轴表示患者在研究中的持续时间(天)。图3还显示了根据RECIST v1.1为每个患者实现的应答应类型(菱形=部分应答;圆圈=稳定疾病;垂直线=进展性疾病;三角形=未评估)。
图4显示了因BRAF突变而破坏的游泳者图中的治疗持续时间。包括所有根据RECIST v1.1应答标准测量的28位患者,以及未通过RECIST v1.1评估的其他患者(菱形=部分应答;圆圈=稳定疾病;竖线=进展性疾病;三角形=未评估)。
发明详述
根据一个方面,本公开提供了用于在携带非V600E/K BRAF突变的受试者中治疗或缓解癌症的影响的方法,该方法包括向受试者施用有效量的ERK抑制剂或其药学上可接受的盐。
如本文所用,术语“V600E/K BRAF突变”,与受试者中的癌症有关,及其语法变化,是指在编码人BRAF(SEQ ID NO:2)的基因中包含非同义取代突变的癌细胞,所述非同义取代突变导致在BRAF的氨基酸位置600的氨基酸缬氨酸(V)被取代为谷氨酸(E)或赖氨酸(K)。如本文所用,术语“携带非V600E/K BRAF突变”,与受试者中的癌症有关,及其语法变化,是指癌细胞包含不是V600E/K BRAF突变的体细胞突变。如本文所用,所有BRAF突变均基于人野生型序列(SEQ ID NO:2)。本文也包括来自其他物种的直系同源物。
如本文所用,术语“治疗”,“在治疗”、“处理”及其语法变化是指使个体受试者接受方法、方案、过程或措施,其中希望在受试者例如患者中获得生理学应答或结果。特别地,本发明的方法和组合物可以用于减缓疾病症状的发展或延迟疾病或病况的发作,或者中止疾病发展的进程。然而,因为每个被治疗的受试者可能对特定的治疗方法、方案、过程或措施没有应答,所以治疗不需要在各个或每个受试者或受试者群体例如患者群体中实现所需的生理应答或结果。因此,给定的受试者或受试者群体,例如患者群体可能对治疗没有应答或应答不足。
如本文所用,术语“缓解”及其语法变化是指降低受试者中疾病症状的严重性。
如本文所用,“受试者”是哺乳动物,优选地地人。除了人以外,在本发明范围内的哺乳动物的类别包括例如农场动物、家养动物、实验动物等。农场动物的一些实例包括牛、猪、马、山羊等。家养动物的一些实例包括狗,猫等。实验动物的一些实例包括灵长类动物、大鼠、小鼠、兔子、豚鼠等。
如本文所用,术语本文所公开的化合物或组合物的“有效量”或“治疗有效量”是当施用给受试者时足以实现如本文所述的有益或所需结果的此类化合物或组合物的量。有效的剂型、施用方式和剂量可以凭经验确定,并且这种确定在本领域技术范围内。本领域技术人员应理解,剂量将随施用途径,排泄速率,治疗持续时间,施用的任何其他药物的特征,哺乳动物例如人类患者的年龄、大小和种类,以及医学和兽医学领域众所周知的类似因素而变化。通常,根据本发明的化合物或组合物的合适剂量将是该组合物的这样的量,其是有效产生所需作用的最低剂量。本发明化合物或组合物的有效剂量可以全天以适当的间隔分开以两个、三个、四个、五个、六个或更多个亚剂量施用。
根据一些实施方案,ERK抑制剂选自BVD-523、SCH-722984(Merck&Co.)、SCH-772984(Merck&Co.)、SCH-900353(MK-8353)(Merck&Co.)、LY3214996(Lilly)、AEZS-140(Aeterna Zentaris)、AEZS-131(Aeterna Zentaris)、AEZS-136(Aeterna Zentaris)、LTT-462(Novartis)、RG-7842(Genentech)、CC-90003(Celgene)、KIN-4050(Kinentia)及其组合。根据一些实施方案,ERK抑制剂是BVD-523。
在本发明中,BVD-523是根据式(I)的化合物:
及其药学上可接受的盐。BVD-523是一种高效的、选择性的、可逆的、ATP竞争性的ERK1/2抑制剂。BVD-523可以根据例如美国专利号7,354,939中公开的方法进行合成,其通过引用并入本文。BVD-523的两个对映异构体的对映异构体和外消旋混合物也包括在本发明的范围内。BVD-523是其作用机理被认为例如与某些其他ERK1/2抑制剂例如SCH772984是独特的和不同的ERK1/2抑制剂。例如,其他ERK1/2抑制剂(例如SCH772984)抑制ERK的自磷酸化(Morris等人,2013),而BVD-523允许ERK的自磷酸化同时仍抑制ERK。
根据一些实施方案,受试者的癌症在BRAF基因中具有体细胞突变。如本文所用,“体细胞突变”是指在不注定要成为生殖细胞的任何细胞中发生的变化。突变可以是例如取代、缺失、插入或融合。下表1显示了BRAF突变的分布概况,如Sanger数据库所示。
表1
在大约66%黑色素瘤中发现了BRAF突变(Davies等人,2002;Brose等人,2002;Hocket等人,2007),并且在其他癌症中相对更低的百分比,36%甲状腺肿瘤和10%结肠癌(Xu等人,2003;Fransen等人,2004)。最普遍的BRAF突变发生在人野生型蛋白激酶(SEQ IDNO:2)的氨基酸600处,通过用谷氨酸取代缬氨酸产生突变体B-RafV600E,其占BRAF突变的约80%(Davies等人,2002;Hocker等人,2007)。与野生型B-Raf的基础活性相比,B-RafV600E激酶结构域具有500倍高的激酶活性(Wan等人,2004)。在黑素瘤中鉴定出的其他BRAF突变中,V600K和V600D/R也很常见,并且分别代表所有BRAF突变的16%和3%(Long等人,2011)。除黑色素瘤外,BRAF突变在许多其他癌症中也很常见,包括甲状腺乳头状癌、卵巢癌和结肠直肠癌。(Wellbrock等人,2004)。在一项研究中,在5/24(21%)的结肠直肠癌细胞系中发现了BRAF剪接变体(剪接第14和15外显子)(Seth等人,2009)。
来自Sanger数据库的下表2显示了人肿瘤中BRAF突变的分布和频率。
表2
下表3显示了BRAF的选择的核酸和氨基酸序列。这些序列可以用于鉴定具有突变BRAF基因型的受试者的方法中(例如在以下阐述的方法中)。
表3
鉴定核酸例如上述鉴定的BRAF基因中突变的方法是本领域已知的。核酸可获自生物样品。在本发明中,生物学样品包括但不限于血液、血浆、尿液、皮肤、唾液和活检样品。通过本领域已知的常规程序和方法从受试者获得生物样品。
用于鉴定突变的方法的非限制性实例包括PCR、测序、杂交捕获、溶液内捕获、分子倒置探针、荧光原位杂交(FISH)测定法及其组合。
多种测序方法是本领域已知的。这些包括但不限于Sanger测序(也称为双脱氧测序)和例如Metzker 2005中公开的多种合成测序(SBS)方法、通过杂交测序、通过连接测序(例如WO2005021786)、通过降解测序(例如,美国专利号5,622,824和6,140,053)和纳米孔测序(其可从Oxford Nanopore Technologies,UK商购获得)。在深度测序技术中,在测序过程中多次读取序列中的给定核苷酸。深度测序技术公开在例如美国专利公开号20120264632和国际专利公开号WO2012125848中。
用于检测突变的基于PCR的方法是本领域已知的并且采用PCR扩增,其中样品中的每个靶序列具有独特的、序列特异性引物的相应对。例如,聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法允许在通过PCR扩增基因组序列后快速检测突变。该突变通过用特异性限制性核酸内切酶的消化来区分并通过电泳来鉴定。参见,例如Ota等人,2007。还可以使用实时PCR检测突变。参见,例如国际申请公开号WO2012046981。
杂交捕获方法是本领域中已知的并且在例如美国专利公开号20130203632和美国专利号8389219和8288520中公开。这些方法基于靶基因组区域对用户设计的寡核苷酸的选择性杂交。杂交可以是与固定化在高密度或低密度微阵列上的寡核苷酸(阵列捕获),或者是与用配体(例如生物素)修饰的寡核苷酸的溶液相杂交,所述配体随后可以固定化在固体表面例如珠上(溶液中捕获)。
分子倒置探针(MIP)方法是本领域已知的并且例如在Absalan等人,2008中公开。此类方法使用MIP分子,其是特殊的“挂锁”探针(Nilsson等人,1994)用于基因分型。MIP分子是线性寡核苷酸,包含特定区域、通用序列、限制位点和Tag(索引)序列(16-22bp)。在这种方法中,MIP在目的遗传标志物/SNP的周围直接杂交。MIP方法也可以使用与基因组DNA平行杂交的许多“挂锁”探针组(Hardenbol等人,2003)。在完美匹配的情况下,通过进行构型反转(如技术名称所暗示的)并创建环状分子来连接基因组同源区域。第一次限制性酶切后,所有分子均用通用引物进行扩增。再次限制性酶切扩增子以确保用于在微阵列上杂交的短片段。标记产生的短片段,并通过Tag序列与阵列上的cTag(索引的互补链)杂交。在形成Tag-cTag双链体后,检测到信号。
根据一些实施方案,非V600E/K BRAF突变是激酶活化的突变、激酶受损的突变、激酶未知的突变及其组合。如本文所用,术语“激酶活化的突变”及其语法变化是指相对于野生型激酶,突变引起突变的激酶的激酶活性升高。如本文所用,术语“激酶受损的突变”及其语法变化是指相对于野生型激酶,突变引起突变的激酶的激酶活性降低。如本文所用,术语“激酶未知的突变”及其语法变化是指突变体激酶的活性是未知的或者突变的激酶的活性约等于野生型激酶的激酶活性。(参见Zheng,G.等人,Clinical detection andcategorization of uncommon and concomitant mutations involving BRAF,BMCCancer,(2015)15:779,通过引用整体并入本文)
根据一些实施方案,BRAF激酶活化的突变选自R462I、I463S、G464E、G464R、G464V、G466A、G469A、N581S、E586K、F595L、L597Q、L597R、L597S、L597V、A598V、T599E、V600R、K601E、S602D、A728V及其组合。根据一些实施方案,BRAF激酶受损的突变选自G466E、G466R、G466V、Y472C、K483M、D594A、D594E、D594G、D594H、D594N、D594V、G596R、T599A、S602A及其组合。根据一些实施方案,BRAF激酶未知的突变选自T440I、S467L、G469E、G469R、G469S、G469V、L584F、L588F、V600_K601delinsE、S605I、Q609L、E611Q及其组合。如本文所用,所有BRAF突变均基于人野生型序列(SEQ ID NO:2)。本文也包括来自其他物种的直系同源物。
在本发明中,用于治疗非V600E/K BRAF突变的方法和组合物对携带单个突变和一个或多个突变的疾病状态有效。实际上,本文公开的(或下文鉴定的)任何单个突变或突变的任何组合都可以用组合物或根据本发明的方法进行处理(例如,非V600E/K突变的任何组合或者非V600E/K突变和V600E/K突变的任何组合)。
根据一些实施方案,非V600E/K BRAF突变选自D594、G469、K601E、L597、T599重复、L485W、F247L、G466V、BRAF融合、BRAF-AGAP3重排、BRAF外显子15剪接变体及其组合。
如本文所用,氨基酸取代突变的注释包括以下的封闭形式:野生型氨基酸;位置;取代的氨基酸(例如K601E)。如本文所用,氨基酸取代的注释还包括以下的开放式形式:野生型氨基酸;位置(例如G469)。如本文所用,开放式注释包括任何氨基酸的取代。例如,G469突变揭示了位置469的甘氨酸被氨基酸A、R、N、D、C、Q、E、H、I、L、K、M、F、P、S、T、W、Y、V中任何一个取代。也如本文所用,封闭的注释包括被任何氨基酸取代,并且优选地被所述取代的氨基酸取代。例如,K601E突变揭示了位置601的赖氨酸被氨基酸A、R、N、D、C、Q、E、G、H、I、L、M、F、P、S、T、W、Y、V,以及更优选地被氨基酸E取代。本文所用的封闭注释的使用不应解释为将本公开内容限制为具体说明的氨基酸取代。
根据一些实施方案,包含携带非V600E/K BRAF突变的癌症的受试者是哺乳动物。根据一些实施方案,所述哺乳动物选自人、灵长类动物、农场动物和家养动物。根据一些实施方案,哺乳动物是人。
根据一些方面,本公开内容提供了实体癌和血液癌。实体癌的非限制性实例包括肾上腺皮质癌、肛门癌、膀胱癌、骨癌(例如骨肉瘤)、脑癌、乳腺癌、类癌、癌(carcinoma)、宫颈癌、结肠癌、子宫内膜癌、食道癌、肝外胆汁导管癌、尤因家族癌、颅外生殖细胞癌、眼癌、胆囊癌、胃癌、生殖细胞瘤、妊娠滋养细胞肿瘤、头颈癌、下咽癌、胰岛细胞癌、肾癌、大肠癌、喉癌、白血病、嘴唇和口腔癌、肝肿瘤/癌、肺肿瘤/癌、淋巴瘤、恶性间皮瘤、默克尔细胞癌、蕈样肉芽肿、骨髓增生异常综合征、骨髓增生性疾病、鼻咽癌、神经母细胞瘤、口腔癌、口咽癌、骨肉瘤、卵巢上皮癌、卵巢生殖细胞癌、胰腺癌、鼻旁窦和鼻腔癌、甲状旁腺癌、阴茎癌、垂体癌、浆细胞瘤、前列腺癌、横纹肌肉瘤、直肠癌、肾细胞癌、肾盂和输尿管的移行细胞癌、唾液腺癌、塞氏综合征、皮肤癌(如皮肤T细胞淋巴瘤、卡波西肉瘤、肥大细胞瘤和黑色素瘤)、小肠癌、软组织肉瘤、胃癌、睾丸癌、胸腺瘤、甲状腺癌、尿道癌、子宫癌、阴道癌、外阴癌和威尔姆斯瘤。
血液癌症的例子包括但不限于白血病,例如成人/儿童急性淋巴细胞白血病、成人/儿童急性髓细胞白血病、慢性淋巴细胞性白血病、慢性骨髓性白血病、和毛细胞白血病、淋巴瘤例如与艾滋病有关的淋巴瘤、皮肤T细胞淋巴瘤、成年/儿童霍奇金淋巴瘤、蕈样真菌病、成年/儿童非霍奇金淋巴瘤、原发性中枢神经系统淋巴瘤、塞氏综合征、皮肤T细胞淋巴瘤和Waldenstrom巨球蛋白血症、以及其他增生性病症例如慢性骨髓增生性疾病、朗格汉斯细胞组织细胞增生症、多发性骨髓瘤/浆细胞瘤、骨髓增生异常综合征和骨髓增生异常/骨髓增生性肿瘤。
根据一些实施方案,受试者的癌症选自胶质母细胞瘤、黑素瘤、胆管癌、小细胞肺癌、结肠直肠癌、前列腺癌、阴道癌、血管肉瘤、非小细胞肺癌、阑尾癌、鳞状细胞癌、唾液管癌、腺样囊性癌、小肠癌和胆囊癌。优选地,癌症选自小肠癌、非小细胞肺癌、胆囊癌和鳞状细胞癌。
根据一些方面,本公开提供了向受试者施用至少一种另外的丝裂原活化蛋白激酶(MAPK)途径抑制剂。根据一些实施方案,至少一种另外的治疗剂选自MEK抑制剂、RAF抑制剂、HDAC抑制剂、ERK抑制剂及其组合。
如本文所用,“丝裂原活化蛋白激酶(MAPK)途径抑制剂”是调控例如降低MAPK途径中蛋白质的活性、表达或磷酸化从而导致细胞生长减少或细胞死亡增加的任何物质。
哺乳动物MAPK级联的概述在图1中显示。关于MAPK途径的细节在例如Akinleye等人,2013中进行了综述。简言之,关于图1中的ERK1/2模块(浅紫色框),MAPK 1/2信号传导级联通过配体与受体酪氨酸激酶(RTK)的结合而被活化。活化的受体募集并磷酸化衔接蛋白Grb2和SOS,后两者然后与膜结合的GTPase Ras相互作用并引起其活化。Ras以其活化的GTP结合形式募集并活化Raf激酶(A-Raf、B-Raf和C-Raf/RaF-1)。活化的Raf激酶活化MAPK 1/2(MKK1/2),其进而催化ERK1/2的活化序列Thr-Glu-Tyr中苏氨酸和酪氨酸残基的磷酸化。对于JNK/p38模块(图1中的黄色框),上游激酶MAP3K(例如MEKK1/4、ASK1/2和MLK1/2/3)活化MAP2K3/6(MKK3/6)、MAP2K4(MKK4)和MAP2K7(MKK7)。然后,这些MAP2K活化JNK蛋白激酶,包括JNK1、JNK2和JNK3以及p38α/β/γ/Δ。为了执行其功能,JNK活化多个转录因子,包括c-Jun、ATF-2、NF-ATc1、HSF-1和STAT3。关于ERK5模块(图1中的蓝色框),MAP2K5(MKK5)上游的激酶是MEKK2和MEKK3。MEK5最具特征的下游靶标是ERK5,也称为大MAP激酶1(BMK1),因为它是其他MAPK大小的两倍。
MAPK途径抑制剂的非限制性实例包括RAS抑制剂、RAF抑制剂、MEK抑制剂、ERK1/2抑制剂、其药学上可接受的盐及其组合。
如本文所用,“RAS抑制剂”是指(i)例如通过与RAS结合而与RAS直接相互作用和(ii)降低RAS的表达或活性的那些物质。非限制性的示例性RAS抑制剂包括但不限于法呢基转移酶抑制剂(例如,替吡法尼(tipifarnib)和洛那法尼(lonafarnib))、含法呢基基团的小分子(例如,salirasib和TLN-4601)、由Maurer(Maurer等人,2012)公开的DCAI、由Shima(Shima等,2013)公开的Kobe0065和Kobe2602、HBS 3(Patgiri等人,2011)和AIK-4(Allinky)。
如本文所用,“RAF抑制剂”是指(i)例如通过与RAF结合而与RAF直接相互作用和(ii)降低RAF的表达或活性的那些物质,例如A-RAF、B-RAF和C-RAF(Raf-1)。非限制性示例性RAF抑制剂包括:
AAL881(Novartis);AB-024(Ambit Biosciences),ARQ-736(ArQule),ARQ-761(ArQule),AZ628(Axon Medchem BV),BAY 43-9006索拉非尼,BaiGene-283(BeiGene),BUB-024(MLN 2480)(Sunesis&Takeda),b-raf抑制剂(Sareum),BRAF激酶抑制剂(SelexagenTherapeutics),BRAF siRNA 313(tacaccagcaagctagatgca)和523(cctatcgttagagtcttcctg)(Liu等人,2007),CHIR-265(Novartis),CTT239065(Instituteof Cancer Research),达拉非尼(GSK2118436),DP-4978(Deciphera Pharmaceuticals),HM-95573(Hanmi),GDC-0879(Genentech),GW-5074(Sigma Aldrich),ISIS 5132(Novartis),L779450(Merck),LBT613(Novartis),LXH254(Novartis),LErafAON(NeoPharm,Inc.),LGX-818(Novartis),帕唑帕尼(GlaxoSmithKline),PLX3202(Plexxikon),PLX4720(Plexxikon),PLX5568(Plexxikon),PLX3603(Daiichi Sankyo),PLX8394(Daiichi Sankyo),RAF-265(Novartis),RAF-365(Novartis),REDX0535(RedXPharma Plc),瑞戈非尼(Bayer Healthcare Pharmaceuticals,Inc.),RO 5126766(Hoffmann-La Roche),SB-590885(GlaxoSmithKline),SB699393(GlaxoSmith Kline),索拉非尼(Onyx Pharmaceuticals),TAK 632(Takeda),TL-241(Teligene),威罗非尼(RG7204或PLX4032)(Daiichi Sankyo),XL-281(Exelixis),ZM-336372(AstraZeneca),其药学可接受的可盐及其组合。
根据一些实施方案,RAF抑制剂包括泛抑制剂;其非限制性实例包括厄洛替尼(Tarceva)、吉非替尼(Iressa)、甲磺酸伊马替尼(Gleevec)、拉帕替尼(Tyverb)、苹果酸舒尼替尼(Sutent)其药学可接受的可盐及其组合。
如本文所用,“MEK抑制剂”是指(i)例如通过与MEK结合而与MEK直接相互作用,和(ii)降低MEK的表达或活性的那些物质。因此,在MEK上游起作用的抑制剂,例如RAS抑制剂和RAF抑制剂,不是根据本发明的MEF抑制剂。MEK抑制剂的非限制性实例包括炭疽毒素、蒽醌(Golden Biotechnology)、ARRY-142886(6-(4-溴-2-氯-苯基氨基)-7-氟-3-甲基-3H-苯并咪唑-5-羧酸(2-羟基-乙氧基)-酰胺)(Array BioPharma)、ARRY-438162(ArrayBioPharma)、贝美替尼(MEK162,ARRY-1662)、AS-1940477(Astellas)、AS-703988(MerckKGaA)、bentamapimod(Merck KGaA)、BI-847325(Boehringer Ingelheim)、E-6201(Eisai)、GDC-0623(Hoffmann-La Roche)、GDC-0973(考比替尼)(Hoffmann-La Roche)、L783277(Merck)、炭疽毒素的致死因子部分、MEK162(Array BioPharma)、PD 098059(2-(2'-氨基-3'-甲氧苯基)-氧萘-4-酮)(Pfizer)、PD 184352(CI-1040)(Pfizer)、PD-0325901(Pfizer)、pimasertib(Santhera Pharmaceuticals)、RDEA119(Ardea Biosciences/Bayer)、瑞美替尼(AstraZeneca)、RG422(Chugai Pharmaceutical Co.)、R0092210(Roche)、R04987655(Hoffmann-La Roche)、R05126766(Hoffmann-La Roche)、司美替尼(AZD6244)(AstraZeneca)、SL327(Sigma)、TAK-733(Takeda)、曲美替尼(Japan Tobacco)、U0126(1,4-二氨基-2,3-二氰基-1,4-双(2-氨基苯硫基)丁二烯)(Sigma)、WX-554(Wilex)、YopJ多肽(Mittal等人,2010)、其药学上可接受的盐及其组合。
如本文所用,“ERK1/2抑制剂”是指(i)例如通过与ERK1/2结合而与ERK1和/或ERK2直接相互作用,和(ii)降低ERK1和/或ERK2蛋白激酶的表达或活性的那些物质。因此,在ERK1/2上游起作用的抑制剂,例如MEK抑制剂和RAF抑制剂,不是根据本发明的ERK1/2抑制剂。ERK1/2抑制剂的非限制性实例包括AEZS-131(Aeterna Zentaris)、AEZS-136(AeternaZentaris),BVD-523,SCH-722984(Merck&Co.)、SCH-772984(Merck&Co.)、SCH-900353(MK-8353)(Merck&Co.)、LY3214996(Lilly)、其药学上可接受的盐及其组合。
如本文所用,“HDAC抑制剂”是指(i)例如通过与HDAC结合而与组蛋白脱乙酰基酶(HDAC)直接相互作用,和(ii)降低HDAC的表达或活性的那些物质。HDAC抑制剂的非限制性例子包括艾贝司他(PCI-24781)、吉诺司他、恩替司他、扶林司他、CI-994、CUDC-101、恩替司他、BML-210、M344、NVP-LAQ824、帕比司他、Pracinosat(SB939)、Mocetinostat、Resminostat、罗米地辛、贝利诺司他、其药学上可接受的盐及其组合。
根据一些实施方案,HDAC抑制剂选自扶林司他、帕比司他、罗米地辛、贝利诺司他、其药学上可接受的盐及其组合。
在另一方面,该方法进一步包括向受试者施用有效治疗或改善癌症的影响的至少一种另外的治疗剂。所述另外的治疗剂可以选自抗体、抗体片段、抗体缀合物、细胞毒性剂、毒素、放射性核素、免疫调控剂、光活化治疗剂、放射增敏剂、激素、抗血管生成剂及其组合。
如本文所用,“抗体”涵盖天然存在的免疫球蛋白以及非天然存在的免疫球蛋白,包括例如单链抗体、嵌合抗体(例如人源化鼠抗体)和杂缀合物抗体(例如双特异性抗体)。抗体的片段包括结合抗原的那些(例如,Fab'、F(ab')2、Fab、Fv和rIgG)。还参见,例如,Pierce Catalog and Handbook,1994-1995(Pierce Chemical Co.,Rockford,Ill);Kuby,J.,Immunology,3rd Ed.,W.H.Freeman&Co.,New York(1998)。术语抗体还包括二价或双特异性分子、双抗体、三抗体和四抗体。术语“抗体”还包括多克隆和单克隆抗体。
可用于本发明的治疗性抗体的实例包括利妥昔单抗(Rituxan)、布伦妥昔单抗维多汀(Adcetriz)、阿多曲妥珠单抗艾坦肽(Kadcyla)、西妥昔单抗(Erbitux)、贝伐单抗(Avastin)、替伊莫单抗(Zevalin)、维多珠单抗(Entyvio)、伊匹单抗(Yervoy)、纳武单抗(Opdivo)、派姆单抗(Keytruda)、阿伦单抗(Alemtuzamab)阿特朱单抗(Tecentriq)、阿维鲁单抗(Bavencio)、德鲁瓦单抗(Imfinzi)、B-701、奥法木单抗、阿托珠单抗(Gazyva)帕尼单抗、plozalizumab、BI-754091、OREG-103、COM-701、BI-754111及其组合。
根据一些实施方案,所述抗体、其片段或其缀合物选自利妥昔单抗(Rituxan)、布伦妥昔单抗维多汀(Adcetriz)、阿多曲妥珠单抗艾坦肽(Kadcyla)、伊匹单抗(Yervoy)、纳武单抗(Opdivo)、派姆单抗(Keytruda)、阿伦单抗阿特朱单抗(Tecentriq)、德鲁瓦单抗(Imfinzi)、奥法木单抗、阿托珠单抗(Gazyva)帕尼单抗及其组合。
根据本发明的细胞毒剂包括DNA破坏剂、抗代谢物、抗微管剂、抗生素剂等。DNA破坏剂包括烷基化剂、铂基试剂、嵌入剂和DNA复制的抑制剂。DNA烷基化剂的非限制性实例包括环磷酰胺、甲氯乙胺、尿嘧啶氮芥、美法仑、苯丁酸甲氯乙胺、异环磷酰胺、卡莫司汀、洛莫司汀、链脲霉素、白消安、替莫唑胺、其药学上可接受的盐、前药及其组合。铂基试剂的非限制性实例包括顺铂、卡铂、奥沙利铂、奈达铂、沙铂、三硝酸四铂、其药学上可接受的盐、前药及其组合。插入剂的非限制性实例包括阿霉素、柔红霉素、伊达比星、米托蒽醌、其药学上可接受的盐、前药及其组合。DNA复制的抑制剂的非限制性实例包括伊立替康、托泊替康、氨水碱、依托泊苷、依托泊苷磷酸酯、替尼泊苷、其药学上可接受的盐、前药及其组合。抗代谢物包括叶酸拮抗剂,例如甲氨蝶呤和培美曲塞(premetrexed);嘌呤拮抗剂,例如6-巯嘌呤、达卡巴嗪和氟达拉滨;和嘧啶拮抗剂,例如5-氟尿嘧啶、阿拉伯糖基胞嘧啶、卡培他滨,吉西他滨、地西他滨、其药学上可接受的盐、前药及其组合。抗微管剂包括但不限于长春花生物碱、紫杉醇多西他赛和依沙贝比隆抗生素试剂包括但不限于放线菌素、蒽环类、缬沙星、表柔比星、博来霉素、普卡霉素、丝裂霉素、其药学上可接受的盐、前药及其组合。
根据一些实施方案,细胞毒性剂选自环磷酰胺、甲氯乙胺、尿嘧啶氮芥、美法仑、苯丁酸甲氯乙胺、异环磷酰胺、卡莫司汀、洛莫司汀、链脲霉素、白消安、替莫唑胺、顺铂、卡铂、奥沙利铂、奈达铂、沙铂、三硝酸四铂、阿霉素、柔红霉素、伊达比星、米托蒽醌、甲氨蝶呤、培美曲塞、6-巯基嘌呤、达卡巴嗪、氟达拉滨、5-氟尿嘧啶、阿拉伯糖胞嘧啶、卡培他滨、吉西他滨、地西他滨、长春花生物碱、紫杉醇(Taxol)、多西他赛(Taxotere)、依沙贝比隆(Ixempra)、放线菌素、蒽环类、缬沙星、表柔比星、博来霉素、普卡霉素、丝裂霉素、其药学上可接受的盐、前药及其组合。
根据本发明的细胞毒性剂还包括PI3K/Akt途径的抑制剂。PI3K/Akt途径的抑制剂的非限制性实例包括A-674563(CAS#552325-73-2)、AGL 2263、AMG-319(Amgen,ThousandOaks,Calif)、AS-041164(5-苯并[1,3]二恶唑-5-基亚甲基-噻唑烷-2,4-二酮)、AS-604850(5-(2,2-二氟-苯并[1,3]二恶唑-5-基亚甲基)-噻唑烷-2,4-二酮)、AS-605240(5-喹喔啉-6-亚甲基-1,3-噻唑烷-2,4-二酮)、AT7867(CAS#857531-00-1)、苯并咪唑系列,Genentech(Roche Holdings Inc.,South San Francisco,Calif)、BML-257(CAS#32387-96-5)、BVD-723、CAL-120(Gilead Sciences,Foster City,Calif)、CAL-129(Gilead Sciences)、CAL-130(Gilead Sciences)、CAL-253(Gilead Sciences)、CAL-263(Gilead Sciences)、CAS#612847-09-3、CAS#681281-88-9、CAS#75747-14-7、CAS#925681-41-0、CAS#98510-80-6、CCT128930(CAS#885499-61-6)、CH5132799(CAS#1007207-67-1)、CHR-4432(ChromaTherapeutics,Ltd.,Abingdon,UK)、FPA 124(CAS#902779-59-3)、GS-1101(CAL-101)(Gilead Sciences)、GSK 690693(CAS#937174-76-0)、H-89(CAS#127243-85-0)、Honokiol、IC87114(Gilead Science)、IPI-145(Intellikine Inc.)、KAR-4139(KarusTherapeutics,Chilworth,UK)、KAR-4141(Karus Therapeutics)、KIN-1(KarusTherapeutics)、KT 5720(CAS#108068-98-0)、米替福新、MK-2206二盐酸化物(CAS#1032350-13-2)、ML-9(CAS#105637-50-1)、盐酸纳曲通、OXY-111A(NormOxys Inc.,Brighton,Mass.)、perifosine、PHT-427(CAS#1191951-57-1)、PI3激酶δ抑制剂,MerckKGaA(Merck&Co.,Whitehouse Station,NJ)、PI3激酶δ抑制剂,Genentech(Roche HoldingsInc.)、PI3激酶δ抑制剂,Incozen(Incozen Therapeutics,Pvt.Ltd.,Hydrabad,India)、PI3激酶δ抑制剂2,Incozen(Incozen Therapeutics)、PI3激酶抑制剂,Roche-4(RocheHoldings Inc.)、PI3激酶抑制剂,Roche(Roche Holdings Inc.)、PI3激酶抑制剂,Roche-5(Roche Holdings Inc.)、PI3-α/δ抑制剂,Pathway Therapeutics(Pathway TherapeuticsLtd.,South San Francisco,CA)、PI3-δ抑制剂,Cellzome(Cellzome AG,Heidelberg,Germany)、PI3-δ抑制剂,Intellikine(Intellikine Inc.,La Jolla,CA)、PI3-δ抑制剂,Pathway Therapeutics-1(Pathway Therapeutics Ltd.)、PI3-δ抑制剂,PathwayTherapeutics-2(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,Cellzome(CellzomeAG)、PI3-δ/γ抑制剂,Cellzome(Cellzome AG)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Pathway Therapeutics(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,PathwayTherapeutics(Pathway Therapeutics Ltd.)、PI3-γ抑制剂,Evotec(Evotec)、PI3-γ抑制剂,Cellzome(Cellzome AG)、PI3-γ抑制剂,Pathway Therapeutics(PathwayTherapeutics Ltd.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、pictilisib(Roche Holdings Inc.)、PIK-90(CAS#677338-12-4)、SC-103980(Pfizer,New York,NY)、SF-1126(SemaforePharmaceuticals,Indianapolis,IN)、SH-5、SH-6、四氢姜黄素、TG100-115(TargegenInc.,San Diego,Calif)、曲西瑞宾、X-339(Xcovery,West Palm Beach,F1a)、XL-499(Evotech,Hamburg,Germany)、其药学上可接受的盐及其组合。
在本发明中,BVD-723是根据式(II)的化合物:
及其药学上可接受的盐。BVD-723是PI3Kγ的选择性抑制剂。BVD-723可以根据例如美国专利申请公开号2016/0214980进行合成,通过引用将其全部内容并入本文。BVD-723的两个对映异构体的对映异构体和外消旋混合物也包括在本发明的范围内。
在本发明中,术语“毒素”是指植物或动物来源的抗原性毒物或毒液。一个例子是白喉毒素或其部分。
在本发明中,术语“放射性核素”是指例如通过静脉内或口服施用给患者的放射性物质,之后其通过患者的正常代谢渗透到靶器官或组织中,在那里其递送局部辐射以短时间。放射性核素的例子包括但不限于I-125、At-211、Lu-177、Cu-67、I-131、Sm-153、Re-186、P-32、Re-188、In-114m和Y-90。
在本发明中,术语“免疫调控剂”是指通过增强或降低免疫系统产生抗体或致敏细胞的能力来改变免疫应答的物质,所述抗体或致敏细胞识别并与引发其产生的抗原反应。免疫调控剂可以是重组的、合成的或天然的制备物,并且包括细胞因子、皮质类固醇、细胞毒性剂、胸腺素和免疫球蛋白。某些免疫调控剂天然存在于体内,并且其中某些可以在药物制备物中获得。免疫调控剂的实例包括但不限于粒细胞集落刺激因子(G-CSF)、LAG-3、IMP-321、JCAR-014、ASLAN-002(BMS-777607)、干扰素、咪喹莫特和来自细菌的细胞膜级分、IL-2、IL-7、IL-12、CCL3、CCL26、CXCL7、合成的胞嘧啶磷酸鸟苷(CpG)、免疫检查点抑制剂及其组合。
在本发明中,术语“光活化治疗剂”是指在暴露于光后变得有活性的化合物和组合物。在例如美国专利申请序列号2011/0152230A1“Photoactive Metal Nitrosyls ForBlood Pressure Regulation And Cancer Therapy”中公开了光活化治疗剂的某些实例。
在本发明中,术语“放射增敏剂”是指使肿瘤细胞对放射疗法更敏感的化合物。放射增敏剂的实例包括米索硝唑、甲硝唑、替拉帕明和反式丁香酸钠及其组合。
在本发明中,术语“激素”是指由身体某一部分中的细胞释放的,影响在身体另一部分中的细胞的物质。激素的实例包括但不限于前列腺素、白三烯、前列环素、血栓烷、淀粉纤维素、抗苗勒管激素、脂联素、促肾上腺皮质激素、血管紧张素原、血管紧张素、血管加压素、心房肽、脑钠尿肽、降血钙素、胆囊收缩素、促肾上腺皮质激素释放激素、脑啡肽、内皮素、促红细胞生成素、促卵泡激素、甘丙肽、胃泌素、生长激素释放肽、胰高血糖素、促性腺激素释放激素、生长激素释放激素、人绒毛膜促性腺激素、人胎盘促泌素、生长激素、抑制素、胰岛素、生长调节素、瘦素、促脂素、促黄体生成素、黑素细胞刺激激素、胃动素、食欲素、催产素、胰多肽、甲状旁腺激素、催乳素、催乳素释放激素、松弛素、肾素、分泌素、生长抑素、血小板生成素、促甲状腺激素、睾丸酮、脱氢表雄酮、雄烯二酮、二氢睾丸酮、醛固酮、雌二醇、雌酮、雌三醇、皮质醇、孕酮、骨化三醇和骨化二醇。
如本文所用,“抗血管生成”剂是指减少或抑制新血管生长的物质,例如,血管内皮生长因子(VEGF)的抑制剂和内皮细胞迁移的抑制剂。抗血管生成剂包括但不限于2-甲氧基雌二醇、血管抑制素、贝伐单抗、软骨衍生的血管生成抑制因子、内皮抑素、IFN-α、IL-12、伊曲康唑、利诺米特、血小板因子4、催乳素、SU5416、苏拉明、他克莫尼、替加仑、四硫代钼酸盐、沙利度胺、血小板反应蛋白、血小板反应蛋白、TNP-470、齐夫-阿柏西普、其药学上可接受的盐、前药及其组合。
根据一个方面,本公开内容提供了用于在受试者中治疗或缓解的癌症的影响的方法,包括:(a)鉴定携带非V600E/K BRAF突变的患有癌症的受试者;和(b)对受试者施用有效量的ERK抑制剂或其药学上可接受的盐。
根据一个实施方案,ERK抑制剂选自BVD-523、SCH-722984(Merck&Co.)、SCH-772984(Merck&Co.)、SCH-900353(MK-8353)(Merck&Co.)、LY3214996(Lilly)、AEZS-140(Aeterna Zentaris)、AEZS-131(Aeterna Zentaris)、AEZS-136(Aeterna Zentaris)、LTT-462(Novartis)、RG-7842(Genentech)、CC-90003(Celgene)、KIN-4050(Kinentia)及其组合。根据一个实施方案,ERK抑制剂是BVD-523。在该实施方案的一个方面中,BVD-523或其药学上可接受的盐以还包含药学上可接受的载体或稀释剂的药物组合物的形式进行施用。
根据一个方面,本公开内容提供了鉴定携带非V600E/K BRAF突变的患有癌症的受试者的方法,包括(i)从受试者获得生物学样品;和(ii)筛选样品以确定受试者是否具有非V600E/K BRAF突变。
合适和优选的主题如本文所公开。在该实施方案中,方法可以用于治疗上文公开的癌症,包括具有以上鉴定的突变背景的那些癌症。鉴定此类突变的方法也如上所述。
在本发明中,生物学样品包括但不限于血液、血浆、尿液、皮肤、唾液和活检样品。通过本领域已知的常规程序和方法从受试者获得生物样品。鉴定突变的方法的非限制性实例包括PCR、测序、杂交捕获、溶液内捕获、分子倒置探针、荧光原位杂交(FISH)测定及其组合。
根据一个实施方案,方法进一步包括向该受试者施用选自MEK抑制剂、RAF抑制剂、HDAC抑制剂及其组合的至少一种另外的治疗剂。合适和优选的主题如本文所公开。在该实施方案中,方法可用于使用一种或多种上文公开的另外的治疗剂来治疗上文公开的癌症,包括具有上文鉴定的突变背景的那些癌症。鉴定此类突变的方法也如上所述。
根据一个方面,本公开内容提供了用于鉴定将从ERK抑制剂或其药学上可接受的盐的疗法中受益的患有癌症的受试者的方法,该方法包括:(a)从受试者获得生物样品;和(b)筛选样品以确定受试者是否具有非V600E/K BRAF突变,其中非V600E/K BRAF突变的存在证实受试者将从ERK抑制剂或其药学上可接受的盐的疗法中受益。根据一些实施方案,方法进一步包括向受试者施用ERK抑制剂或其药学上可接受的盐。根据一些实施方案,方法进一步包括向受试者施用至少一种另外的治疗剂。在该实施方案中,方法可用于鉴定在上述癌症中的上文鉴定的突变背景。鉴定此类突变的方法也如上所述。在该实施方案中,所鉴定的患者将受益于其的ERK抑制剂如上所述。另外的治疗剂如上所述。合适和优选的主题如上所述。
根据一个方面,本公开内容提供了用于在受试者中治疗或缓解癌症的影响的方法,包括:(a)鉴定携带非V600E/K BRAF突变的患有癌症的受试者;和(b)向受试者施用有效量的BVD-523或其药学上可接受的盐。根据一个方面,本公开内容提供了用于鉴定将从BVD-523或其药学上可接受的盐的疗法中受益的患有癌症的受试者的方法,该方法包括:(a)从受试者获得生物样品;和(b)筛选样品以确定受试者是否具有非V600E/K BRAF突变,其中非V600E/K BRAF突变的存在证实受试者将从BVD-523或其药学上可接受的盐的疗法中受益。在这些实施方案中,方法可用于鉴定在上述癌症中的上文鉴定的突变背景。鉴定此类突变的方法也如上所述。合适和优选的主题如上所述。
本公开内容的另一方面提供了用于在携带非V600E/K BRAF突变的受试者中治疗或改善癌症的影响的试剂盒。根据一些实施方案,试剂盒包含有效量的如上所述的ERK抑制剂,和任选地如上所述的另外的治疗剂。
试剂盒还可包括用于本发明的每种抗癌剂(其可以例如以药物组合物的形式)和其他反应剂(例如,缓冲剂、平衡盐溶液等)的合适的储存容器,例如安瓿、小瓶、试管等,用于向受试者施用抗癌剂。本发明的抗癌剂和其他反应剂可以以任何方便的形式存在于试剂盒中,例如以溶液或粉末形式。试剂盒可进一步包括包装容器,任选地具有用于容纳药物组合物和其他任选试剂的一个或多个隔区。
在本发明中,本发明的抗癌剂包括包含本文所公开的该抗癌剂的药物组合物的“有效量”或“治疗有效量”是当施用于受试者时,足以实现本文所述有益的或所需的结果的这种试剂或组合物的量。有效的剂型、施用方式和剂量可以凭经验确定,并且这种确定在本领域技术范围内。本领域技术人员应理解,剂量将随施用途径,排泄速率,治疗持续时间,在施用的任何其他药物的特征,哺乳动物例如人类患者的年龄、大小和种类,以及医学和兽医学领域众所周知的类似因素而变化。通常,根据本发明的试剂或组合物的合适剂量将是试剂或组合物的这样的量,其是有效产生所需的作用的最低剂量。本发明的试剂或组合物的有效剂量可以全天以适当的间隔分开以两个、三个、四个、五个、六个或更多个亚剂量施用。
本文公开的BVD-523、RAF抑制剂、ERK抑制剂或另一种抗癌剂的剂量的非限制性实例为每天约1mg/kg至约2400mg/kg,例如每天约1mg/kg至约1200mg/kg、每天75mg/kg至约300mg/kg,包括每天约1mg/kg至约100mg/kg。此类试剂的其他代表性剂量包括约1mg/kg、5mg/kg、10mg/kg、15mg/kg、20mg/kg、25mg/kg、30mg/kg、35mg/kg、40mg/kg、45mg/kg、50mg/kg、60mg/kg、70mg/kg、75mg/kg、80mg/kg、90mg/kg、100mg/kg、125mg/kg、150mg/kg、175mg/kg、200mg/kg、250mg/kg、300mg/kg、400mg/kg、500mg/kg、600mg/kg、700mg/kg、800mg/kg、900mg/kg、1000mg/kg、1100mg/kg、1200mg/kg、1300mg/kg、1400mg/kg、1500mg/kg、1600mg/kg、1700mg/kg、1800mg/kg、1900mg/kg、2000mg/kg、2100mg/kg、2200mg/kg和2300mg/kg每天。本文公开的BVD-523、RAF抑制剂、ERK抑制剂或另外的抗癌剂的有效剂量可以全天以适当的间隔分开以两个、三个、四个、五个、六个或更多个亚剂量施用。
本发明的BVD-523、RAF抑制剂、ERK抑制剂或另外的治疗剂或者包含其的药物组合物可以以任何所需和有效的方式施用:用于口服摄取,或作为软膏或滴剂用于局部施用给眼,或以任何适当方式(例如腹膜内、肿瘤内、皮下、局部、皮内、吸入、肺内、直肠、阴道、舌下、肌肉内、静脉内、动脉内、鞘内或淋巴管内)进行肠胃外或其他施用。此外,可以将本发明的BVD-523、RAF抑制剂或另外的治疗剂或者包含其的药物组合物与其他治疗联合施用。如果需要,可以将本发明的BVD-523、RAF抑制剂或另外的治疗剂或者包含其的药物组合物包封或以其他方式保护以免受胃或其他分泌物。
本发明的药物组合物包含一种或多种活性成分,例如治疗剂,与一种或多种药学上可接受的稀释剂或载体以及任选的一种或多种其他化合物、药物、成分和/或材料混合。不管选择的施用途径如何,通过本领域技术人员已知的常规方法将本发明的试剂/化合物配制成药学上可接受的剂型。参见,例如,Remington,The Science and Practice ofPharmacy(21st Edition,Lippincott Williams and Wilkins,Philadelphia,Pa)。
药学上可接受的稀释剂或载体是本领域众所周知的(参见,例如,Remington,TheScience and Practice of Pharmacy(21st Edition,Lippincott Williams andWilkins,Philadelphia,Pa)和The National Formulary(American PharmaceuticalAssociation,Washington,D.C.)),并且包括糖(例如乳糖、蔗糖、甘露醇和山梨糖醇),淀粉,纤维素制备物,磷酸钙(例如磷酸二钙、磷酸三钙和磷酸氢钙),柠檬酸钠,水,水溶液(例如,盐水、氯化钠注射液、林格注射液、葡萄糖注射液、葡萄糖和氯化钠注射液、乳酸林格氏注射液),醇类(例如乙醇、丙醇和苄醇),多元醇(例如甘油、丙二醇和聚乙二醇),有机酯(例如油酸乙酯和甘油三酸酯),生物可降解的聚合物(例如聚丙交酯-聚乙交酯、聚(原酸酯)和聚(酐)),弹性基质,脂质体,微球,油(例如玉米、胚芽、橄榄、蓖麻、芝麻、棉籽和花生),可可脂,蜡(例如栓剂蜡),石蜡,硅酮,滑石,硅酸酯等。在与制剂的其他成分相容并且对受试者无害的意义上,用于本发明药物组合物中的每种药学可接受的稀释剂或载体必须是“可接受的”。适用于所选剂型和预期施用途径的稀释剂或载体是本领域众所周知的,并且用于所选剂型和施用方法的可接受的稀释剂或载体可以使用本领域的普通技术来确定。
本发明的药物组合物可以任选地包含药物组合物中常用的其他成分和/或材料。这些成分和材料在本领域中是众所周知的,并且包括(1)填充剂或增量剂,例如淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(2)粘合剂,例如羧甲基纤维素、藻酸盐、明胶、聚乙烯吡咯烷酮、羟丙基甲基纤维素、蔗糖和阿拉伯胶;(3)保湿剂,如甘油;(4)崩解剂,例如琼脂、碳酸钙、马铃薯或木薯淀粉、海藻酸、某些硅酸盐、淀粉羟乙酸钠、交联的羧甲基纤维素钠和碳酸钠;(5)缓溶剂,如石蜡;(6)吸收促进剂,例如季铵化合物;(7)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(8)吸收剂,例如高岭土和膨润土;(9)润滑剂,例如滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇和月桂基硫酸钠;(10)悬浮剂,例如乙氧基化异硬脂醇、聚氧乙烯山梨糖醇和失水山梨醇酯、微晶纤维素、偏氢氧化铝、膨润土、琼脂和黄蓍胶;(11)缓冲剂;(12)赋形剂,例如乳糖、奶糖、聚乙二醇、动植物脂肪、油、蜡、石蜡、可可脂、淀粉、黄蓍胶、纤维素衍生物、聚乙二醇、硅酮、膨润土、硅酸、滑石、水杨酸盐、氧化锌、氢氧化铝、硅酸钙和聚酰胺粉;(13)惰性稀释剂,例如水或其他溶剂;(14)防腐剂;(15)表面活性剂;(16)分散剂;(17)控释或吸收延迟剂,例如羟丙基甲基纤维素、其他聚合物基质、生物可降解的聚合物、脂质体、微球、单硬脂酸铝、明胶和蜡;(18)遮光剂;(19)佐剂;(20)润湿剂;(21)乳化悬浮剂;(22)增溶剂和乳化剂,例如乙醇、异丙醇、碳酸乙酯、乙酸乙酯、苄醇、苯甲酸苄酯、丙二醇、1,3-丁二醇、油(尤其是棉籽、花生、玉米、胚芽、橄榄、蓖麻和芝麻油)、甘油、四氢呋喃醇、聚乙二醇和失水山梨醇的脂肪酸酯;(23)推进剂,例如氯氟烃和挥发性未取代的烃,例如丁烷和丙烷;(24)抗氧化剂;(25)使制剂与预期接受者的血液等渗的试剂,例如糖和氯化钠;(26)增稠剂;(27)包衣材料,例如卵磷脂;和(28)甜味剂、调味剂、着色剂、芳香剂和防腐剂。在与制剂的其他成分相容并且对受试者无害的意义上,每种这样的成分或材料必须是“可接受的”。适用于所选剂型和预期施用途径的成分和材料是本领域众所周知的,并且可以使用本领域普通技术来确定用于所选剂型和施用方法的可接受的成分和材料。
适用于口服施用的本发明药物组合物可以是胶囊、扁囊剂、丸剂、片剂、粉末、颗粒、在水性或非水性液体中的溶液或悬浮液、水包油或油包水型液体乳剂、驰剂或糖浆、锭剂、大丸剂、舐剂或糊剂。这些制剂可以通过本领域已知的方法,例如通过常规的锅包衣、混合、制粒或冻干方法来制备。
可以例如通过将一种或多种活性成分与一种或多种药学上可接受的稀释剂或载体以及任选地一种或多种填充剂、增量剂、粘合剂、保湿剂、崩解剂、溶液阻滞剂、吸收促进剂、润湿剂、吸收剂、润滑剂和/或着色剂混合来制备用于口服施用的固体剂型(胶囊、片剂、丸剂、糖衣丸、粉末、颗粒等)。可以使用合适的赋形剂将相似类型的固体组合物用作软和硬填充明胶胶囊中的填充剂。片剂可以任选地与一种或多种辅助成分一起通过压制或模制制成。可以使用合适的粘合剂、润滑剂、惰性稀释剂、防腐剂、崩解剂、表面活性剂或分散剂来制备压制的片剂。模制片剂可以通过在合适的机器中模制来制备。片剂和其他固体剂型,例如糖衣丸、胶囊、丸剂和颗粒,可以任选地用包衣和衣壳,例如肠溶衣和药物配制领域众所周知的其他包衣进行刻痕或制备。它们也可以被配制为提供其中的活性成分的缓慢或受控释放。它们可以例如通过保留细菌的过滤器的过滤来灭菌。这些组合物还可以任选地包含遮光剂,并且可以是这样的组合物,使得它们仅或优选地在胃肠道的特定部分中任选地以延迟的方式释放活性成分。活性成分也可以是微囊形式。
用于口服施用的液体剂型包括药学上可接受的乳剂、微乳剂、溶液、悬浮剂液、糖浆和驰剂。液体剂型可包含本领域通常使用的合适的惰性稀释剂。除惰性稀释剂外,口服组合物还可包含佐剂,例如润湿剂、乳化和悬浮剂、甜味剂、调味剂、着色剂、芳香和防腐剂。悬浮液可以含有悬浮试剂。
用于直肠或阴道施用的本发明药物组合物可以以栓剂形式存在,其可以通过将一种或多种活性成分与一种或多种合适的无刺激性稀释剂或载体混合来制备,所述无刺激性稀释剂或载体在室温下为固体,但在人体温度下为液体,并且因此会在直肠或阴道腔内融化并释放活性化合物。适用于阴道施用的本发明药物组合物还包括阴道栓、棉塞、乳膏、凝胶、糊剂、泡沫或喷雾制剂,其含有本领域已知合适的药学上可接受的稀释剂或载体。
用于局部或透皮施用的剂型包括粉末、喷雾剂、软膏、糊剂、乳膏、洗剂、凝胶、溶液、贴剂、滴剂和吸入剂。活性剂/化合物可以在无菌条件下与合适的药学上可接受的稀释剂或载体混合。软膏、糊剂、乳膏和凝胶可以包含赋形剂。粉末和喷雾剂可以包含赋形剂和推进剂。
适用于肠胃外施用的本发明药物组合物可包含一种或多种试剂/化合物与以下组合:一种或多种药学上可接受的无菌等渗水性或非水性溶液、分散液、悬浮液或乳液,或者可以就在使用前重构为无菌可注射溶液或分散液的无菌粉末,其可以包含合适的抗氧化剂、缓冲液、溶质(使制剂与预期接受者的血液等渗),或者悬浮剂或增稠剂。可以例如通过使用包衣材料,在分散液的情况下通过维持所需的粒径以及通过使用表面活性剂来维持适当的流动性。这些药物组合物还可包含合适的佐剂,例如润湿剂、乳化剂和分散剂。也可能需要包括等渗剂。另外,可通过包含延迟吸收的试剂来引起可注射药物形式的延长吸收。
在某些情况下,为了延长药物(例如,药物制剂)的作用,需要减慢其从皮下或肌肉内注射的吸收。这可以通过使用水溶性差的结晶或无定形材料的液体悬浮液来实现。
然后,活性剂/药物的吸收速率取决于其溶解速率,而溶解速率又取决于晶体尺寸和晶体形式。备选地,可以通过将活性剂/药物溶解或悬浮在油性媒介物中来实现肠胃外施用的试剂/药物的延迟吸收。可通过在生物可降解的聚合物中形成活性成分的微胶囊基质来制备可注射的贮库形式。取决于活性成分与聚合物的比例以及所使用的特定聚合物的性质,可以控制活性成分释放的速率。还可以通过将药物截留在与身体组织相容的脂质体或微乳剂中来制备可注射储库的制剂。可注射材料可以例如通过保留细菌的过滤器的过滤而进行灭菌。
制剂可以存在于单位剂量或多剂量的密封的容器中,例如安瓿和小瓶,并且可以在冻干条件下储存,仅需要在使用前立即添加无菌液体稀释剂或载体,例如注射用水。临时注射溶液和悬浮液可以由上述类型的无菌粉末、颗粒和片剂制备。
提供以下实施例以进一步示例说明本发明的方法。这些实施例仅是说明性的并无意以任何方式限制本发明的范围。
实施例1
以下实施例显示了BVD-523的实体瘤1b期试验的结果。图2中描绘的瀑布图提供了人类临床试验患者信息的图示,显示了每个个体患者对BVD-523治疗的应答,以肿瘤负担变化%进行测量。患者通常每天两次(BID)接受600mg,如果通过其他缓和医疗无法控制副作用,则某些患者接受降级剂量300mg–400mg BID。
如图2所示,使用Response Evaluation Criteria in Solid Tumors 1.1版(RECIST v1.1),在28位可评估患者中评估对BVD-523的肿瘤应答。一名患者未同时接受两次靶病变扫描,因此未进行评估。图上的水平轴用作每个患者的基线测量。垂直轴是相对于基线的最大百分比变化的测量;即,根据RECIST v1.1通过放射学测量的肿瘤负担的生长或减少的百分比。放射学测量包括计算机断层扫描(CT)扫描并且极少数情况下包括磁共振成像(MRI)。
由图2表示的肿瘤负荷数据从图左侧的最差值(即,肿瘤负荷的最大进展)到图右侧的最佳值(即,肿瘤负荷的最大减少)来排列。先前已描述了用于测量靶病变的RECISTv1.1应答标准。(参见Eisenhauer,E.A.等人,New response evaluation criteria insolid tumours:Revised RECIST guideline(version 1.1),European J.of Cancer 45,228-247(2009),通过引用整体并入本文)。应答标准如下:
完全应答(CR)-所有靶病变的消失;
部分应答(PR)-以基线总和直径为参考,靶病变的直径总和降低至少30%;如在图2中所示,用水平线指示部分应答的30%降低阈值。
进展性疾病(PD)-以研究中的最小和(如果是研究中的最小值,包括基线总和)作为参考,靶病变的直径总和增加至少20%。除了相对增加20%外,总和还必须显示至少5mm的绝对增加(注意:一个或多个新病变的出现也被视为进展);
稳定疾病(SD)–以研究时最小的总直径作为参考,既没有足够的收缩符合PR,也没有足够的增长符合PD。
图2还显示了测量每位患者肿瘤负担的癌症或器官的类型,以及患者肿瘤样品中鉴定出的非典型BRAF突变的类型。在代表的28位患者中,有13位患者肿瘤包含BRAF D594突变(7位是D594G,6位是D594N);1位患者肿瘤包含BRAF F247L突变;1位患者肿瘤包括BRAF基因与核因子IC(NFIC)基因融合(即BRAF-NFIC融合突变);1位患者肿瘤包含BRAF G466V突变;5位患者肿瘤包含BRAF G469突变(1位是G469V,4位是G469A);3位患者肿瘤包含BRAFK601E突变;1位患者肿瘤包含BRAF L485W突变;3位患者肿瘤包含BRAF L597突变(一位不明确,2位是L597Q),并且2位患者肿瘤包含T599重复。对于每位患者,BRAF突变的类型通过颜色代码和癌症类型来指示(见图2)。
五位PR患者的靶病变总数相对于基线减少了35%至100%。这些患者表现出:包含L485W突变的胆囊肿瘤;包含G469A突变的头/颈部鳞状细胞瘤;包含BRAF L597Q突变或BRAFT599复制的非小细胞肺癌;以及包含BRAF G469A突变的小肠肿瘤。19位患者表现出稳定的疾病。初次评估时三位患者表现出进展性疾病。(见图2)。因此,BVD-523治疗出人意料地导致了具有非典型(即非V600E/K)BRAF突变的28位患者中24位的部分应答或稳定疾病。
图3显示了按组分类的游泳者图的治疗持续时间。第1组的成员是具有在除结肠直肠癌(CRC)和非小细胞肺癌(NSCLC)以外的任何肿瘤类型中的任何BRAF突变,并且先前未接受过MAPK途径抑制剂的治疗的任何患者。第2组的成员是具有在CRC中的任何BRAF突变,先前未接受过MAPK途径抑制剂的治疗的患者。第3组的成员是患有具有BRAF V600E/K突变的肿瘤,该肿瘤对MAPK抑制剂治疗无效的患者。第6组的成员是具有在NSCLC中存在的任何BRAF突变的患者。如图3所示,包括所有28位患者通过横线表示,每个受试者一个横线。从组的顶部(最长治疗持续时间)到底部(最短治疗持续时间)说明了每个组中每个受试者的治疗持续时间。水平轴表示患者在研究中的持续时间(天)。图3还显示了根据RECIST v1.1为每个患者实现的应答类型(菱形=部分应答;圆圈=稳定疾病;垂直线=进展性疾病;三角形=未评估)。
图4显示了在因BRAF突变破坏的瀑布图中的治疗持续时间。包括所有根据RECISTv1.1应答标准测量的28位患者,以及未通过RECIST v1.1评估的其他患者(菱形=部分应答;圆圈=稳定疾病;竖线=进展性疾病;三角形=未评估)。对于携带相同BRAF突变的肿瘤,在中断之前BVD-523治疗的平均持续时间为:D594,73.6天;G469,208.14天;K601E,50.25天;L597,73.3天;T599 Dup,63.5天。对于代表特定BRAF突变的单个患者,治疗持续时间为:L485W,304天;F247L,84天;G466V,77天;BRAF融合,65天;BRAF-AGAP3重排,43天;BRAF外显子15剪接变体,15天。通过对癌症患者进行BRAF突变的基因组筛选,并在对这些突变(作为驱动突变)进行完整的体外表征之前对其进行治疗,BVD-523被证明可用于研究和发现携带BRAF中突变的患者的有效治疗选择。患者的临床人群和功效主要不是由肿瘤类型决定,而是由ERK 1/2激酶活化上游的酶如BRAF的突变状态决定。
总之,所提供的实施例提供了来自新型ERK抑制剂BVD-523的实体瘤1b期试验的数据,用于治疗患有携带非典型BRAF突变的癌症的患者。连续的每天两次用BVD-523进行治疗在几位患者中产生抗肿瘤作用,并且不仅限于任何一种特定的癌症类型或非典型的BRAF突变。
文件资料
ABSALAN,Farnaz,Mostafa Ronaghi(2008).Molecular Inversion ProbeAssay.Methods in Molecular Biology 396.Humana Press.pp.315–330.
AHRONIAN LG,Sennott EM,Van Allen EM,Wagle N,Kwak EL,Faris JE,etal.Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutantcolorectal cancer through MAPK pathway alterations.Cancer Discov 2015;5:358–67.
ARCILA ME,Drilon A,Sylvester BE,Lovly CM,Borsu L,Reva B,et al.MAP2K1(MEK1)mutations define a distinct subset of lung adenocarcinoma associatedwith smoking.Clin Cancer Res 2015;21:1935-43.
ARONOV AM,Baker C,Bemis GW,Cao J,Chen G,Ford PJ,et al.Flipped out:structure-guided design of selective pyrazolylpyrrole ERK inhibitors.J MedChem 2007;50:1280-7.
ARONOV AM,Tang Q,Martinez-Botella G,Bemis GW,Cao J,Chen G,etal.Structure-guided design of potent and selective pyrimidylpyrroleinhibitors of extracellular signal-regulated kinase(ERK)using conformationalcontrol.J Med Chem 2009;52:6362-8.
ARRINGTON AK,Heinrich EL,Lee W,Duldulao M,Patel S,Sanchez J,etal.Prognostic and predictive roles of KRAS mutation in colorectal cancer.IntJ Mol Sci 2012;13:12153-68.
CARGNELLO M,Roux PP.Activation and function of the MAPKs and theirsubstrates,the MAPK-activated protein kinases.Microbiol Mol Biol Rev 2011;75:50-83.
CARLINO MS,Fung C,Shahheydari H,Todd JR,Boyd SC,Irvine M,etal.Preexisting MEK1P124 mutations diminish response to BRAF inhibitors inmetastatic melanoma patients.Clin Cancer Res 2015;21:98-105.
CHAPMAN PB,Hauschild A,Robert C,Haanen JB,Ascierto P,Larkin J,etal.Improved survival with vemurafenib in melanoma with BRAF V600E mutation.NEngl J Med 2011;364:2507-16.
CORCORAN,R.B.,et al.BRAF gene amplification can promote acquiredresistance to MEK inhibitors in cancer cells harboring the BRAF V600Emutation.Sci Signal(2010);3(149):ra84.
DAI,B.,et al.STAT3 mediates resistance to MEK inhibitor throughmicroRNA miR-17.Cancer Res(2011);71:3658-3668.
DAVIES H,Bignell GR,Cox C,Stephens P,Edkins S,Clegg S,et al.Mutationsof the BRAF gene in human cancer.Nature 2002;417:949–54.
DESCHENES-SIMARD X,Kottakis F,Meloche S,Ferbeyre G.ERKs in cancer:friends or foes?Cancer Res 2014;74:412–9.
DOBRZYCKA B,Terlikowski SJ,Kowalczuk O,Niklinska W,Chyczewski L,Kulikowski M.Mutations in the KRAS gene in ovarian tumors.Folia HistochemCytobiol 2009;47:221–4.
EMERY,C.M.,et al.MEK1 mutations confer resistance to MEK and B-RAFinhibition.PNAS(2009);106(48):20411-6.
FEDOROV O,Niesen FH,Knapp S.Kinase inhibitor selectivity profilingusing differential scanning fluorimetry.Methods Mol Biol 2012;795:109-18.
FLAHERTY KT,Infante JR,Daud A,Gonzalez R,Kefford RF,Sosman J,etal.Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.NEngl J Med 2012;367:1694-703.
GOETZ EM,Ghandi M,Treacy DJ,Wagle N,Garraway LA.ERK mutations conferresistance to mitogen-activated protein kinase pathway inhibitors.Cancer Res2014;74:7079-89.
GOLLOB JA,Wilhelm S,Carter C,Kelley SL.Role of Raf kinase in cancer:therapeutic potential of targeting the Raf/MEK/ERK signal transductionpathway.Semin Oncol 2006;33:392-406.
GREGER,James G.,et al."Combinations of BRAF,MEK,and PI3K/mTORinhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436dabrafenib,mediated by NRAS or MEK mutations."Molecular cancer therapeutics11.4(2012):909-920.
GROENENDIJK FH,Bernards R.Drug resistance to targeted therapies:dejavu all over again.Mol Oncol 2014;8:1067-83.
HALL RD,Kudchadkar RR.BRAF mutations:signaling,epidemiology,andclinical experience in multiple malignancies.Cancer Control 2014;21:221-30.
HARDENBOL,P.,et al.Multiplexed genotyping with sequence-taggedmolecular inversion probes.Nat.Biotechnol.2003,no.21,p.673-678.
HATZIVASSILIOU,Georgia,et al."RAF inhibitors prime wild-type RAF toactivate the MAPK pathway and enhance growth."Nature 464.7287(2010):431-435.
HATZIVASSILIOU G,Liu B,O'Brien C,Spoerke JM,Hoeflich KP,Haverty PM,etal.ERK inhibition overcomes acquired resistance to MEK inhibitors.Mol CancerTher 2012;11:1143-54.
HAUSCHILD A,Grob J-J,Demidov LV,Jouary T,Gutzmer R,Millward M,etal.Dabrafenib in BRAF-mutated metastatic melanoma:a multicentre,open-label,phase 3randomised controlled trial.Lancet 2012;380:358-65.
HAYES TK,Neel NF,Hu C,Gautam P,Chenard M,Long B,et al.Long-Term ERKInhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYCDegradation and Senescence-like Growth Suppression.Cancer Cell 2016;29:75-89.
HEZEL AF,Noel MS,Allen JN,Abrams TA,Yurgelun M,Faris JE,et al.PhaseII study of gemcitabine,oxaliplatin in combination with panitumumab in KRASwild-type unresectable or metastatic biliary tract and gallbladder cancer.BrJ Cancer 2014;111:430–6.
JHA S,Morris EJ,Hruza A,Mansueto MS,Schroeder G,Arbanas J,etal.Dissecting therapeutic resistance to ERK inhibition.Mol Cancer Ther 2016;15:548-59.
JOHANNESSEN,C.M.,et al.COT/MAP3K8 drives resistance to RAF inhibitionthrough MAP kinase pathway reactivation.Nature(2010);468(7326):968-972.
JOHNSON DB,Menzies AM,Zimmer L,Eroglu Z,Ye F,Zhao S,et al.AcquiredBRAF inhibitor resistance:A multicenter meta-analysis of the spectrum andfrequencies,clinical behaviour,and phenotypic associations of resistancemechanisms.Eur J Cancer 2015;51:2792-9.
KANDA M,Matthaei H,Wu J,Hong SM,Yu J,Borges M,et al.Presence ofsomatic Mutations in most early-stage pancreatic intraepithelialneoplasia.Gastroenterology 2012;142:730-733.
KHATTAK M,Fisher R,Turajlic S,Larkin J.Targeted therapy andimmunotherapy in advanced melanoma:an evolving paradigm.Ther Adv Med Oncol2013;5:105–18.
KING,Alastair J.,et al."Dabrafenib;preclinical characterization,increased efficacy when combined with trametinib,while BRAF/MEK toolcombination reduced skin lesions."PloS one 8.7(2013):e67583.
LARKIN J,Ascierto PA,Dréno B,Atkinson V,Liszkay G,Maio M,etal.Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.N Engl J Med2014;371:1867-76.
LITTLE,A.S.,et al.,Amplification of the Driving Oncogene,KRAS orBRAF,Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal CancerCells.Sci.Signal.4,ra17(2011).
LIU,Dingxie,et al."BRAF V600E maintains proliferation,transformation,and tumorigenicity of BRAF-mutant papillary thyroid cancer cells."Journal ofClinical Endocrinology&Metabolism 92.6(2007):2264-2271.
LIU B,Fu L,Zhang C,Zhang L,Zhang Y,Ouyang L,et al.Computationaldesign,chemical synthesis,and biological evaluation of a novel ERK inhibitor(BL-EI001)with apoptosis-inducing mechanisms in breast cancer.Oncotarget2015;6:6762-75.
LONG GV,Fung C,Menzies AM,Pupo GM,Carlino MS,Hyman J,et al.IncreasedMAPK reactivation in early resistance to dabrafenib/trametinib combinationtherapy of BRAF-mutant metastatic melanoma.Nat Commun 2014;5:5694.
LONG GV,Stroyakovskiy D,Gogas H,Levchenko E,de Braud F,Larkin J,etal.Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma:a multicentre,double-blind,phase 3 randomised controlledtrial.Lancet 2015;386:444-51.
MANANDHAR SP,Hildebrandt ER,Schmidt WK.Small-molecule inhibitors ofthe Rce1p CaaX protease.J Biomol Screen.2007;12(7):983–993.
MASSEY PR,Prasad V,Figg WD,Fojo T.Multiplying therapies and reducingtoxicity in metastatic melanoma.Cancer Biol Ther 2015;16:1014-8.
MAURER,T,Garrenton,LS,Oh,A,Pitts,K,Anderson,DJ,Skelton,NJ,Fauber,BP,Pan,B,Malek,S,Stokoe,D,Ludlam,MJC,Bowman,KK,Wu,J,Giannetti,AM,Starovasnik,MA,Mellman,I,Jackson,PK,Rudolph,J,Wang,W,Fang,G.Small-molecule ligands bind to adistinct pocket in Ras and inhibit SOS-mediated nucleotide exchangeactivity.PNAS.2012;109(14):5299-304.
MCARTHUR GA,Chapman PB,Robert C,Larkin J,Haanen JB,Dummer R,etal.Safety and efficacy of vemurafenib in BRAFv600E and BRAFv600K mutation-positive melanoma (BRIM-3):extended follow-up of a phase 3,randomised,open-label study.Lancet Oncol 2014;15:323–32.
MEKINIST[package insert].Research Triangle Park,NC:GlaxoSmithKline;2014.
METZKER,Emerging technologies in DNA sequencing Genome Res.2005.15:1767-1776.
MITTAL,Rohit et al."The acetyltransferase activity of the bacterialtoxin YopJ of Yersinia is activated by eukaryotic host cell inositolhexakisphosphate."Journal of Biological Chemistry 285.26(2010):19927-19934.
MORRIS EJ,Jha S,Restaino CR,Dayananth P,Zhu H,Cooper A,etal.Discovery of a novel ERK inhibitor with activity in models of acquiredresistance to BRAF and MEK inhibitors.Cancer Discov 2013;3:742-50.
NAZARIAN,R.,et al.Melanomas acquire resistance to B-RAF(V600E)inhibition by RTK or N-RAS upregulation.Nature.2010;468(7326):973-977.
NIKOLAEV SI,Rimoldi D,Iseli C,Valsesia A,Robyr D,Gehrig C,et al.Exomesequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations inmelanoma.Nat Genet 2012;44:133–9.
NILSSON,M.,et al.Padlock probes:circularizing oligonucleotides forlocalized DNA detection.Science.1994,no.265,p.2085-2088.
O'HARA AJ,Bell DW.The genomics and genetics of endometrial cancer.AdvGenomics Genet 2012;2012:33–47.
OJESINA AI,Lichtenstein L,Freeman SS,Pedamallu CS,Imaz-Rosshandler I,Pugh TJ,et al.Landscape of genomic alterations in cervical carcinomas.Nature2014;506:371-5.
OTA et al.,Single nucleotide polymorphism detection by polymerasechain reaction-restriction fragment length polymorphism.Nat Protoc.2007;2(11):2857-64.
PARAISO KHT,Fedorenko IV,Cantini LP,Munko AC,Hall M,Sondak VK,etal.Recovery of phospho-ERK activity allows melanoma cells to escape from BRAFinhibitor therapy.Br J Cancer 2010;102:1724–30.
PATGIRI A,Yadav,KK,Arora,PS,Bar-Sagi,D.An orthosteric inhibitor ofthe Ras-Sos interaction.Nat Chem Biol.2011;7:585-587.
PENNYCUICK A,Simpson T,Crawley D,Lal R,Santis G,Cane P,et al.RoutineEGFR and KRAS mutation analysis using COLD-PCR in non-small cell lungcancer.Int J Clin Pract 2012;66:748–52.
PORTER SB,Hildebrandt ER,Breevoort SR,Mokry DZ,Dore TM,SchmidtWK.Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl(acyloxy)methyl ketones.Biochim Biophys Acta.2007;1773(6):853–862.
POULIKAKOS PI,Persaud Y,Janakiraman M,Kong X,Ng C,Moriceau G,etal.RAF inhibitor resistance is mediated by dimerization of aberrantly splicedBRAF(V600E).Nature 2011;480:387-90.
QUEIROLO P,Picasso V,Spagnolo F.Combined BRAF and MEK inhibition forthe treatment of BRAF-mutated metastatic melanoma.Cancer Treat Rev 2015;41:519-26.
RASOLA A,Sciacovelli M,Chiara F,Pantic B,Brusilow WS,BernardiP.Activation of mitochondrial ERK protects cancer cells from death throughinhibition of the permeability transition.Proc Natl Acad Sci U S A 2010;107:726–31.
RIZOS H,Menzies AM,Pupo GM,Carlino MS,Fung C,Hyman J,et al.BRAFinhibitor resistance mechanisms in metastatic melanoma:spectrum and clinicalimpact.Clin Cancer Res 2014;20:1965-77.
ROBERT C,Karaszewska B,Schachter J,Rutkowski P,Mackiewicz A,Stroiakovski D,et al.Improved overall survival in melanoma with combineddabrafenib and trametinib.N Engl J Med 2015;372:30-9.
ROMEO Y,Zhang X,Roux PP.Regulation and function of the RSK family ofprotein kinases.Biochem J 2012;441:553–69.
RUDOLPH J,Xiao Y,Pardi A,Ahn NG.Slow inhibition and conformationselective properties of extracellular signal-regulated kinase 1 and 2inhibitors.Biochemistry 2015;54:22-31.
SHAUL YD,Seger R.The MEK/ERK cascade:from signaling specificity todiverse functions.Biochim Biophys Acta 2007;1773:1213–26.
SHI H,Hugo W,Kong X,Hong A,Koya RC,Moriceau G,et al.Acquiredresistance and clonal evolution in melanoma during BRAF inhibitortherapy.Cancer Discov 2014;4:80-93.
SHIMA,F,Yoshikawa,Y,Ye,M,Araki,M,Matsumoto,S,Liao,J,Hu,L,Sugimoto,T,Ijiri,Y,Takeda,A,Nishiyama,Y,Sato,C,Muraoka,S,Tamura,A,Osoda,T,Tsuda,K-I,Miyakawa,T,Fukunishi,H,Shimada,J,Kumasaka,Yamamoto,M,Kataoka,T.In silicodiscovery of small-molecule Ras inhibitors that display antitumor activity byblocking the Ras-effector interaction.PNAS.2013;110(20):8182-7.
SCHUBBERT S,Shannon K,Bollag G.Hyperactive Ras in developmentaldisorders and cancer.Nat Rev Cancer 2007;7:295–308.
SUN C,Hobor S,Bertotti A,Zecchin D,Huang S,Galimi F,et al.Intrinsicresistance to MEK inhibition in KRAS mutant lung and colon cancer throughtranscriptional induction of ERBB3.Cell Rep 2014;7:86-93.
TAFLINAR[package insert].Research Triangle Park,NC:GlaxoSmithKline;2015.
TRUNZER K,Pavlick AC,Schuchter L,Gonzalez R,McArthur GA,Hutson TE,etal.Pharmacodynamic effects and mechanisms of resistance to vemurafenib inpatients with metastatic melanoma.J Clin Oncol 2013;31:1767-74.
VILLANUEVA,J.,et al.Acquired resistance to BRAF inhibitors mediatedby a RAF kinase switch in melanoma can be overcome by cotargeting MEK andIGF-1R/PI3K.Cancer Cell.2010;18:683-695.
WAGLE,N.,et al.Dissecting therapeutic resistance to RAF inhibition inmelanoma by tumor genomic profiling.Journal of Clinical Oncology 2011;29(22):3085-3096.
WAGLE N,Van Allen EM,Treacy DJ,Frederick DT,Cooper ZA,Taylor-WeinerA,et al.MAP kinase pathway alterations in BRAF-mutant melanoma patients withacquired resistance to combined RAF/MEK inhibition.Cancer Discov 2014;4:61-8.
Wainstein E,Seger R.The dynamic subcellular localization of ERK:mechanisms of translocation and role in various organelles.Curr Opin CellBiol 2016;39:15-20.
WANG,H.,et al.Identification of the MEK1(F129L)activating mutation asa potential mechanism of acquired resistance to MEK inhibition in humancancers carrying the B-RAF V600E mutation.Cancer Res(2011);71(16):5535-45.
YANG W,Soares J,Greninger P,Edelman EJ,Lightfoot H,Forbes S,etal.Genomics of Drug Sensitivity in Cancer(GDSC):a resource for therapeuticbiomarker discovery in cancer cells.Nucleic Acids Res 2013;41:D955-D961.
YAO Z,Torres NM,Tao A,Gao Y,Luo L,Li Q,et al.BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivityto Pharmacologic Inhibition.Cancer Cell 2015;28:370-83.
YOHE S.Molecular genetic markers in acute myeloid leukemia.J Clin Med2015;4:460–78.
ZELBORAF[package insert].South San Francisco,CA:Genentech USA,Inc.;2015.
该申请中引用的所有文件都通过引用并入本文,如同在此全文引用一样。
尽管这里已经描述了本发明的示例说明性实施方案,但是应该理解本发明不限于所描述的实施方案,并且本领域技术人员可以在不背离本发明的范围或精神的情况下做出多种其他改变或修改。
Claims (35)
1.ERK抑制剂或其药学上可接受的盐在制备用于在具有癌症的受试者中减缓实体瘤生长的药物中的用途,其中所述受试者携带非V600E/K BRAF突变。
2.根据权利要求1的用途,其中ERK抑制剂选自BVD-523、SCH-722984(Merck&Co.)、SCH-772984(Merck&Co.)、SCH-900353(MK-8353)(Merck&Co.)、LY3214996(Lilly)、AEZS-140(Aeterna Zentaris)、AEZS-131(Aeterna Zentaris)、AEZS-136(Aeterna Zentaris)、LTT-462(Novartis)、RG-7842(Genentech)、CC-90003(Celgene)、KIN-4050(Kinentia)及其组合。
3.根据权利要求1的用途,其中ERK抑制剂是BVD-523。
4.根据权利要求1的用途,其中非V600E/K BRAF突变是激酶活化的突变、激酶受损的突变或激酶未知的突变及其组合。
5.根据权利要求4的用途,其中激酶活化的突变选自R462I、I463S、G464E、G464R、G464V、G466A、G469A、N581S、E586K、F595L、L597Q、L597R、L597S、L597V、A598V、T599E、V600R、K601E、S602D、A728V及其组合。
6.根据权利要求4的用途,其中激酶受损的突变选自G466E、G466R、G466V、Y472C、K483M、D594A、D594E、D594G、D594H、D594N、D594V、G596R、T599A、S602A及其组合。
7.根据权利要求4的用途,其中激酶未知的突变选自T440I、S467L、G469E、G469R、G469S、G469V、L584F、L588F、V600_K601delinsE、S605I、Q609L、E611Q及其组合。
8.根据权利要求1的用途,其中非V600E/K BRAF突变选自D594、G469、K601E、L597、T599重复、L485W、F247L、G466V、BRAF融合、BRAF-AGAP3重排、BRAF外显子15剪接变体及其组合。
9.根据权利要求1的用途,其中受试者是哺乳动物。
10.根据权利要求9的用途,其中哺乳动物选自灵长类动物、农场动物和家养动物。
11.根据权利要求9的用途,其中哺乳动物是人。
12.根据权利要求1的用途,其中癌症选自胶质母细胞瘤、黑素瘤、胆管癌、小细胞肺癌、结肠直肠癌、前列腺癌、阴道癌、血管肉瘤、非小细胞肺癌、阑尾癌、鳞状细胞癌、唾液管癌、腺样囊性癌、小肠癌和胆囊癌。
13.根据权利要求12的用途,其中癌症选自小肠癌、非小细胞肺癌、胆囊癌和鳞状细胞癌。
14.根据权利要求1的用途,其中所述药物进一步包括选自MEK抑制剂、RAF抑制剂、HDAC抑制剂及其组合的至少一种另外的治疗剂。
15.根据权利要求14的用途,其中MEK抑制剂选自炭疽毒素、蒽醌(GoldenBiotechnology)、ARRY-142886(6-(4-溴-2-氯-苯基氨基)-7-氟-3-甲基-3H-苯并咪唑-5-羧酸(2-羟基-乙氧基)-酰胺)(Array BioPharma)、ARRY-438162(Array BioPharma)、AS-1940477(Astellas)、AS-703988(Merck KGaA)、bentamapimod(Merck KGaA)、BI-847325(Boehringer Ingelheim)、E-6201(Eisai)、GDC-0623(Hoffmann-La Roche)、GDC-0973(考比替尼)(Hoffmann-La Roche)、L783277(Merck)、炭疽毒素的致死因子部分、MEK162(ArrayBioPharma)、PD 098059(2-(2'-氨基-3'-甲氧苯基)-氧萘-4-酮)(Pfizer)、PD 184352(CI-1040)(Pfizer)、PD-0325901(Pfizer)、PD318088(Pfizer)、PD334581(Pfizer)、6-甲氧基-7-(3-吗啉-4-基-丙氧基)-4-(4-苯氧基-苯基氨基)-喹啉-3-甲腈、4-[3-氯-4-(1-甲基-1H-咪唑-2-基硫烷基)-苯基氨基]-6-甲氧基-7-(3-吗啉-4-基-丙氧基)-喹啉-3-甲腈、pimasertib(Santhera Pharmaceuticals)、RDEA119(Ardea Biosciences/Bayer)、RG422(Chugai Pharmaceutical Co.)、R0092210(Roche)、R04987655(Hoffmann-La Roche)、R05126766(Hoffmann-La Roche)、SL327(Sigma)、TAK-733(Takeda)、曲美替尼(JapanTobacco)、U0126(1,4-二氨基-2,3-二氰基-1,4-双(2-氨基苯硫基)丁二烯)(Sigma)、WX-554(Wilex)、YopJ多肽(Mittal等人,2010)、其药学上可接受的盐及其组合。
16.根据权利要求14的用途,其中所述RAF抑制剂选自AAL881(Novartis)、AB-024(Ambit Biosciences)、ARQ-736(ArQule)、ARQ-761(ArQule)、AZ628(Axon Medchem BV)、BAY 43-9006索拉非尼、BeiGene-283(BeiGene)、BUB-024(MLN 2480)(Sunesis&Takeda)、b-raf抑制剂(Sareum)、BRAF激酶抑制剂(Selexagen Therapeutics)、BRAF siRNA 313(tacaccagcaagctagatgca)和523(cctatcgttagagtcttcctg)(Liu等人,2007)、CHIR-265(Novartis)、CTT239065(Institute of Cancer Research)、达拉非尼(GSK2118436)、DP-4978(Deciphera Pharmaceuticals)、HM-95573(Hanmi)、GDC-0879(Genentech)、GW-5074(Sigma Aldrich)、ISIS 5132(Novartis)、L779450(Merck)、LBT613(Novartis)、LXH254(Novartis)、LErafAON(NeoPharm,Inc.)、LGX-818(Novartis)、帕唑帕尼(pazopanib)(GlaxoSmithKline)、PLX3202(Plexxikon)、PLX4720(Plexxikon)、PLX5568(Plexxikon)、PLX3603(Daiichi Sankyo)、PLX8394(Daiichi Sankyo)、RAF-265(Novartis)、RAF-365(Novartis)、REDX0535(RedX Pharma Plc)、瑞戈非尼(regorafenib)(Bayer HealthcarePharmaceuticals,Inc.)、RO 5126766(Hoffmann-La Roche)、SB-590885(GlaxoSmithKline)、SB699393(GlaxoSmithKline)、索拉非尼(sorafenib)(OnyxPharmaceuticals)、TAK 632(Takeda)、TL-241(Teligene)、维拉非尼(vemurafenib)(RG7204或PLX4032)(Daiichi Sankyo)、XL-281(Exelixis)、ZM-336372(AstraZeneca)、其药学上可接受的盐及其组合。
17.根据权利要求14的用途,其中HDAC抑制剂选自艾贝司他(PCI-24781)、吉诺司他、恩替司他、扶林司他、CI-994、CUDC-101、恩替司他、BML-210、M344、NVP-LAQ824、帕比司他、Pracinosat(SB939)、Mocetinostat、Resminostat、罗米地辛、贝利诺司他、其药学上可接受的盐及其组合。
18.根据权利要求1的用途,其中所述药物进一步包括选自抗体、抗体片段、抗体缀合物、细胞毒性剂、毒素、放射性核素、免疫调控剂、光活化治疗剂、放射增敏剂、激素、激素干扰性化合物、抗血管生成剂及其组合的至少一种另外的治疗剂。
19.根据权利要求18的用途,其中抗体、其片段或其缀合物选自利妥昔单抗(Rituxan)、布伦妥昔单抗维多汀(Adcetriz)、阿多曲妥珠单抗艾坦肽(Kadcyla)、西妥昔单抗(Erbitux)、贝伐单抗(Avastin)、替伊莫单抗(Zevalin)、维多珠单抗(Entyvio)、伊匹单抗(Yervoy)、纳武单抗(Opdivo)、派姆单抗(Keytruda)、阿伦单抗、阿特朱单抗(Tecentriq)、阿维鲁单抗(Bavencio)、德鲁瓦单抗(Imfinzi)、B-701、奥法木单抗、阿托珠单抗(Gazyva)、帕尼单抗、plozalizumab、BI-754091、OREG-103、COM-701、BI-754111及其组合。
20.根据权利要求18的用途,其中细胞毒性剂选自环磷酰胺、甲氯乙胺、尿嘧啶氮芥、美法仑、苯丁酸甲氯乙胺、异环磷酰胺、卡莫司汀、洛莫司汀、链脲霉素、白消安、替莫唑胺、顺铂、卡铂、奥沙利铂、奈达铂、沙铂、三硝酸四铂、阿霉素、柔红霉素、伊达比星、米托蒽醌、甲氨蝶呤、培美曲塞、6-巯基嘌呤、达卡巴嗪、氟达拉滨、5-氟尿嘧啶、阿拉伯糖胞嘧啶、卡培他滨、吉西他滨、地西他滨、长春花生物碱、紫杉醇(Taxol)、多西他赛(Taxotere)、依沙贝比隆(Ixempra)、放线菌素、蒽环类、缬沙星、表柔比星、博来霉素、普卡霉素、丝裂霉素、其药学上可接受的盐、前药及其组合。
21.根据权利要求18的用途,其中毒素是白喉毒素或其部分。
22.根据权利要求18的用途,其中放射性核素选自I-125、At-211、Lu-177、Cu-67、I-131、Sm-153、Re-186、P-32、Re-188、In-114m、Y-90及其组合。
23.根据权利要求18的用途,其中免疫调控剂选自粒细胞集落刺激因子(G-CSF)、LAG-3、IMP-321、JCAR-014、ASLAN-002(BMS-777607)、干扰素、咪喹莫特和来自细菌的细胞膜组分、IL-2、IL-7、IL-12、CCL3、CCL26、CXCL7、合成的胞嘧啶磷酸鸟苷(CpG)、免疫检查点抑制剂及其组合。
24.根据权利要求18的用途,其中放射增敏剂选自米索硝唑、甲硝唑、替拉帕明、反式丁香酸钠及其组合。
25.根据权利要求18的用途、其中激素选自前列腺素、白三烯、前列环素、血栓烷、淀粉纤维素、抗苗勒管激素、脂联素、促肾上腺皮质激素、血管紧张素原、血管紧张素、血管加压素、心房肽、脑钠尿肽、降血钙素、胆囊收缩素、促肾上腺皮质激素释放激素、脑啡肽、内皮素、促红细胞生成素、促卵泡激素、甘丙肽、胃泌素、生长激素释放肽、胰高血糖素、促性腺激素释放激素、生长激素释放激素、人绒毛膜促性腺激素、人胎盘促泌素、生长激素、抑制素、胰岛素、生长调节素、瘦素、促脂素、促黄体生成素、黑素细胞刺激激素、胃动素、食欲素、催产素、胰多肽、甲状旁腺激素、催乳素、催乳素释放激素、松弛素、肾素、分泌素、生长抑素、血小板生成素、促甲状腺激素、睾丸酮、脱氢表雄酮、雄烯二酮、二氢睾丸酮、醛固酮、雌二醇、雌酮、雌三醇、皮质醇、孕酮、骨化三醇、骨化二醇及其组合。
27.根据权利要求18的用途、其中抗血管生成剂选自2-甲氧基雌二醇、血管抑制素、贝伐单抗、软骨衍生的血管生成抑制因子、内皮抑素、IFN-α、IL-12、伊曲康唑、利诺米特、血小板因子4、催乳素、SU5416、苏拉明、他克莫尼、替加仑、四硫代钼酸盐、沙利度胺、血小板反应蛋白、血小板反应蛋白、TNP-470、齐夫-阿柏西普、其药学上可接受的盐、前药及其组合。
28.根据权利要求18的用途,其中另外的治疗剂是PI3K/Akt途径的抑制剂。
29.根据权利要求28的用途、其中PI3K/Akt途径的抑制剂选自A-674563(CAS#552325-73-2)、AGL 2263、AMG-319(Amgen,Thousand Oaks,CA)、AS-041164(5-苯并[1,3]二恶唑-5-基亚甲基-噻唑烷-2,4-二酮)、AS-604850(5-(2,2-二氟-苯并[1,3]二恶唑-5-基亚甲基)-噻唑烷-2,4-二酮)、AS-605240(5-喹喔啉-6-亚甲基-1,3-噻唑烷-2,4-二酮)、AT7867(CAS#857531-00-1)、苯并咪唑系列,Genentech(Roche Holdings Inc.,South San Francisco,CA)、BML-257(CAS#32387-96-5)、BVD-723、CAL-120(Gilead Sciences,Foster City,CA)、CAL-129(Gilead Sciences)、CAL-130(Gilead Sciences)、CAL-253(Gilead Sciences)、CAL-263(Gilead Sciences)、CAS#612847-09-3、CAS#681281-88-9、CAS#75747-14-7、CAS#925681-41-0、CAS#98510-80-6、CCT128930(CAS#885499-61-6)、CH5132799(CAS#1007207-67-1)、CHR-4432(Chroma Therapeutics,Ltd.,Abingdon,UK)、FPA 124(CAS#902779-59-3)、GS-1101(CAL-101)(Gilead Sciences)、GSK 690693(CAS#937174-76-0)、H-89(CAS#127243-85-0)、Honokiol、IC87114(Gilead Science)、IPI-145(Intellikine Inc.)、KAR-4139(Karus Therapeutics,Chilworth,UK)、KAR-4141(Karus Therapeutics)、KIN-1(Karus Therapeutics)、KT 5720(CAS#108068-98-0)、米替福新、MK-2206二盐酸化物(CAS#1032350-13-2)、ML-9(CAS#105637-50-1)、盐酸纳曲通、OXY-111A(NormOxys Inc.,Brighton,MA)、perifosine、PHT-427(CAS#1191951-57-1)、PI3激酶δ抑制剂,Merck KGaA(Merck&Co.,Whitehouse Station,NJ)、PI3激酶δ抑制剂,Genentech(Roche HoldingsInc.)、PI3激酶δ抑制剂,Incozen(Incozen Therapeutics,Pvt.Ltd.,Hydrabad,India)、PI3激酶δ抑制剂2,Incozen(Incozen Therapeutics)、PI3激酶抑制剂,Roche-4(RocheHoldings Inc.)、PI3激酶抑制剂,Roche(Roche Holdings Inc.)、PI3激酶抑制剂,Roche-5(Roche Holdings Inc.)、PI3-α/δ抑制剂,Pathway Therapeutics(Pathway TherapeuticsLtd.,South San Francisco,CA)、PI3-δ抑制剂,Cellzome(Cellzome AG,Heidelberg,Germany)、PI3-δ抑制剂,Intellikine(Intellikine Inc.,La Jolla,CA)、PI3-δ抑制剂,Pathway Therapeutics-1(Pathway Therapeutics Ltd.)、PI3-δ抑制剂,PathwayTherapeutics-2(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,Cellzome(CellzomeAG)、PI3-δ/γ抑制剂,Cellzome(Cellzome AG)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Intellikine(Intellikine Inc.)、PI3-δ/γ抑制剂,Pathway Therapeutics(Pathway Therapeutics Ltd.)、PI3-δ/γ抑制剂,PathwayTherapeutics(Pathway Therapeutics Ltd.)、PI3-γ抑制剂,Evotec(Evotec)、PI3-γ抑制剂,Cellzome(Cellzome AG)、PI3-γ抑制剂,Pathway Therapeutics(PathwayTherapeutics Ltd.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、PI3Kδ/γ抑制剂,Intellikine-1(Intellikine Inc.)、pictilisib(Roche Holdings Inc.)、PIK-90(CAS#677338-12-4)、SC-103980(Pfizer,New York,NY)、SF-1126(SemaforePharmaceuticals,Indianapolis,IN)、SH-5、SH-6、四氢姜黄素、TG100-115(TargegenInc.,San Diego,CA)、曲西瑞宾、X-339(Xcovery,West Palm Beach,FL)、XL-499(Evotech,Hamburg,Germany)、其药学上可接受的盐及其组合。
30.BVD-523或其药学上可接受的盐在制备用于在具有癌症的受试者中减缓实体瘤生长的药物中的用途,其中所述受试者携带非V600E/K BRAF突变。
31.根据权利要求14所述的用途,其中所述RAF抑制剂选自厄洛替尼(Tarceva)、吉非替尼(Iressa)、甲磺酸伊马替尼(Gleevec)、拉帕替尼(Tyverb)、苹果酸舒尼替尼(Sutent)、其药学上可接受的盐及其组合。
32.根据权利要求14所述的用途,其中RAF抑制剂选自LXH254(Novartis)、PLX3603(Daiichi Sankyo)、PLX8394(Daiichi Sankyo)、REDX0535(RedX Pharma Plc)、其药学上可接受的盐及其组合。
33.根据权利要求14所述的用途,其中HDAC抑制剂选自扶林司他、帕诺比司他、罗米地辛、贝利司他、其药学上可接受的盐及其组合。
34.根据权利要求18所述的用途,其中抗体、其片段或其缀合物选自利妥昔单抗(Rituxan)、布伦妥昔单抗维多汀(Adcetriz)、阿多曲妥珠单抗艾坦肽(Kadcyla)、伊匹单抗(Yervoy)、纳武单抗(Opdivo)、派姆单抗(Keytruda)、阿伦单抗阿特朱单抗(Tecentriq)、德鲁瓦单抗(Imfinzi)、奥法木单抗、阿托珠单抗(Gazyva)、帕尼单抗(Panitumumab)及其组合。
35.根据权利要求28所述的用途,其中PI3K/Akt途径的抑制剂是BVD-723。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762506995P | 2017-05-16 | 2017-05-16 | |
US62/506,995 | 2017-05-16 | ||
CN201880040655.8A CN110799245B (zh) | 2017-05-16 | 2018-05-15 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
PCT/US2018/032755 WO2018213302A1 (en) | 2017-05-16 | 2018-05-15 | Compositions and methods for treating cancer with atypical braf mutations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880040655.8A Division CN110799245B (zh) | 2017-05-16 | 2018-05-15 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116036278A true CN116036278A (zh) | 2023-05-02 |
Family
ID=64274828
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210881186.0A Pending CN116036278A (zh) | 2017-05-16 | 2018-05-15 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
CN201880040655.8A Active CN110799245B (zh) | 2017-05-16 | 2018-05-15 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880040655.8A Active CN110799245B (zh) | 2017-05-16 | 2018-05-15 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210085663A1 (zh) |
EP (1) | EP3624896A4 (zh) |
JP (2) | JP7405408B2 (zh) |
CN (2) | CN116036278A (zh) |
AU (1) | AU2018269982B2 (zh) |
BR (1) | BR112019024007A2 (zh) |
CA (1) | CA3063614A1 (zh) |
MX (1) | MX2019013634A (zh) |
WO (1) | WO2018213302A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
US20190225689A1 (en) | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
CN109771436A (zh) * | 2019-03-06 | 2019-05-21 | 康赋葆(深圳)生物医药科技有限公司 | 四氢姜黄素与卡培他滨联合治疗大肠癌的应用 |
EP3968995A1 (en) * | 2019-05-16 | 2022-03-23 | Eli Lilly and Company | Triple combination of an erk1/2 inhibitor with a braf inhibitor and an egfr inhibitor for use in the treatment of brafv600e colorectal cancer |
GB201913121D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
GB201913123D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
GB201913124D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
CN110538316B (zh) * | 2019-10-17 | 2021-10-15 | 滨州医学院 | 5-fu和胰高血糖素联合用于制备治疗结直肠癌的药物的用途和药物组合物 |
EP4106756A1 (en) * | 2020-02-18 | 2022-12-28 | Novartis AG | Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc |
CN117377683A (zh) * | 2021-02-25 | 2024-01-09 | 西湖生物医药科技(杭州)有限公司 | 新抗原肽及其在治疗braf基因突变相关疾病中的用途 |
US20240173329A1 (en) * | 2021-03-09 | 2024-05-30 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
WO2023049798A1 (en) * | 2021-09-22 | 2023-03-30 | Henry Ford Health System | Hdac3 inhibitors for the treatment of langerhans cell histiocytosis and langerhans cell sarcoma |
CN116570599B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合ly3009120的应用及药物组合物 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101418340A (zh) * | 2007-09-11 | 2009-04-29 | 霍夫曼-拉罗奇有限公司 | B-raf激酶抑制剂易感性的诊断检测 |
WO2015095835A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers |
CN105209073A (zh) * | 2013-03-21 | 2015-12-30 | 诺华股份有限公司 | 包含B-Raf抑制剂和第二抑制剂的组合疗法 |
WO2016008853A1 (en) * | 2014-07-14 | 2016-01-21 | Universität Zürich Prorektorat Mnw | Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor |
WO2016025650A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
CN105451750A (zh) * | 2013-03-29 | 2016-03-30 | 生物医学谷探索股份有限公司 | 治疗人的实体肿瘤的诺氏梭菌 |
CN105530931A (zh) * | 2013-07-12 | 2016-04-27 | 皮拉马尔企业有限公司 | 用于治疗黑素瘤的药物组合 |
US20160310477A1 (en) * | 2013-12-20 | 2016-10-27 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mek type 1 and erk inhibitors |
US20160317517A1 (en) * | 2013-12-20 | 2016-11-03 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |
US20160317538A1 (en) * | 2013-12-20 | 2016-11-03 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of cdk and erk inhibitors |
CN106211755A (zh) * | 2013-12-20 | 2016-12-07 | 生物医学谷探索股份有限公司 | 使用erk和raf抑制剂的组合的癌症治疗 |
US20160362407A1 (en) * | 2015-06-15 | 2016-12-15 | Asana Biosciences, Llc | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
US20160367539A1 (en) * | 2013-12-20 | 2016-12-22 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of type 2 mek and erk inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2882442B1 (en) * | 2012-08-09 | 2021-06-09 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
WO2014028461A2 (en) * | 2012-08-13 | 2014-02-20 | The Rockefeller University | Treatment and diagnosis of melanoma |
WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
CA3000775A1 (en) * | 2015-07-08 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using slncr isoforms |
-
2018
- 2018-05-15 US US16/613,480 patent/US20210085663A1/en active Pending
- 2018-05-15 CN CN202210881186.0A patent/CN116036278A/zh active Pending
- 2018-05-15 AU AU2018269982A patent/AU2018269982B2/en active Active
- 2018-05-15 EP EP18801345.2A patent/EP3624896A4/en active Pending
- 2018-05-15 CA CA3063614A patent/CA3063614A1/en active Pending
- 2018-05-15 MX MX2019013634A patent/MX2019013634A/es unknown
- 2018-05-15 JP JP2019563125A patent/JP7405408B2/ja active Active
- 2018-05-15 WO PCT/US2018/032755 patent/WO2018213302A1/en unknown
- 2018-05-15 CN CN201880040655.8A patent/CN110799245B/zh active Active
- 2018-05-15 BR BR112019024007-1A patent/BR112019024007A2/pt unknown
-
2022
- 2022-10-05 JP JP2022160828A patent/JP2022176316A/ja active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101418340A (zh) * | 2007-09-11 | 2009-04-29 | 霍夫曼-拉罗奇有限公司 | B-raf激酶抑制剂易感性的诊断检测 |
CN105209073A (zh) * | 2013-03-21 | 2015-12-30 | 诺华股份有限公司 | 包含B-Raf抑制剂和第二抑制剂的组合疗法 |
CN105451750A (zh) * | 2013-03-29 | 2016-03-30 | 生物医学谷探索股份有限公司 | 治疗人的实体肿瘤的诺氏梭菌 |
CN105530931A (zh) * | 2013-07-12 | 2016-04-27 | 皮拉马尔企业有限公司 | 用于治疗黑素瘤的药物组合 |
US20160317538A1 (en) * | 2013-12-20 | 2016-11-03 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of cdk and erk inhibitors |
US20160310477A1 (en) * | 2013-12-20 | 2016-10-27 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mek type 1 and erk inhibitors |
US20160317517A1 (en) * | 2013-12-20 | 2016-11-03 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |
WO2015095835A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers |
CN106211755A (zh) * | 2013-12-20 | 2016-12-07 | 生物医学谷探索股份有限公司 | 使用erk和raf抑制剂的组合的癌症治疗 |
US20160367539A1 (en) * | 2013-12-20 | 2016-12-22 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of type 2 mek and erk inhibitors |
WO2016008853A1 (en) * | 2014-07-14 | 2016-01-21 | Universität Zürich Prorektorat Mnw | Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor |
WO2016025650A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
US20160362407A1 (en) * | 2015-06-15 | 2016-12-15 | Asana Biosciences, Llc | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
Non-Patent Citations (4)
Title |
---|
ASCIERTO, PAOLO A.等: "The role of BRAF V600 mutation in melanoma", 《JOURNAL OF TRANSLATIONAL MEDICINE》, vol. 10, 3 May 2012 (2012-05-03), pages 85 * |
THIEL, ALEXANDRA等: "Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF", 《FRONTIERS IN ONCOLOGY》, vol. 3, 3 July 2014 (2014-07-03), pages 281 * |
刘斌等: "MAPK/ERK和PI3K/Akt信号通道的基因变异与甲状腺癌的发生发展及诊治", 《生物医学工程学杂志》, vol. 29, no. 06, 25 December 2012 (2012-12-25), pages 1221 - 1225 * |
肖帅帅等: "单极纺锤体蛋白激酶1与BRafV600E/ERK通路在乳腺癌中的相关性分析", 《中国药物与临床》, vol. 2014, no. 7, 13 August 2014 (2014-08-13), pages 873 - 875 * |
Also Published As
Publication number | Publication date |
---|---|
MX2019013634A (es) | 2020-01-21 |
RU2019141300A3 (zh) | 2022-02-25 |
CN110799245A (zh) | 2020-02-14 |
CA3063614A1 (en) | 2018-11-22 |
AU2018269982A1 (en) | 2020-01-02 |
AU2018269982B2 (en) | 2024-06-13 |
JP2020519660A (ja) | 2020-07-02 |
EP3624896A4 (en) | 2021-03-31 |
JP7405408B2 (ja) | 2023-12-26 |
JP2022176316A (ja) | 2022-11-25 |
US20210085663A1 (en) | 2021-03-25 |
BR112019024007A2 (pt) | 2020-07-07 |
EP3624896A1 (en) | 2020-03-25 |
RU2019141300A (ru) | 2021-06-16 |
WO2018213302A1 (en) | 2018-11-22 |
CN110799245B (zh) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116036278A (zh) | 用于治疗具有非典型braf突变的癌症的组合物和方法 | |
US11679112B2 (en) | Cancer treatments using combinations of CDK and ERK inhibitors | |
CN106211755B (zh) | 使用erk和raf抑制剂的组合的癌症治疗 | |
JP7427212B2 (ja) | 非erk mapk経路阻害剤耐性のがんを処置するための方法および組成物 | |
JP6727127B2 (ja) | Pi3k/aktシグナル経路阻害剤およびerk阻害剤の組み合わせを使用するがん処置 | |
JP6678583B2 (ja) | 2型mek阻害剤およびerk阻害剤の組み合わせを用いるがん処置 | |
WO2015095807A1 (en) | Cancer treatments using combinations of egfr and erk inhibitors | |
RU2812706C2 (ru) | Композиции и способы для лечения злокачественной опухоли с атипичными мутациями braf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40086947 Country of ref document: HK |